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Abstract 
------------------------------------------------------------------------------------------------------- --------------------------------- 
 
Cancer is a large group of diseases that can result in substantially increased mortality. This 
increased mortality occurs not only due to the limited effectiveness of the available 
treatments, but also because the diagnosis usually occurs late in the tumour development. 
Therefore, the identification of new cancer-specific biomarkers is extremely important in 
order to improve patient diagnosis at an early stage. Humans possess a class of genes that are 
normally expressed in the testes of adult males, and are also characteristic of several types of 
cancer cells. These genes are known as cancer-testis (CT) antigen genes and they might be 
helpful for both diagnosis and immunotherapy drug targeting. For this reason, identifying new 
CTA genes has significant clinical importance. Meiosis is restricted to germ cells and a 
number of meiotic proteins have previously been identified as CT antigens; consequently, we 
postulated that meiosis-specific genes may provide a good source for identifying potential 
novel CTA genes. 
 
Potential meiotic genes were identified from a bioinformatics analysis. The specificity of 
these meiosis genes was validated in several types of normal human tissues. Genes that were 
found to display testis-restricted/selective or testis-CNS-restricted/selective expression 
profiles in the normal tissues were further screened in a wide range of cancer tissues and 
cancer cell lines. Out of the 32 genes screened by RT-PCR in the present study, the results 
identified 11 genes as novel CT genes. From the 11 candidate CT genes, STRA8 and 
C20orf201 were further functionally characterised in cancer cells. 
 
The STRA8 and C20orf201 genes are considered to be good CT candidate genes since they 
are expressed in different types of cancer. Further analysed of STRA8 and C20orf201 by 
developing overexpression cell lines and this work indicates they have CTA potential. 
Expression of STRA8 subcloned into Flp-In T-REx-293 cells did not reveal obvious functional 
activity. 
 
C20orf201 gene was validated in this study at the protein levels in different normal and 
cancer tissue and cell lines. C20orf201 was found in the normal human testes and central 
nervous tissues. However, C20orf201 was also found to be present in a range of cancer cells 
suggesting it could be a CTA; biochemical evidence is also presented to indicate it might have 
functional activity as it appears to be modified in cancer-specific fashion.   
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Chapter 1.0: Introduction 
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
1.1 Cancer in humans 
1.1.1 Overview of cancer 
Cancer is a major public health problem worldwide; more than 7 million people died in 2008 
due to cancer. The number of cancer deaths is expected to increase rapidly to over 11 million 
per year globally by 2030 (http://www.who.int/cancer/en/). In the United States, for example, 
one out of four human deaths are caused by cancer and among child deaths, leukaemia and 
brain cancer are considered to be the second most frequent causes, compared with other types 
of cancer (Siegel et al., 2012). There are also distinctions in cancer deaths in males and 
female; for example, breast cancer is the second leading cause of cancer related deaths in 
women in the United Kingdom (Jemal et al., 2010).  
 
Cancer is a term for a large group of diseases which are often associated with multiple genetic 
and epigenetic changes of the cellular genome. Cancer cells proliferate without restriction and 
changes in cellular adhesion can result in cancer spreading to other locations in the human 
body and destroying multiple tissues, through a process termed metastasis (Brábek et al., 
2010; Geutjes et al., 2011; Sharma et al., 2010). A cancer can arise from a single cell, which 
is considered the site of the primary cancer. The primary tumour displays uncontrolled 
growth, invasion and often metastasis through the blood or the lymphatic system, which 
enables the cancer to spread quickly to different sites. These are the features of malignant 
cells (Hanahan and Weinberg, 2011; Kopfstein and Christofori, 2006; Shacter and Weitzman, 
2002) and distinguish malignant cancers from benign tumours, which grow more slowly and 
do not invade or metastasise (Klein, 2008; Player et al., 2004).  
 
1.1.2 Classification of human cancers 
Human cancers are currently classified into various types according to factors such as the 
origin of the cells, the pathological properties of malignant cells and the phase of tumour 
progression. The four main types of cancer are carcinoma, sarcoma, leukaemia and 
lymphoma. (1) Carcinoma is a term which refers to malignant tumours of epithelial tissues, 
and is found in organs such as the skin, lung and breast. The great majority (approximately 
90%) of human cancers are carcinomas; this prevalence may arise because epithelial tissues 
tend to proliferate during humans life and are most directly exposed to exogenous agents that 
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assist in promoting tumourigenesis. (2) Sarcomas are cancers that develop in connective 
tissue, such as muscles, bone and cartilage. (3) Leukaemia and (4) lymphoma arise from 
haematopoietic cells. Leukaemia is cancer of the white blood cells, while lymphomas begin in 
B and T lymphocytes. Benign and malignant tumours differ greatly; most benign tumours are 
adenomas; a type of cancer that generally occurs in glandular tissues, whereas malignant 
tumours in glandular tissues are named adenocarcinomas (Ruddon, 2007; Weinberg, 2007). 
Further classification of cancers is available at the National Cancer Institute website 
(http://www.cancer.gov). 
 
1.1.3 The causes of human cancers 
Cancer is caused by exogenous and endogenous agents (Morley and Turner, 1999). The 
endogenous (internal) agents arise as a result of natural errors in processes occurring during 
metabolism, DNA duplication, DNA repair and chromosome segregation. Errors in DNA 
repair or chromosome segregation can lead to alterations in chromosome number and/or 
structure, thereby causing an increase or decrease in gene copy number. Errors in DNA 
replication can also result in genetic recombination products that considerably increase or 
decrease the number of gene copies. Exogenous (external) agents usually enter the human 
body from the environment. Exogenous agents are classified into three types: physical, 
chemical and biological (Belpomme et al., 2007; Lutz, 2002; Vogelstein and Kinzler, 2004). 
Exposure to ultraviolet radiation, a physical agent, can lead to the induction of pyrimidine 
dimers in DNA, which can cause skin cancer (Douki, 2013). Chemical mutagens, like those 
inhaled in tobacco smoke, can induce diverse forms of nucleotide damage observed in lung 
cancer (Gibbons et al., 2014). Biological agents can also cause human cancer; for example, 
hepatitis B or C virus (HBV or HCV) infections are causally associated with hepatocellular 
carcinoma (Lupinacci et al., 2013).  
 
Cancers can be induced by genetic and/or epigenetic changes to tumour suppressor genes and 
oncogenes. These genetic changes may increase tumour progression, which leads to tumour 
proliferation, invasion and spreading (Gnoni et al., 2013). Nevertheless, recent studies 
propose that cancer also has a universal foundation in polyclonal epigenetic disruption of 
stem cells, mediated by tumour stem cells, which can lead to changes in gene expression that 
commonly contribute to the development and progression of tumours (Choi and Lee, 2013; 
Feinberg et al., 2006; Vogelstein and Kinzler, 2004). 
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1.1.4 Genetic alterations and cancer progression  
Genetic variations in DNA can result in cancer because failures in chromosome segregation 
and DNA repair can result in chromosomal aberration, as regularly observed in malignant 
cells (Ström and Sjögren, 2007). Chromosomal aberrations include amplifications, deletions 
and chromosomal translocations. However, chromosomal translocations are the main cause of 
several cancers in humans; for example, leukaemia, lymphoma and some solid tumours 
(Nambiar et al., 2008). The simplest genetic alteration that can occur in cancer is a point 
mutation, where a single nucleotide is mutated or deleted. If a mutation is not repaired, the 
mutated cells can change their behaviour and cancer may initiate (Lengauer et al., 1998; 
Zheng, 2013).  
 
Amplification is a regional copy number increase, and is often associated with overexpression 
of some of the affected genes. Amplification of a DNA sequence has been observed in various 
kinds of lymphoma and solid tumours (Santarius et al., 2010). Deletion is the loss of genetic 
material and can be limited in size or involve entire chromosome arms. Abnormal changes in 
the numbers of chromosome are termed aneuploidy (Albertson et al., 2003; Munger, 2002). 
Chromosomal translocation is a term generally used to describe chromosomal 
rearrangements, including exchanges of segments between two non-homologous 
chromosomes. The majority of translocations in humans are related to lymphoid tumours 
(Küppers, 2005; Nussenzweig and Nussenzweig, 2010). Chromosomal translocations are 
generally used as diagnostic markers for malignant cells. Chromosomal translocation can lead 
to the generation of a new gene product by bringing genes close to enhancer or promoter 
elements, thereby resulting in an alteration in their expression or by the fusion of genes to 
generate new oncogenic variants (Nambiar et al., 2008).   
 
1.1.5 Epigenetic alterations in cancer development  
Cancer is considered to be both a genetic and an epigenetic disease. It is now widely 
recognised that epigenetic events underlie cancer progression. Epigenetic variations result in 
altered gene expression due to factors other than alteration in the DNA sequence itself. 
Epigenetic changes can change the phenotype without altering genotype. The main epigenetic 
factors that may affect global gene expression involve DNA methylation and histone 
modifications (Hatzimichael and Crook, 2013).  
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1.1.5.1 DNA methylation    
DNA methylation refers to the addition of a methyl group to the 5-carbon position of the 
cytosine within the dinucleotide CpG (-cytosine–phosphate–guanine-) of a DNA strand, 
catalysed by DNA methyltransferases (DNMTs). Regions of DNA that are CG rich are called 
‘CpG islands’ and are usually associated with gene promoters (Vinson and Chatterjee, 2012). 
DNA methylation has a fundamental role in mammalian development (Robertson, 2005; 
Smith and Meissner, 2013) and an essential function in X-chromosome inactivation (Lee and 
Bartolomei, 2013) and genomic imprinting (Girardot et al., 2013).  
 
The promoter regions of a normal mammalian cell genome comprise approximately 70–80% 
of all CpG islands being methylated (Ziller et al., 2013). On the contrary, DNA 
hypomethylation in non-promoter regions and hypermethylation in the promoter region of 
genes is associated with transcription silencing of tumour suppressor and DNA repair genes, 
and is often identified in different cancerous cells (Akhavan-Niaki and Samadani, 2013). 
Hypermethylation also leads to genomic instability and can affect apoptosis, DNA repair and 
cell-cycle control, thereby giving rise to tumourigenesis (Esteller and Herman, 2002; Wu and 
Bekaii-Saab, 2012). The expression levels and activity of DNMTs are generally greater in 
distinct human cancers than in normal tissues (Ibrahim et al., 2011). 
 
1.1.5.2 Histone modifications   
The length of a strand of human DNA is large enough to exceed the borders of the cell 
nucleus, so it requires packaging in to higher order structures. The nuclei of eukaryotic cells 
contain both histone and non-histone proteins that organised the genomic DNA into a 
condensed structure, termed chromatin. Chromatin is typically found in two different 
functional forms: heterochromatin, a highly condensed and transcriptionally repressive form, 
and euchromatin, a less condensed form that can be generally permissive for gene 
transcription. The basic unit of chromatin is termed the nucleosome and consists of 147 base 
pairs of genomic DNA wrapped twice around a histone octamer, consisting of isoforms of 
two copies each of the core histones H2A, H2B, H3 and H4. Histones; however, are not only 
packaging elements, but also critical regulators of gene expression (Clausell et al., 2009; 
Eickbush and Moudrianakis, 1978; Luger et al., 1997; Russ et al., 2012).  
 
Histone may be subjected many post-translational chemical modifications; for instance, 
acetylation, methylation, phosphorylation and ubiquitination of the N-terminal regions. This 
is also limited to H3 and H4 isoforms. These modifications can change the structure of 
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chromatin and gene expression in human cancers from an open to a closed, condensed form, 
and vice versa (Figure 1.1). Histone modifications also have an important role in different 
processes involving transcriptional repression, gene activation and DNA repair (Kouzarides, 
2007). For example, the transcriptional activity of euchromatin is often associated with high 
levels of histone acetylation, while silent heterochromatin is correlated with low levels of 
histone acetylation (Bannister and Kouzarides, 2011; Nakazawa et al., 2012). Histone 
modifications can alter cellular activity in an oncogenic fashion; for example, acetylation and 
methylation are the most active in colorectal cancer pathogenesis (Nakazawa et al., 2012). 
 
Histone acetylation changes the chromatin structure by altering the interaction between the 
negatively charged phosphate group of DNA, and the positively charged histone. Most 
acetylation sites characterised to date are found within the N-terminal tail of histones, which 
are more accessible for modification (Han et al., 2007). Histone acetylation at the histone tails 
is controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs) that 
ordinarily serve as transcriptional co-activators or co-repressors, respectively. HDACs 
promote the removal of the acetyl group from the amino group of the lysine residue of the 
histone and are the most characterised proteins among the histone modification enzymes that 
play important roles in cancer development (Ashktorab et al., 2009). 
 
Epigenetic modification can control tissue specific gene regulation; for example, some cancer 
associated genes are normally expressed in the testis and are controlled by differential 
epigenetic regulation (see Section 1.2.4). 
 
1.1.6 Antigen markers in cancer 
Cancer markers can be defined as factors found in the human body that indicate the presence 
of cancer (Mäbert et al., 2014). Some cancer markers are found in the solid tumour itself or in 
lymph nodes, in bone marrow, or in other body fluids (urine or blood). These markers can be 
made by either the body in response to cancer or by the cancerous cells themselves. Many 
markers in different cancers are proteins, but some of the new types of markers are genes or 
levels of genetic materials (DNA or RNA) (Mäbert et al., 2014). Two distinct types of cancer 
markers are recognised: specific markers that are associated only with one kind of cancer and 
unspecific markers that are found in several different cancers (Freidlin and Korn, 2014; 
Lindblom and Liljegren, 2000).  
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Figure 1.1 Euchromatin and Heterochromatin structure. Euchromatin is an open form of 
chromatin and is normally associated with active gene transcription. In contrast, heterochromatin is 
characterised by high nucleosome density, which results in a closed form of chromatin. Therefore, 
heterochromatin is normally associated with the repression of gene transcription. DNA is wrapped 
around the histone octamer of the four core histones H2A, H2B, H3 and H4. Each histone has an 
amino terminal tail that can be covalently changed by specific epigenetic reactions such as 
methylation, acetylation and phosphorylation (Adapted from Russ et al., 2012). 
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Cancer markers can be helpful in different ways: (a) Screening and early detection of cancer. 
The primary goal of a cancer marker is to aid diagnosis of cancer in individuals who have no 
clinical symptoms of the disease, as early diagnosis of a tumour is important for survival 
(Duffy, 2001; Thomas and Sweep, 2001). A widely used cancer diagnosis marker is currently 
the prostate-specific antigen (PSA). The PSA blood test is used to screen men for prostate 
cancer, as men with prostate cancer usually have high PSA levels (Schröder et al., 2009); (b) 
Diagnosis of a specific type of cancer. Cancer markers in some cases cannot be used alone to 
diagnose a specific cancer, but can complement biopsy for diagnosis; (c) Determining the 
prognosis for certain cancers; and (d) Monitoring how well a cancer treatment is working. If a 
specific type of cancer has a marker, changes in the level of the marker (increased or 
decreased) can indicate if the treatment is working well (Duffy, 2001; Thomas and Sweep, 
2001). Importantly, a number of cancer biomarkers can be used both in diagnosis and in target 
therapy; for example, CEA and HER2 are biomarkers used for human colon and breast 
cancer, respectively. However, both markers can be used in passive and active therapy (Even-
Desrumeaux et al., 2011)  
 
A number of studies have shown that cancer cells can change the expression of genes from up 
regulated to down regulated or vice versa. Up regulated genes are considered to be cancer 
markers in different tumours; nevertheless, their use as therapeutic and/or diagnostic targets is 
restricted for several genes, since the resulting antigens are recognised by the human immune 
system (Caballero and Chen, 2009; Costa et al., 2007). 
 
Several lab studies have focused on a particular class of antigens in order to identify specific 
biomarkers with potential use in the early detection of malignancy. One such group of 
antigens have been identified as the cancer-testis antigens (CTAs), and these could play an 
essential role in clinical studies (Mirandola et al., 2011). 
 
1.2 Cancer testis antigens (CTAs) 
1.2.1 Overview of CTAs 
Van der Bruggen and his colleagues identified the first human cancer testis (CT) genes in 
1991 in a patient with malignant melanoma and named the melanoma antigen family 
(MAGE-1) (van der Bruggen et al., 1991). Further studies showed that the mRNA of MAGE 
was observed in different types of human tumours and also in testis and placental cells of 
somatic tissues (Fratta et al., 2011; Zendman et al., 2003). The term cancer testis antigen 
8 
 
(CTA) was first used in 1997 by Old and Chen (Chen et al., 1997; Old and Chen, 1998) for 
this promising class of tumour-associated antigens (TAA), because of their limited presence 
in somatic tissues (de Carvalho et al., 2012). These antigens are also known as cancer 
germline antigens (Chen et al., 1997). Many of the CTAs were discovered from the 
examination of melanoma samples. The initial discovery of the early CT-antigens, MAGE-A1, 
PAGE and GAGE1, was reported between 1991 and 1995 (Boël et al., 1995; Van den Eynde 
et al., 1995; van der Bruggen et al., 1991), followed by SSX2 and NY-ESO-1 in the late 1990s 
(Chen et al., 1997; Tuereci et al., 1998). 
 
CTAs are a heterogeneous group of proteins whose corresponding genes are normally 
expressed solely in the testes of adult males and in several types of malignant human tumour 
cells (Whitehurst, 2014). These antigens are encoded by the CT genes (Scanlan et al., 2004; 
Simpson et al., 2005; Whitehurst, 2014), whose expression levels have been shown to vary in 
tumours of different histology. For example, these genes display low expression levels in 
lymphomas, leukaemia, colon and pancreatic cancers, whereas they show high expression in 
melanoma, ovarian cancer and lung tumours (Caballero and Chen, 2009). In some cases, CT 
genes are also expressed in the ovaries, the placenta, and the thymus; one example is NY-
ESO-1, a CT gene originally identified from oesophageal squamous cell carcinoma of a 58-
year-old female (Caballero and Chen, 2009).  
 
Due to their unique gene expression profiles, the CTAs are considered attractive targets for 
use as immunotherapy for tumours, as biomarkers for the early diagnosis of cancer and as 
strong candidates for cancer vaccines (Simpson et al., 2005; Valmori et al., 2007; van Duin et 
al., 2011). In biological studies, CT genes are considered as good models for understanding 
complex gene regulation and abnormal gene activation throughout cancer development. 
Currently, any gene that displays testis-specific expression and expression in tumour cells is 
defined as a CT gene (Mirandola et al., 2011; Scanlan et al., 2004; Whitehurst, 2014).  
 
The majority of CT genes discovered to date are localised on the X chromosome (Kalejs and 
Erenpreisa, 2005). Examples of CTAs which have been proposed to be used as tumour 
biomarkers are MAGE-A1/A3 for hepatocellular carcinoma and lung adenocarcinoma (Qiu et 
al., 2006), BORIS for breast cancer (D'Arcy et al., 2006) and NY-ESO-1 for lung 
adenocarcinoma (Gure et al., 2005).  
 
Recent study showed that germline genes, including testis-specific/placenta-specific (TS/PS) 
genes, can be used as prognostic markers in lung cancer patients at all disease stages. These 
9 
 
are good sources of cancer biomarkers because their expressions were not observed in the 
healthy normal tissues other than the testis or placenta (Rousseaux et al., 2013).  
 
1.2.2 Classification and expression of CT genes 
The available CTA database has identified more than 100 gene families of potential CT 
genes, with over 280 members known to date. The CTA members, their gene expression 
profiles and other characteristics are summarised on a single website supported by the Ludwig 
Institute (http://www.cta.lncc.br/) (Almeida et al., 2009).  
 
CT genes can be classified into two groups according to their chromosomal location. The X-
CT group is located on the X chromosome, and those located on the autosomes are called the 
non-X-CT group. In the normal testis, most of the X-CT genes are expressed in the 
spermatogonia stage of spermatogenesis, and their function remains poorly understood. The 
X-CT genes such as MAGE-A3, MAGE-8, MAGE-A10, XAGE-2 and XAGE-3 are also 
expressed in the placenta in addition to the testis (Caballero and Chen, 2009). Some somatic 
tissues such as the liver, pancreas and spleen show the expression of mRNA of distinct CTAs, 
but quantitative RT-PCR analysis indicates these mRNA levels are normally less than about 
1% of their expression in testicular germ cells (Caballero and Chen, 2009). In contrast, many 
of the non-X-CT genes are expressed in spermatocytes and perform several tasks during 
meiotic cell division (Caballero and Chen, 2009; Simpson et al., 2005). It has been proposed 
that the aberrant expression of CTA genes in malignant cells may result in abnormal 
chromosome segregation and aneuploidy, thereby giving rise to tumourigenesis (de Carvalho 
et al., 2011; Fratta et al., 2011; Whitehurst, 2014).  
 
Members of X-CT genes are found mostly as multi-copy, paralogous gene families, some also 
express splice variants. Examples of these families are MAGEA, GAGE, PAGE, XAGE1, and 
SSX (Figure 1.2). The CT genes located on autosomal chromosomes are mostly single-copy 
genes. A many as 10% of the genes on the X chromosome have been estimated to be X-CT 
genes (Ross et al., 2005). Of the CT genes identified, 52% are distributed on the X 
chromosome, while the remaining (non-X-CT genes) are located on the 22 autosomal 
chromosomes and the Y chromosome (Rajagopalan et al., 2011). 
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Figure 1.2 Distribution of X-CT genes on the X-chromosome. Different families of cancer testis 
genes located on the X-chromosome. The number of individual gene families is shown between 
brackets (Adapted from Caballero and Chen, 2009). 
11 
 
The expression of CT genes in the testis is restricted exclusively to spermatogenic germ cells, 
which include spermatogonia, primary spermatocytes, secondary spermatocytes, spermatids 
and spermatozoa. However, the various CT genes are expressed at different stages of sperm 
development. The expression of some CT genes is controlled by promoter demethylation, 
indicating as the presence of a testis-specific demethylation mechanism (Fratta et al., 2011; 
Shichijo et al., 1996). 
 
CT antigens have been further classified according to their gene expression profiles into four 
groups: (a) Testis-restricted (expressed only in the adult testis, placenta and at least one cancer 
type); (b) Testis-brain-restricted [expressed in the adult testis, central nervous system (CNS) 
and at least one cancer type]; (c) Testis-selective (expressed in the adult testis and no more 
than two additional normal tissues at lower expression levels than in the testis, and at least 
one cancer type) (Hofmann et al., 2008); and (d) Testis-brain-selective (expressed in the adult 
testis, CNS tissue, and no more than two additional normal tissues at lower expression levels 
than in the testis, and at least one cancer type) (Feichtinger et al., 2012a). 
 
According to Hofmann et al. (2008), 153 distinct CT genes or isoforms have been described 
in normal and cancer gene expression libraries. These genes are divided into three categories: 
testis-restricted, testis-selective and testis-brain-restricted. The chromosomal distribution for 
each group is shown in the following table:  
 
CT gene group X-CT Non-X-CT mRNA expression in normal tissue 
Testis-restricted 35 genes 4 genes In testis and sometimes in placenta 
Testis-selective 36 genes 64 genes In testis and different normal tissues 
Testis-brain-restricted 12 genes 2 genes In testis and CNS tissue 
 
1.2.3 Functions of cancer testis genes in normal and tumour cells 
CTAs have become the most widely studied antigen group in the cancer immunology field. 
The biological functions of the majority of these genes in both the germ line and tumour cells 
remain largely unexplored and the connection between gametogenesis and cancer is very 
poorly understood (Kalejs and Erenpreisa, 2005). However, some CT genes have been 
identified by their functions in normal cells. For instance, synaptonemal complex protein 1 
(SYCP1) functions in chromosome synapsis during meiosis I (Schramm et al., 2011; Tuereci 
et al., 1998). The OY-TES-1 gene plays an essential role in acrosin packaging in the 
acrosome of sperm heads (Ono et al., 2001). SPO11 acts as a meiotic endonuclease and 
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generates DNA double-strand breaks to initiate meiotic homologous recombination (Yamada 
and Ohta, 2013). BORIS has an important role in regulating the promoter methylation process 
through spermatogenesis by removing imprinting from genes during the final round of mitosis 
in spermatocytes (Klenova et al., 2002; Loukinov et al., 2002; Martin-Kleiner, 2012).  
 
Although the function of many of these tumour-associated antigens in the disease process is 
not completely clear, limited evidence infers that they function in many vital cellular 
processes such as cell growth and transcriptional regulation (Scanlan et al., 2002). Some also 
appear to function as putative proto-oncogenes, such as Piwil2 that promotes cell proliferation 
(Cheng et al., 2011). 
 
A soma-to-germline transition may result in cancer progression. For example, investigation of 
the expression patterns of the human orthologues of the Drosophila melanogaster germline 
genes that are normally expressed in brain tumours indicated that most of these genes are 
generally expressed in germlines and in various human cancer types (Feichtinger et al., 2014). 
Therefore, the expression of these germline genes has a core role in oncogenesis in D. 
melanogaster (Janic et al., 2010) and potentially in humans (Feichtinger et al., 2014). 
Inhibition of some of germline genes leads to repression of tumour development, 
demonstrating that these genes could play a fundamental role in tumourigenesis (Janic et al., 
2010). 
 
1.2.4 Regulation of CTA gene expression 
The expression of some CT genes is regulated by DNA methylation and by modification of a 
specific amino acid in the N-terminal tail of histone (see Section 1.1.5). DNA methylation 
mainly occurs in the gene promoter region, and is carried out by DNA methyltransferase 
enzymes (DNMTs). This process is responsible for CTA gene silencing (for example, see Bai 
and Zhang, 2010). In somatic tissues, the promoter regions for all X-CT genes contain CpG 
islands and are often methylated and therefore not expressed (Simpson et al., 2005). DNA 
hypomethylation is the most frequently reported mechanism for gene expression activation in 
many cancer types (Wang et al., 2004). DNA hypomethylation reportedly promotes the 
expression of some CT genes; for instance, the melanoma-associated antigen family A 
(MAGE-A1) gene in different cancer cells (De Smet and Loriot, 2010) and the cancer-
associated gene (CAGE) in gastric cancer (Lee et al., 2006). Hypermethylation of the MAGE 
promoter results in repression of its expression (Wischnewski et al., 2007).  
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DNA methylation is the primary silencing mechanism for CT genes. Inhibition of CT gene 
transcription is caused either by preventing the binding of specific transcription factors (TFs) 
to the DNA via methylated recognition sequence, or by the binding of methyl-CpG-binding 
proteins, which prevent gene expression of methylated genes (Fratta et al., 2011). On the 
other hand, demethylation is necessary for their expression. For instance, a direct correlation 
exists between demethylated CpG islands in the MAGE-A1 5' promoter region and its 
expression (De Smet et al., 1999). The expression of CT genes such as SSX and NY-ESO-1 
can be induced or upregulated in tumour cells by treatment of the cell lines with either DNA 
methyl-transferase 1 inhibitor (DNMTi), the DNA methyl transferase inhibitor 5-aza-2'-
deoxycytidine (5-azaC) (Grunwald et al., 2006; Wang et al., 2004), and/or by histone 
deacetylase inhibitor (HDACi) (Akers et al., 2010). Indeed, 5-azaC has been shown to induce 
expression of many of CT genes, especially the X-CT genes (Almstedt et al., 2010). 
Treatment of different human ovarian cancer cell lines with 5-azaC results in increases in the 
mRNA expression of 11 out of 12 CT genes, which include MAGE-A1, MAGE-A3, MAGE-
A4, MAGE-A6, MAGE-A10, MAGE-A12, NY-ESO1, TAG-1, TAG-2a, TAG-2b and TAG-2c 
(Adair and Hogan, 2009).  
 
Deacetylation is achieved by histone deacetylases (HDACs); consequently, repression of the 
HDACs by a specific inhibitor will result in up regulation of many CT genes (Akers et al., 
2010; Barneda-Zahonero and Parra, 2012). The CTA genes MAGE-A9 and MAGE-A11 are 
silenced by DNA hypermethylation and also by histone deacetylation in breast cancers (Hou 
et al., 2013a). 
 
1.2.5 CTAs as targets for immunotherapy and cancer vaccines 
Many studies have been published about the medical use of CTAs as potential targets for 
cancer bio-markers and immunotherapy (Houghton et al., 2001; Mellman et al., 2011; Rosa et 
al., 2012). 
  
Most tumour specific antigens contain small antigenic peptides regions of the protein that can 
be presented on the surface of cancerous cells by the major histocompatibility complex 
(MHC) molecule, also known as the human leukocyte antigen (HLA). This MHC peptide 
complex can be recognised by the cytotoxic T lymphocytes (CTLs), which then kill the 
tumour cell (Adair and Hogan, 2009). The presence of the blood-testis barrier (BTB) (Li et 
al., 2012) and the absence of HLA class I expression on the surface of testis germ cells 
(Ghafouri-Fard and Modarressi, 2012a) prevent the human immune system from interacting 
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with CTA proteins in the testis, so that these antigens are not recognised as self-structures and 
are immunologically targeted (Kalejs and Erenpreisa, 2005). 
 
Treatment of cancer via chemotherapy and radiotherapy is often characterised by a high level 
of toxicity and a low level of efficiency. However, immunotherapy can target tumour cells 
with less toxicity to normal tissues (Aly, 2012). Immunotherapy is considered as a potentially 
powerful form of cancer therapy (Mellman et al., 2011; O’Shea et al., 2014). For example, 
autologous CD4
+
 T-cells harvested from a patient diagnosed with a metastatic melanoma 
using an immune reactive CTA, NY-ESO-1 peptide; these isolated T-cells were cultured and 
expanded in vitro for cellular therapy and infused back into the same patient, whose tumour 
burden was depleted; a CT scan done two months after the infusion showed that the 
metastasised tumours were completely lost and the patient remained disease free for over two 
years after receiving the adoptive therapy (Hunder et al., 2008). This is just one example of 
successful adoptive therapeutics using CTAs in immunologically reactive cancers, such as 
melanomas. 
 
Neither normal testicular germ cells nor placental cells express the human leukocyte antigen 
class I molecule. Therefore, CTAs are not normally targeted by CD8
+ 
cytotoxic T 
lymphocytes. For this reason, CTAs are considered attractive targets for antitumour cell 
vaccines (Jungbluth et al., 2005). Vaccination with CT antigens has considerable potential for 
treating cancer (Renkvist et al., 2001; Blanchard et al., 2013). The majority of cancer 
vaccines are antigens expressed by human cancer cells and recognised by the human CD8
+
 
and CD4
+ 
T-cells (Greten and Jaffee, 1999; Blanchard et al., 2013). Cancer vaccines based on 
the CT antigens MAGE-A1 (melanoma antigen A1) and NY-ESO-1, are currently being tested 
in an attempt to stimulate the T-lymphocyte response against malignancy (Caballero and 
Chen, 2009) and as an essential target for vaccination against various human tumours 
(Campos-Perez et al., 2013).  
 
1.3 Spermatogenesis 
1.3.1 Spermatogenesis overview  
Gamete cells act as a link between generations and they transfer genetic information from 
parents to child. The father contributes genetic information via the sperm. In humans, sperm 
production begins at puberty and usually continues into old age (Mruk and Cheng, 2010; 
Rooij and Russell, 2000). Spermatogenesis is a very complex, highly organised and regulated 
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process that occurs in the seminiferous tubules, the functional unit of the testis that can 
produce sperm (O’Donnell et al., 2006). The seminiferous tubules are highly coiled loops; 
they contain Sertoli cells and germ cells and are bordered by a layer of peritubular cells, 
which provide structural support (Figure 1.3A). The production of spermatozoa in humans is 
regulated by follicle stimulating hormone (FSH) and luteinising hormone (LH) 
(O’Shaughnessy, 2014) and through the effects of retinoic acid (RA) (Hogarth and Griswold, 
2013). Both hormones are released by the pituitary gland (Holdcraft and Braun, 2004). LH 
binds to the LH receptors in Leydig cells, which are found in the space between the 
seminiferous tubules, to produce the male steroid hormone testosterone. Sertoli cells are 
regulated by FSH and testosterone. Therefore, any mutations or changes in the genes that 
encode these hormones or their receptors may have effects on normal sperm production (Ge et 
al., 2009; Holdcraft and Braun, 2004; Phillips et al., 2010). 
 
1.3.2 Structure of the seminiferous tubule  
Spermatogenesis consists of four major phases: (a) Proliferation of progenitor cells via 
mitosis; (b) Meiotic division of diploid cells to form haploid cells; (c) Cellular differentiation 
of spermatids to form spermatozoa; and (d) The release of sperm from the seminiferous tubule 
epithelium into the seminiferous tubule lumen (Hess and de Franca, 2009).  
 
The progenitor cells are normally called spermatogonia, and are divided into undifferentiated 
and differentiation spermatogonia. The undifferentiated spermatogonia include the stem cells, 
which are termed spermatogonial stem cells (SSCs). When the SSCs undergo division, they 
produce two types of cells with different functions: self-renewal (A type) and differentiation 
(A1 type). Cells destined for self-renewal remain as stem cells, while cells that undergo 
differentiation continue to undergo the phases of mitotic division before entering meiosis to 
produce primary spermatocytes (Griswold et al., 2012; Mruk and Cheng, 2010). The primary 
spermatocytes undergo the first phase of meiotic division (see Section 1.4.3) to form 
secondary spermatocytes. These cells will also divide through meiosis II to produce four 
haploid cells, the round spermatids, which result from the division of every spermatocyte. 
Each round spermatid cell then differentiates to form elongated spermatids; this process ends 
when the cells are released from the seminiferous epithelium into the seminiferous tubule 
lumen. At this point, the released cells are termed spermatozoa (Figure 1.3B) (Rooij and 
Russell, 2000). These spermatogenesis cell types are associated with and supported by Sertoli 
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cells via cell-cell contact with the germ cells. From the testis tubules, spermatozoa flow into 
the epididymis via the rete testis to become mature (Holstein et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epididymis 
Seminiferous tubule 
A 
Peritubular tissue 
Spermatogonium 
Primary spermatocyte 
Round spermatids 
Elongated spermatids 
B 
Figure 1.3 The structure of the human seminiferous tubule. (A) The human testis is 
composed of seminiferous tubules. (B) A cross-section of an adult human testis, showing a 
section of seminiferous tubule at different stages of their development of sperm cell 
production during spermatogenesis (Adapted from Holstein et al., 2003). 
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1.3.3 Structure and functions of the blood-testis barrier  
The testis is a site of immune privilege, protected by the BTB, which is one of the tightest 
blood-tissue barriers in mammals (Li et al., 2012; Lie et al., 2013; Mruk and Cheng, 2010). 
The seminiferous epithelium is anatomically divided into two distinct basal and luminal 
compartments by the BTB, which is found near the basement membrane in the human testis. 
The SSC and spermatogonia reside in the basal compartment of the seminiferous epithelium, 
whereas the remaining germ cells reside in the luminal compartment (Fijak and Meinhardt, 
2006; Mruk and Cheng, 2010). The BTB is formed by specialised tight junctions between 
adjacent Sertoli cells in the seminiferous epithelium (Figure 1.4) (Su et al., 2011).  
 
Large molecules, particularly proteins, cannot diffuse from the blood into the lumen of a 
seminiferous tubule owing to the presence of the BTB. This prevents the production of anti-
sperm antibodies, which would result in infertility (Mirandola et al., 2011). The presence of 
autoantigens in the germ cells, outside of the BTB in the basal compartment of the 
seminiferous epithelium is quite remarkable. Cancer-testis antigens are produced in these 
germ cells; however, no male human antibodies are developed against those autoantigens 
within germ cells, except in pathological conditions even through the cells reside outside the 
BTB (Caballero and Chen, 2009; Simpson et al., 2005). This is because the human leukocyte 
antigen is not expressed in germ cells. Therefore, gene expression does not result in the direct 
presentation of the antigenic peptides and these normal germ cells should not be the immune 
responses targets (Ghafouri-Fard and Modarressi, 2012a).    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 The blood-testis barrier. The location of the blood-testis barrier during the seminiferous 
epithelium cycle of spermatogenesis in the human testes. The main task of the BTB is to protect the 
developing germ cells from autoimmune attack (Adapted from Modarressi and GhafouriFard, 2011). 
Blood 
Testis 
Barrier 
r 
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Luminal compartment  
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1.3.4 The role of retinoic acid in spermatogenesis  
Spermatogenesis is a highly regulated process of cellular differentiation that leads to to the 
initiation of mature sperm from spermatogonial stem cells. One regulatory compound is 
retinoic acid (RA), a metabolite of Vitamin A (retinol), which is essential for male 
reproduction. The action of RA in the testis is mediated by activation of its receptors (Livera 
et al., 2002; Wang and Wu, 2013). Vitamin A is normally stored in the liver and Sertoli cells 
and transported to target tissues. However, spermatids and testicular and epididymal sperm 
also store retinoids (Ren and Bishop, 1989). Oxidation of Vitamin A to produce RA generally 
occurs within the target tissues (Paik et al., 2004).  
 
RAs have two distinct families of intercellular receptors. The first type is the retinoic acid 
receptors (RARs), which bind all-trans and 9-cis RA and the second receptor type is the 
retinoid X receptors (RXRs), which bind 9-cis retinoic acid only (Livera et al., 2002). In 
addition, each family comprises three classes, α, β, and γ, each encoded by different genes. 
RARα is expressed mainly in the Sertoli cells, RARβ in spermatids and RARγ in 
spermatogonia (Vernet et al., 2006).  
 
These receptors are present in the testis at different developmental stages. The function of 
these receptors is to regulate gene expression by binding to specific elements in the promoter 
regions of genes under the control of retinoic acids (Doyle et al., 2007). Regulation of the 
expression of RA receptors is clearly essential for mammalian spermatogenesis and fertility. 
In the mouse, the spermatogenesis process is arrested at the A spermatogonia stage under 
conditions of Vitamin A deficiency. However, addition of Vitamin A restores the 
differentiation of spermatogonia to A1 spermatogonia (Hogarth and Griswold, 2010). Recent 
studies support the conclusion that retinoic acid is required for adult male spermatogonial 
differentiation (transition from A to A1) and the entrance into meiosis (Figure 1.5) (Matson et 
al., 2010; Snyder et al., 2010). 
     
Sertoli cells have been determined to be the main site of RA synthesis in the testis and are 
also responsible for delivering RA to germ cells. The Sertoli cells also distribute Vitamin A to 
germ cells or spermatogonia, which can access Vitamin A and RA directly from serum by 
means of the vascular system (Livera et al., 2002). Inside the cells, such as in spermatogonia, 
RA is mainly produced from Vitamin A by two biochemical steps. The first step is the 
oxidation of Vitamin A into retinaldehyde and the second step is conversion of retinaldehyde 
to RA (Figure 1.6) (Griswold et al., 2012). 
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Mitosis 
RA 
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Meiosis 
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A spermatogonia 
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Figure 1.5 Regulation of cellular differentiation in the mammalian testis. The different stages 
of spermatogenesis in the adult, which takes place in the seminiferous epithelium of the testis 
tubules. These germ cells are regulated by different regulators. For example, undifferentiated (A 
type) and differentiated (A1 type) spermatogonia undergo mitotic division, regulated by the FSH 
hormone. Retinoic acid (RA) also appears to be a requirement for the proliferation and 
differentiation of spermatogonia A to A1 and for the production of spermatocytes. The initiation 
of meiotic division also requires RA. Testosterone is needed for the differentiation of secondary 
spermatocytes and spermiogenesis, which includes round spermatids, elongated spermatids and 
finally forms functional gametes called spermatozoa or sperm (Adapted from Hogarth and 
Griswold, 2010). 
Figure 1.6 Metabolism of Vitamin A in the spermatogonia.  The metabolisme of Vitamin A and the 
cellular mechanism of RA action in the spermatogonia. Vitamin A is provided to the germ cells by the 
blood, where it circulates and binds to retinol-binding protein (RBP). The RBP carries the majority of 
retinol in the circulation and binds to the membrane receptor, STRA6 to facilitate the cellular uptake 
of retinol inside the cells. However, RA is also provided directly inside the spermatogonia by means of 
Sertoli cells or by serum. Vitamin A can also be converted to RA by a two-step process. The produced 
RA is then bound to cellular RA binding protein (CRABP), which facilitates its transport to the 
nucleus. In the nucleus, RA is bound to the RARs, such as RARγ, to form the RA/RAR complex, 
which allows chromatin opening and stimulates transcriptional activity of a number of genes, such as 
STRA8 that has been identified to have an essential role in meiotic progression. Degradation of RA is 
also an important process to protect cells from excessive RA stimulation. The RA degradation occurs 
by CYP26B1 enzyme to produce 4-oxo and 4-hydroxy forms, which are then secreted across the cell 
membrane (Adapted from Hogarth and Griswold, 2010). 
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1.4 Meiotic division in eukaryotic cells 
1.4.1 Meiosis and sexual reproduction 
In the sexual reproduction process, two gametes fuse during fertilisation to produce a zygote. 
However, to prevent the doubling of the genetic material during cell division with every new 
generation, the number of chromosomes must be reduced by half during the formation of the 
gametes. This reduction process is performed by a specialised nuclear division termed meiosis 
(Petronczki et al., 2003). Non-reproductive cells comprise two distinct copies of each 
chromosome, called homologues. One homologous chromosome is inherited from the 
paternal lineage, and one from the maternal lineage (Lee and Amon, 2001; Villeneuve and 
Hillers, 2001). 
 
Meiosis takes place solely in the testes (males) and ovaries (females) to produce haploid sex 
cells or gametes, the sperm and egg, from diploid progenitor cells (Page and Hawley, 2003). 
Meiotic division consists of two types of cell division: the first is a reductional division 
(meiosis I) and the second is an equational division (meiosis II) (Gerton and Hawley, 2005).   
 
1.4.2 Phases of cell division 
The interval time between each mitotic cell division is termed a cell cycle (Boydston-White et 
al., 2005). The mitotic cell cycle consists of two basic stages: interphase and M phase. 
Interphase can be subdivided into three ordered stages: G1 (Gap 1), S (DNA synthesis) and 
G2 (Gap 2) (Figure 1.7). S phase is defined as the stage where the DNA replication occurs 
and the M phase is where the cell is ready to divide into 2 daughter cells (mitosis). There are 
two gaps before the S phase and after the M phase, G1 and G2. In the G1 phase, the cell is 
growing and also preparing for the process of DNA replication, whereas in the second gap, 
G2, which comes after the S phase, the cell prepares for the process of division (Strahm and 
Capra, 2005; Thomas and Goodyer, 2003). Non-dividing cells exist outside of the cell cycle 
in a phase called G0 (O’Farrell, 2011). Most cells spend the majority of their time in 
interphase; M phase makes up only a relatively short period (Boydston-White et al., 2005). 
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Figure 1.7 The progression of mitotic cell cycle. The phases of the cell cycle are designated G1, S, 
G2, and M. In the first gap, the cells increase in size. In the S phase, DNA synthesis occurs to produce 
DNA ready for cell division. In the second gap, the cells grow and produce new proteins. In the M 
phase, cell growth stops, and each cell undergoes orderly division. In the G0 phase, the cell is in a 
resting state and does not progress through the cell cycle. (Adapted from Foster, 2008). 
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1.4.3 The first meiotic division, Meiosis I 
Meiosis I is divided into four phases: prophase I, metaphase I, anaphase I, and telophase I. 
Prior to meiosis, chromosome duplication occurs during the interphase stage in order to 
double the sister chromatid pairs. The sister chromatids remain associated at the centromeres; 
consequently, each set of chromosomes is composed of two identical sister chromatids (Lee 
and Amon, 2001).  
 
Many unique events take place during prophase I, including homologous chromosome 
pairing, synapsis, DNA double-strand break (DSB) formation and repair, crossover, and 
chromosome condensation (Kleckner, 1996). Prophase I can be sub-classified into five stages: 
leptotene, zygotene, pachytene, diplotene and diakinesis, on the basis of the morphology of 
chromosomes and the association of homologous chromosomes during synapsis (Klutstein 
and Cooper, 2014; Tsai and McKee, 2011).  
 
In the first sub-stage, leptotene, the duplicated sister chromatids start to condense and coil, 
and the chromosomes become shorter and thicker. In the zygotene sub-stage, homologous 
chromosomes draw close to each other to a distance of roughly 100 nm mediated by a special 
structure celled the synaptonemal complex (SC), which begins to form between paired 
homologous chromosomes in a process termed synapsis. As a result, the pairs of 
chromosomes consist of four chromatids, with one chromosome coming from each parent. 
Each pair of homologous chromosomes is known as a bivalent. By the third sub-stage, 
pachytene, synapsis is complete and the paired chromosomes are held together tightly with 
the aid of the SC and structures termed chiasmata (Youds and Boulton, 2011). The chiasma is 
the physical link between homologous chromosomes during meiosis (Hirose et al., 2011). In 
addition, crossing over between homologous chromosomes occurs and DNA is exchanged 
between the bivalents in a process called homologous recombination (Bowles and Koopman, 
2007; Youds and Boulton, 2011). One consequence of crossing over is the generation of a 
new combination of genetic material in the gametes. In the fourth sub-stage, diplotene, the 
homologous chromosomes begin to separate in a process called desynapsis, but remain 
connected through sister chromatid cohesion and chiasmata until anaphase I. The final 
subdivision of prophase I is diakinesis. In this sub-stage, the SC has completely dissociated, 
the chromosomes continue to condense further and spindle formation occurs (Tsai and 
McKee, 2011). 
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In metaphase I, spindle fibres are formed and the bivalents are aligned in a double row along 
the metaphase plate of the cell. The chiasmata promote the monopolar orientation of the sister 
kinetochores, which leads to the correct segregation of the maternal and paternal 
chromosomes to opposite poles (Hirose et al., 2011). In anaphase I, sister chromatid cohesion 
along the chromosome arms is resolved, but the sister chromatids remain bound to each other 
at the centromeres until the beginning of anaphase II. At this stage, the microtubules pull one 
set of homologous chromosomes toward the opposite poles of the cell (Lee and Amon, 2001; 
Villeneuve and Hillers, 2001). The microtubule has two ends; one end links to the kinetochore 
on the chromosome centromere, but the other end is linked to a centrosome or a spindle pole 
body in human and yeast cells, respectively (Miller et al., 2012). In telophase I, a new nuclear 
membrane forms around the segregating chromosomes to produce two separate nuclei. The 
resulting nuclei comprise half the number of chromosomes of the original cell and so   
meiosis I is reductional in nature (Villeneuve and Hillers, 2001).  
 
1.4.4 The Second meiotic division, Meiosis II 
Meiosis II, an equational division that does not reduce chromosome number, is a mitosis-like 
division. When meiosis II begins, each daughter nucleus contains the haploid number of 
chromosomes, and each chromosome consists of two chromatids associated at the centromere. 
For this reason, the second meiotic division is necessary to segregate the chromatids from 
each other (Page and Hawley, 2003). It is shorter than meiosis I, although it consists of four 
phases: prophase II, metaphase II, anaphase II, and telophase II. It occurs without further 
DNA replication (Wassmann, 2013).  
 
During prophase II, the chromosomes condense again and the membrane of the nucleus 
breaks down. In metaphase II, each chromosome contains two chromatids, and these are 
arrayed on the cell equator by spindle fibres. In anaphase II, the centromere of each 
chromosome separates, and the spindle fibres pull one chromatid of each chromosome to the 
opposite end of the cell (Tsai and McKee, 2011). At the end of meiosis II, cytokinesis (the 
division of the cytoplasm) occurs to divide the original cell into four new haploid cells 
containing half the original number of chromosomes, each with a diverse genotype. This stage 
is called telophase II (Page and Hawley, 2004; Zickler and Kleckner, 1998). During meiosis 
II, the sister kinetochores are attached to microtubules from the different pole (Bio-orientated) 
(Dudas et al., 2011). The key stages of the two divisions of meiosis are shown in Figure 1.8. 
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Figure 1.8 The process of meiotic cell division. Meiosis consists of one round of DNA replication 
that occurs in S phase followed by two nuclear divisions including meiosis I and meiosis II. Each 
sister chromatid in a non-homologous chromosome, before entering meiosis I, joins by cohesin 
complexes (yellow). In prophase I, homologous chromosomes connect to each other and 
recombination takes place to form chiasmata. Homologous centromeres attach to the microtubules 
from the spindle poles (SPB), which is known as the centrosome in eukaryotes. The paired 
homologues (bivalents) are aligned on the metaphase plate during metaphase I. This is followed by 
segregation of homologues to the opposite poles of the cell to initiate anaphase I with the resolution of 
chiasmata. The generation of two daughter cells occurs at telophase I. In meiosis II, chromosomes 
align along the metaphase plate during metaphase II and then the sister chromatids separate from each 
other in anaphase II. The process ends with telophase II producing four haploid cells containing half 
the original number of chromosomes. Cohesin along chromosome arms in meiosis I is cleaved from 
the bivalent at anaphase I to facilitate segregation of homologues, but the cohesin at the centromeres 
(sister kinetochores) is protected, which keeps the two sister chromatids bound to each other. 
However, at anaphase II, the cohesin remaining (centromeric cohesin) between sister kinetochores is 
removed, which allows the sister chromatids to orient, segregate and to move to the opposite poles 
(Adapted from Miller et al., 2013). 
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1.4.5 Differences between meiosis in human males and females  
Gametes are haploid, and are produced by meiosis starting from a diploid germ cell. The 
process of meiosis is extremely important for both males and females; however, there are 
some essential differences between the sexes. Meiosis begins during foetal development in 
females and after birth in males. The primary oocytes are analogous to the primary 
spermatocytes in the male. In females, the primary oocyte undergoes meiosis I up to the 
diplotene sub-stage of prophase I, and then meiosis is arrested. Once the female reaches 
puberty, in every menstrual cycle, one of the arrested primary oocytes will proceed to 
complete meiosis I to form secondary oocyte and a first polar body (PB1). However, the 
secondary oocyte will enter meiosis II and arrest again in metaphase II and it remains in arrest 
until fertilisation occurs, at which time the entire meiotic process is completed and a second 
polar body (PB2) is formed. One oocyte will only produce one functional gamete termed an 
ovum or egg (Bowles and Koopman, 2007; Holt and Jones, 2009; Hou et al., 2013b). In 
contrast, in males, germ cells are arrested in spermatogonia at G0/G1 stage of the mitotic cell 
cycle. Therefore, the mitotic division will not complete and meiosis will not initiate until the 
embryos are born. After the first week of life, meiosis I is completed and secondary 
spermatocytes are formed, but the division is arrested again until puberty. Once the male 
reaches puberty, the arrested secondary spermatocytes will continue to complete meiosis II, 
forming 4 functional gametes termed spermatozoa from one spermatocyte (Figure 1.9) 
(Clagett-Dame and Knutson, 2011; Hunt and Hassold, 2002). 
 
1.4.6 Generation and repair of meiotic DNA Double-Strand Breaks (DSBs) 
Meiotic DSBs are generated by the SPO11 protein (topoisomerase type II-like) (Bergerat et 
al., 1997; Keeney et al., 1997). Most organisms have only one copy of SPO11, and the 
protein acts as a homodimer to make DSBs (Kenney and Neale, 2006). SPO11 is also 
essential for the assembly of the SC (Keeney, 2001). SPO11 relies on many accessory factors 
that support its activation (Keeney and Neale, 2006). Meiotic DSBs are concentrated in 
narrow regions of chromosomes known as hotspots, which have high rates of meiotic 
recombination (Baudat et al., 2013; de Massy, 2013). After generating DSBs, SPO11 remains 
covalently bound to the 5' end of each DNA strand and must be removed to generate single-
strand 3' ends (Longhese et al., 2010).  
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Figure 1.9 Schematic diagrams showing the distinction between meiosis in the testes and 
ovaries. Meiosis in women initiates in embryogenesis (before birth) and arrests in the prophase 
of meiosis I. The primary oocytes remain in this state until just before ovulation, at which point 
they complete of the first division and begin the second division, which is arrested again in 
metaphase II. After fertilisation of the egg, meiosis II is completed. By contrast, in men, germ 
cells are arrested in mitotic process in embryogenesis and are completed after birth. Primary 
spermatocytes initiate both meiotic divisions after birth and complete at puberty (Adapted from 
Clagett-Dame and Knutson, 2011). 
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SPO11 is removed by the MRN complex, which also functions in the early steps of meiotic 
DSB repair in somatic cells (Neale and Keeney, 2006). The MRN complex is an 
endonuclease, and consists of three proteins, MRE11, RAD50 and NBS1 in mammals and 
fission yeast and the MRX (Mre11, Rad50 and Xrs2) in budding yeast (Lisby et al., 2004). 
These proteins have an important role in repairing DSBs in somatic and meiotic cells (Borde, 
2007; Stracker and Petrini, 2011).  
 
1.4.7 Mechanism of meiotic recombination 
Meiotic recombination is essential to meiotic division among most eukaryotes. It may result 
in both the formation of crossovers (resulting from reciprocal exchange between homologous 
chromosomes), or non-crossover (nonreciprocal exchange). A minority of the meiotic DSBs 
result in crossover products in eukaryotic cells (Sung et al., 2003; Youds and Boulton, 2011). 
In mitotic cells, repair of DSBs occurs mostly via the sister chromatid, and noncrossover 
recombination is the predominant pathway. In meiotic cells, sister chromatid repairing is 
repressed, and the invasion of one chromatid of the homologues is stimulated (see Section 
1.4.8) (Niu et al., 2005). 
 
The functions of recombination in mitotic cells and meiotic cells are distinct. Mitotic 
recombination occurs in somatic cells to repair DSBs caused by either a DNA replication 
problem or exposure to DNA damaging agent, such as ionising radiation and/or genotoxic 
chemicals. In contrast, meiotic recombination has two functions. First, it is very important in 
forming a physical connection between homologues and it plays a fundamental role in 
chromosome alignment and segregation in meiosis I. Second, homologous recombination 
promotes genetic variation by generating new combinations of paternal and maternal alleles 
(Strom and Sjogren, 2007). 
 
1.4.8 Induction of crossover (CO) and non-crossover (NCO) 
Two main models for the meiotic recombination mechanism have been proposed for both 
meiotic and mitotic divisions. The first model is DSB repair (DSBR) and the second is the 
synthesis-dependant strand annealing (SDSA) pathway (Figure 1.10). Meiotic recombination 
starts when a DSB occurs in one chromatid in a homologue pair. Fragments of DNA around 
the 5'
 
ends of the break are cut away by MRN complex. The generated 3' ends are covered 
with proteins called RAD51 and DMC1 in mammals (Rad51 and Dmc1 in S. cerevisiae) (San 
Filippo et al., 2008), which promote the invasion of the opposite homologous DNA duplex in 
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a process called strand invasion, to generate a heteroduplex and a displacement loop (D-loop) 
that is completed by DNA synthesis (de Massy, 2003; Handel and Schimenti, 2010; Hunter 
and Kleckner, 2001; Youds and Boulton, 2011). The recombinase, RAD51, is essential for 
both meiotic and mitotic recombination, but DMC1 is a meiosis-specific protein that is 
required for normal meiosis (Serrentino and Borde, 2012). 
 
The result of this process is either crossover or non-crossover products. Most DSBs are 
repaired by SDSA, but about 15% of DSBs are repaired by DSBR. In the DSBR pathway, the 
second end of the DSB is captured; as a result, a structure called a double Holliday junction 
(dHJ) is formed by DNA synthesis and ligation. The Holliday junction is then cleaved in the 
same direction (vertical or horizontal) or the opposite direction (vertical and horizontal) 
followed by DNA ligation to produce non-crossover (NCO) or crossover (CO), respectively 
(Cromie and Smith, 2007; de Massy, 2003; Hunter and Kleckner, 2001; Youds and Boulton, 
2011). Models have also been proposed involving single Holliday Junctions, but it remains 
unknown which is correct for human meiosis (Cromie and Smith, 2007). 
 
In the SDSA model, the DSBs occurs without the formation of the dHJs, so the D-loop is 
released by displacement of the newly synthesised DNA, which anneals to the other ssDNA 
end of the break. Repair of the break leads to generate either gene conversion or non-
crossover (de Massy, 2003; Hunter and Kleckner, 2001). Resolution of dHJ during meiosis in 
budding yeast can be performed via three different resolvase enzymes (nucleases), Mus81-
Mms4, Slx1-Slx4 and GEN1/Yen1, but can also be resolved by the Exo1 exonuclease, Sgs1 
and the MutLγ complex (M1h1-M1h3) (Zakharyevich et al., 2012). 
 
1.4.9 The cohesin complex 
The cohesin complex is a complex protein that binds the sister chromatids together along 
chromosome arms and at the centromere (Figure 1.11). The cohesin complex associates with 
chromosomes during the DNA replication (S phase) of both mitotic and meiotic cells (Mehta 
et al., 2013; Nasmyth, 2001). Defects in sister chromatid cohesion may result in the 
generation of aneuploidy and cancer (Barber et al., 2008; Sajesh et al., 2013). Cohesin is 
responsible for sister chromatids pairing and separating, as well as the repair of DNA DSBs 
during either mitosis or meiosis (Ishiguro et al., 2014; Sjögren and Ström, 2010) and it is also 
important for the generation of tension across centromeres (Ishiguro and Watanabe, 2007). 
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Figure 1.10 The mechanism of DSB repair for meiotic recombination in meiosis I. The DSBs 
are mainly formed by SPO11 and one SPO11 protein remains covalently bound at each 5' end of the 
DSB. The 5' end is removed by the MRN complex and single strand (ssDNA) overhangs is generated 
in both sides of the DSB ends. One of the overhanging 3' ended tail invades the homologous 
chromosome (single end invasion). However, the repair mechanism can follow two different 
pathways. First, in the DSBR pathway, the second 3' overhang invades the displaced strand (second 
end capture) and DNA synthesis produces a double Holliday junction (dHJ). Therefore, the dHJ 
resolution gives rise to either CO or NCO products. Second, in the SDSA pathway, the DSBs occur 
without the creation of a dHJ, which results in an NCO product. Meiotic recombination of the 
majority of DSBs results in either the formation of NCO or gene conversion (Adapted from 
Szekvoelgyi and Nicolas, 2010). 
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The cohesin complex is a tripartite ring-shaped structure. In mammalian germ cells, for 
example, cohesin complex contains: (a) Two members of the structural maintenance of 
chromosomes (SMC) protein family, named SMC1 and SMC3. Two variants also exist for the 
SMC1 subunits (SMC1α and SMC1β); (b) Three members of the Kleisin family proteins 
(RAD21/SCC1; REC8 and RAD21L); and (c) Three accessory subunits, SCC3/SA (STAG1, 
STAG2 and STAG3) (Nasmyth, 2011; Uhlmann, 2004). Four of these proteins have been 
identified as being meiosis-specific cohesin subunits, REC8, SMC1β, RAD21L and STAG3 
(Nasmyth, 2011). By contrast, the mitotic cohesin complex consists of four subunits including 
SMC1α, SMC3, RAD21/SCC1 and SCC3/SA (STAG1 and STAG2) (Nasmyth and Haering, 
2009). 
 
During mitosis, cohesin is destroyed to allow the separation of sister chromatids, but this is 
not possible in meiosis, because sister chromatids in the bivalent are connected by 
homologues arm cohesion. Therefore, the removal of sister chromatid cohesion in meiotic 
cells is performed in two steps. The first step allows the segregation of bivalent chromosomes 
by REC8 degradation from the chromosome arms through a specific protease called separase, 
which is active during anaphase I, while the second step is cleavage of REC8 from the 
centromeric regions during anaphase II by separase activity, which results in sister chromatid 
segregation from each other towards opposite poles (Brar et al., 2006; Mehta et al., 2012).    
 
In the first meiotic division, the sister kinetochores are mono-orientated and the centromeric 
cohesions are protected (Dudas et al., 2011). Chromosome segregation during cell division in 
mammals is regulated by two member of the Shugoshin (SGO) protein family, SGO1 and 
SGO2. The function of these proteins is to protect centromeric sister cohesion of sister 
chromatids and to facilitate bio-orientation attachment of the sister kinetochores (Yao and 
Dai, 2012). SGO1 plays an essential role in cohesin protection in mitosis and meiosis, but 
SGO2 functions in meiosis only (Gómez et al., 2007; Yao and Dai, 2012). In fission yeast, the 
Shugoshin proteins attach with protein phosphatase SA (PP2A), which leads to 
dephosphorylation of REC8 during meiosis I and inhibits separase activity (Xu et al., 2009).   
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Anaphase II Anaphase I Prophase I 
Pairing 
Synapsis 
Recombination 
Release of 
cohesion in 
chromosome 
arms 
Release of 
centromeric 
cohesion 
Figure 1.11 Sister chromatid cohesion in mammalian undergoes meiosis. The sister chromatids in 
each homologue connect to each other via cohesin (black bars). A pair of homologous chromosomes 
consists of two pairs of sister chromatids and synapsis occurs through the formation of synaptonemal 
complex (yellow). Meiotic recombination takes place between non-sister chromatids. In anaphase I, 
cohesin at chromosomal arms is dissolved and the bivalent chromosomes segregate, but cohesion at  the 
centromeric is retained. In anaphase II, centromeric cohesion is destroyed, and the sister chromatids 
separate to the opposite sides of the cells with the aid of bio-orientation of kinetochores (green 
arrowheads) (Adapted from Revenkova and Jessberger, 2005). 
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1.4.10 Homologous chromosome pairing 
The homologous chromosomes align and pair during the meiotic prophase in order to 
recombine and form chiasmata between one sister chromatid from one homologue and 
another sister chromatid from the other homologue. In several organisms, such as mammals 
and yeast, homologous chromosome pairing requires the formation and repair of DNA DSBs 
(Inagaki et al., 2010; Klutstein and Cooper, 2014). During meiotic prophase I, three basic 
events occur: the pairing of homologous chromosomes, synapsis and meiotic recombination. 
Chromosome pairing begins in the leptotene stage, progresses in the zygotene stage, and it is 
completed in the pachytene stage (Klutstein and Cooper, 2014; Page and Hawley, 2004).  
 
1.4.11 Chromosome synapsis 
Most of the studies in synapsis and meiotic recombination have been conducted on different 
organisms, such as Saccharomyces cerevisiae, Drosophila melanogaster and Caenorhabditis 
elegans (Page and Hawley, 2004). Synapsis takes place along the entire length of the 
homologous chromosomes and is achieved by the SC formation (Fraune et al., 2012). 
However, synapsis does not occur between the sex chromosomes of male mammalian cells 
(Handel, 2004). 
 
The formation of the SC, the tripartite protein structure that forms between two homologous 
chromosomes, leads to the stable association of these homologues during prophase I of 
meiotic cells (Page et al., 2008). The SC consists of three distinct structural parts: two 
structures known as the lateral (axial) elements (LEs) along the axes of homologous 
chromosomes, a central connecting element (CE) and transverse filaments (TFs) that connect 
the lateral and central elements (Figure 1.12). The SC is gradually detached in the diplotene 
stage (Fung et al., 2004; Page and Hawley, 2004). 
 
Cytological observations indicate that synapsis in humans is initiated from the ends of 
telomeres of homologous chromosomes (Brown et al., 2005). During the first phase of 
chromosome pairing, all telomeres on the nuclear membrane are clustered, whilst the arms of 
homologous chromosomes are moved to the nucleus centre (Harper et al., 2004; Scherthan, 
2007). Chromosomal movement is very important for the correct pairing of homologous 
chromosomes (Ding et al., 2006; Klutstein and Cooper, 2014). The induction and repair of the 
meiotic DSBs are also fundamental to achieving synapsis (Kuznetsov et al., 2007). 
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The SC in mammals is composed of seven known proteins, which play a fundamental role in 
its structure during the prophase of meiosis I. These proteins are synaptonemal complex 
protein 1, 2 and 3 (SYCP1, SYCP2 and SYCP3); synaptonemal complex central element 
protein 1, 2, and 3 (SYCE1, SYCE2 and SYCE3), as well as the testis expressed 12 (TEX12) 
(Davies et al., 2012).  
 
Synapsis particularly relies on the central element and transverse filament proteins of the SC. 
Four central element proteins have been determined in mammalian cells including SYCE1, 
SYCE2, SYCE3 and TEX12 (Yang and Wang, 2009). Mutation in the CE and TF proteins 
leads to male/female infertility in mice (Schramm et al., 2011). In mammals, the transverse 
filament consists of a single known protein named SYCP1 (Page and Hawley, 2004).  
 
In contrast, the lateral element proteins consist of SYCP2, SYCP3, HORMA-domain proteins 
(HORMAD1), and the sister chromatid cohesion provided by the meiotic cohesin complex 
arises due to four proteins REC8, STAG3, SMC1β and SMC3 (Page and Hawley, 2004). 
These proteins are also essential for the correct pairing of homologous chromosomes, and the 
formation of crossovers (Kouznetsova et al., 2005; Yang et al., 2006). For instance, deletion 
of the SYCP3 gene in male mice causes heterologous synapsis, and apoptosis occurs in 
spermatocytes (Yuan et al., 2000). In female mice; however, meiotic division is not 
completely blocked by this deletion, but during the first week of postnatal follicle 
development, many oocytes are lost in the SYCP3 gene knockout line. Those that survive 
show a high frequency of embryonic aneuploidy (Yuan et al., 2002). 
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Figure 1.12 The synaptonemal complex structure. The SC is created by lateral elements (LEs), a 
central element (CE) and proteins known as transverse filaments, which bind the LEs to the CE. In 
mammals, the LEs contain meiotic cohesins; the structural proteins (SYCP2 and SYCP3) and the 
HORMA-domain proteins. The CE is composed of four essential proteins including SYCE1; 
SYCE2; SYCE3 and TEX12. In contrast, the transverse filaments are linked to the LEs by a protein 
known as the SYCP1 molecule, with the C-terminal embedded in the LEs and interaction of the N-
terminal in the middle of the CE. C= carboxyl-terminus; N= amino-terminus (Adapted from Page 
and Hawley, 2004). 
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1.5 Project aims 
The overall purpose of the present study was to identify candidate genes that could serve as 
cancer-specific markers. A bioinformatics screening program, which included microarray 
analysis and an EST analysis pipeline, indicated potential meiotic genes which could serve 
this purpose. A core aim was to validate these candidate genes, and further explore their 
potential as oncogenes and/or clinical useful biomarkers 
 
The overarching aims and objectives: 
1. Identify new CTA genes via RT-PCR analysis using RNAs isolated from normal 
human tissues and cancer cells. 
2. Functional analysis of two of identified candidate genes (STRA8 and C20orf201) using 
human cancer cell lines. 
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Chapter 2.0: Materials and Methods  
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
2.1 Human cell lines and cell culture 
2.1.1 Source of human cell lines  
The Flp-In T-REx-293 cell line and the liver cancer cell line HEP-G2, were gifted by Dr. J. 
Müller (University of Warwick). The embryonal carcinoma cell line NTERA-2 clone D1) was 
gifted by Prof. P.W. Andrews (University of Sheffield) and the A2780 cell line was gifted by 
Prof. P. Workman (Cancer Research UK Centre for Cancer Therapeutics, Surrey, UK). The 
following cell lines were obtained from the European Collection of Cell Cultures (ECACC); 
1321N1, HT29, HCT116, T84, LoVo, SW480, MCF7, G-361, MM127, COLO800 and 
COLO857. H460 and MDA-MB-453 cells were purchased from the American Type Culture 
Collection (ATCC), and human ovarian adenocarcinoma from the cell lines, PEO14 and 
TO14, were obtained from Cancer Research Technology Ltd.  
 
2.1.2 Culturing the cell lines 
All cell lines were maintained at 37°C in a humidified atmosphere containing 5% or 10% CO2 
and passaged based on recommended dilutions and confluences from ATCC. The cell lines 
were grown in a media containing 10% foetal bovine serum (FBS) (Invitrogen, Catalogue 
number; 10270, Lot 41Q6208K). The media, cell line description, CO2 concentration and any 
other standard condition of each cell line are summarised in Table 2.1. The LookOut® 
Mycoplasma PCR Detection kit (Sigma Aldrich; MP0035) was routinely used according to 
the manufacturer’s instructions to check for mycoplasma contamination in cell culture. 
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Table 2.1 Description of the cell standard conditions of different human cancer cell lines 
Cell line names Origin CO2 Culture Media conditions 
Flp-In T-REx-293 Human embryo kidney 
carcinoma 
5%  
Dubeco’s modified Eagle’s medium 
(DMEM) + GLATAMAXTM 
(Invitrogen; 61965) + 10% FBS 
HEP-G2 Hepatocellular carcinoma 5%  
NTERA-2  
(clone D1) 
Human Caucasian 
pluripotent embryonal 
carcinoma  
10%  
SW480 Human colon 
adenocarcinoma 
5%  
LoVo Human colon 
adenocarcinoma 
5%  Ham's F12 + 2mM Glutamine + 10% 
Foetal Bovine Serum (FBS). 
1321N1 Human brain astrocytoma  5%   
HT29 Human Caucasian colon 
adenocarcinoma  
5%  
McCoy’s 5A medium + 
GLUTAMAXTM (Invitrogen; 
36600) + 10% FBS 
 
HCT116 Human colon carcinoma  5%  
G-361 Human Caucasian malignant 
melanoma 
 
A2780 Human ovarian carcinoma 5% DMEM + GLATAMAXTM + 10% 
FBS and 1xNEAA (non-essential 
amino acids)  
MCF7 Human Caucasian breast 
adenocarcinoma  
5%  
MM127 Human malignant melanoma  5%  RPMI 1640 + GLUTAMAXTM + 
10% FBS and 25 mM HEPES  
COLO800 Human melanoma  5%  Roswell Park Memorial Institute 
1640 medium (RPMI 1640) + 
GLUTAMAXTM (Invitrogen; 
61870) + 10% FBS  
COLO857 Human melanoma  5%  
H460 Large cell lung carcinoma  5%  
MDA-MB-453 Human breast carcinoma  0%  Leibovitz’s (L-15) medium + 
GLUTAMAXTM (Invitrogen; 
31415) + 10% FBS  
PEO14 Ovarian Adenocarcinoma, 
peritoneal ascites  
5%  RPMI 1640 + GLUTAMAXTM + 
10% FBS and 2 mM sodium 
pyruvate 
 
TO14 Ovarian Adenocarcinoma, 
solid metastasis  
5%  
T84 Human colon carcinoma  5%  Ham's F12 + DMEM (1:1) + 
GLUTAMAXTM (Invitrogen; 
31331) + 10% FBS  
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2.1.3 Preparing of thawing frozen cells and recovery 
Vials of frozen cells were removed from the -80°C freezer or the liquid nitrogen tank and 
immediately immersed in a 37°C water bath. The cells was quickly thawed by gently swirling 
the vial in the 37°C water bath until there was just a small bit of ice left in the vial. Before 
opening, the outside of the vial was wiped with 70% ethanol and then the cells transferred 
from the cryotube to 5 ml of the complete medium in a Falcon tube then collected by 
centrifugation at 1,500 xg for 5 minutes. The cells were re-suspended in 10 ml of fresh 
complete media and transferred into T75 cm
2
 flask. The cells were then incubated in 37°C 
incubator at appropriate CO2 concentration. 
 
2.1.4 Cell harvesting and freeze preparation of cultured cells 
Cells were cultured to an approximately 80% confluence prior to freezing. The culture 
medium was removed and discarded using a sterile pipette. Subsequently, the cells were 
washed with 5 ml 1xPBS (Invitrogen; 14190-094) to remove all traces of FBS. 1 ml of 1x 
trypsin-EDTA (Sigma-Aldrich; T3924) was added to the T75 cm
2
 flask and incubated for 1 
minute. A further 5 ml of complete medium was added to the cell culture to stop 
trypsinuzation. The cells were counted using a hemocytometer and then centrifuged for 5 
minutes at 1,500 xg to obtain a cell pellet. The supernatant was removed from the centrifuged 
cells and the pellets were re-suspended at a density of at least 3×10
6
 cells/ ml in fresh chilled 
freezing media containing 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich; D8418) and 
90% FBS. The cells were then transferred into a cryotube and stored overnight at -80°C and 
then the frozen cells were transferred to the liquid nitrogen tank for long-term storage. The 
viability and recovery of frozen cells were checked 24 hours after storing cryovials in liquid 
nitrogen.  
 
2.2 Cell counting using hemocytometer  
The cells were trypsinized and pipetted up and down for several times to resuspend the cells. 
Hemocytometer and coverslips were cleaned by rinsing with 70% ethanol followed by 
deionized water. A 10 μl cell culture was mixed thoroughly with an equal amount of 0.4% 
Trypan blue (Invitrogen; 15250-061) in a clean Eppendorf tube to determine cell viability. 
The tube was allowed to stand for 5 minutes at room temperature before loading. The cover 
slip was placed squarely above the grid of the hemocytometer. 10 μl of the cells and Trypan 
blue mixture was loaded to each side of the grid (chamber). The average number of cells was 
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counted on 25 squares for both the girds under the light microscope 10× objectives. The blue 
cells are dead ones, and the unstained cells are alive. The total number of viable cells was 
determined per millilitre by using the following calculation: 
Cells/ ml = Average count of unstained cells × dilution factor × 10
4
. 
 
2.3 Total RNA isolation from cultured cells 
Total RNA from the cell lines grown in the lab (Table 2.1) were extracted. Confluent cells at 
a density of 5×10
6
 cells were collected in 1 ml TRIzol reagent (Invitrogen; 15596-026) and 
incubated for 5 minutes at room temperature. A volume of 200 μl chloroform was added to 
the TRIzol and the samples were shaken vigorously by vortex for 15 seconds and then 
incubated for 5 minutes at room temperature. The samples were spun at 12,000 xg for 15 
minutes at 4°C. The colourless upper aqueous phase was transferred into a clean 1.5 ml 
Eppendorf tube. RNA precipitation was carried out by adding 200 μl of 100% isopropanol, 
followed by incubation for 10 minutes at room temperature. The samples were then 
centrifuged at 12,000 xg for 20 minutes at 4°C. The RNA pellet was washed using 1 ml of 
75% ethanol in DEPC treated water and centrifuged again at 7,500 xg for 5 minutes at 4°C. 
The supernatant was discarded and the pellet was dried. The total RNA pellet was dissolved 
in 100 μl DEPC treated water and incubated in heating block at 56°C for 10 minutes. Finally, 
the RNA sample was treated with 1 μl DNase I (Sigma-Aldrich; D5319), and incubated at 
37°C for 10 minutes and inactivated at 75°C for 10 minutes. The RNA concentration and 
quality of each sample was determined via a NanoDrop (ND_1000) spectrophotometer and 
agarose gel electrophoresis. 
 
2.4 cDNA synthesis  
Total RNA from the normal human tissue panel (Clontech; 636643) and many cell lines and 
tumour tissues were purchased from Clontech and Ambion. cDNA synthesis was performed 
according to the instructions of the manual of the SuperScript III First Strand synthesis system 
for RT-PCR (Invitrogen; 18080-051). 1 μg of the total RNA was transcribed into single-
strand cDNA using oligo-dT primer that specifically binds to the poly-A tail of mRNAs. The 
cDNA was subsequently diluted 1:8 in sterile distilled water and store at -20°C. Primers for 
human β ACT were used in PCR reaction as a control for the quality of the cDNA samples. 
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2.5 Reverse transcription PCR (RT-PCR) and agarose gel electrophoresis  
RT-PCR begins with reverse transcription of RNA into cDNA, and is followed by PCR 
amplification of the cDNA. A volume of 2 μl diluted cDNA was used in the PCR with 1 μl of 
each primer (10 pmol) and 25 μl of BioMix Red (BioLine; BIO-25006) and added to a final 
volume of 50 μl with distilled water. Samples were amplified with a pre-denaturation hold at 
96°C for 5 minutes, followed by 40 cycles of denaturing at 96°C for 30 seconds, annealing 
temperature as described in Table 2.2 for 30 seconds and extension at 72°C for 30 seconds/kb, 
followed by a final extension step at 72°C for 5 minutes. PCR products were run on 1% 
agarose gels using 1x TBE buffer and 0.5 μg/ml ethidium bromide (Sigma-Aldrich; 46067) 
was added to the gel for later visualisation of the DNA. 5 μl of 100 bp DNA marker (NEB; 
N0467) was loaded for size determination of PCR products. 
 
2.5.1 Primer design for RT-PCR 
The specific sequence of all genes was found in the databases of National Center for 
Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/) and all primers were 
carefully designed to span at least one intron where possible. The Primer3 software (available 
from: http://www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi) was used for design 
the primers. All primers for this study were synthesised from Eurofins MWG operon 
(http://www.eurofinsgenomics.eu/) and diluted with sterile distilled water to final 
concentration of 10 pmol. The primers used for RT-PCR screening and their expected size for 
each gene are listed in Table 2.2.   
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Table 2.2 Primer sequences for RT-PCR and their expected amplicon size 
Human gene Primer name Primer sequence Ta* 
Expected 
amplicon size 
β ACT  ACTB F1 
ACTB R1 
5'-AGAAAATCTGGCACCACACC-3' 
5'-AGGAAGGAAGGCTGGAAGAG-3' 
58.4°C 553 bp 
BTG4 BTG4 F1 
BTG4 R1 
5'-AGTCACTGGCACTCTGATTG-3' 
5'-GAATGACACGAGGTTCCTTG-3' 
58.4°C 349 bp 
CCNA1 CCNA1 F1 
CCNA1 R1 
5'-CAGCTGGAAAGAAAGCACTC-3' 
5'-GAGAAACTGGTTGGTGGTTG-3' 
58.4°C 698 bp 
C2orf69 C2orf69 F1 
C2orf69 R1 
5'-GCATCACGTCCTCTATTTCC-3' 
5'-CCAAGTATTGCTTCCTCCAG-3' 
58.4°C 631 bp 
C5orf50 C5orf50 F1 
C5orf50 R1 
5'-CATTGCTGATCTTGGTGCTG-3' 
5'-GCACCTCTTCCTCTAACTTC-3' 
58.4°C 219 bp 
C11orf65 C11orf65 F1 
C11orf65 R1 
5'-AGAGCTTCTAGATGCTGCTG-3' 
5'-GATGTGTTGACTTAGCCTCC-3' 
58.4°C 422 bp 
C11orf70 C11orf70 F1 
C11orf70 R1 
5'-CCAGACCTTTCAGTCCTATCG-3' 
5'-GTCTCCCACACCATAACAGTG-3' 
58.4°C 643 bp 
C20orf201 C20orf201 F1 
C20orf201 R1 
C20orf201 F2 
C20orf201 R2 
5'-ATCTGCTCTTCGGCGACCTG-3' 
5'-ACACTCTCAGTCGCCGTCAC-3' 
5'-ATCTGCTCTTCGGCGACC-3' 
5'-GACTTCTGCCGCTGGATG-3' 
60°C 
 
58.4°C 
505 bp 
(variant 1) 
256 bp 
(variant 2) 
C20orf195 C20orf195 F1 
C20orf195 R1 
5'-CCTGGACAAGATGAAGCTG-3' 
5'-GTCAAACACGACAGGCATC-3' 
58.4°C 613 bp 
COX7B2 COX7B2 F1 
COX7B2 R1 
5'-TCTGCAAAGCATGGCAAGAC-3' 
5'-ACAGGGGATAGGTTCCATTC-3' 
58.4°C 156 bp 
CST8 CST8 F1 
CST8 R1 
5'-CAATGCCTCAAATGCCAACG-3' 
5'-TCCTACCAAAAAGCTGCAGC-3' 
58.4°C 259 bp 
DAZL DAZL F1 
DAZL R1 
5'-ACTGATCGAACTGGTGTGTC-3' 
5'-GGTGGAGTAGCTTCATGAAC-3' 
58.4°C 497 bp 
DMC1  DMC1 F1 
DMC1 R1 
5'-GAACCAGGATTCTTGACTGC-3' 
5'-TGGAGTCGTGACAACATCTG-3' 
58.4°C 518 bp 
FABP9 FABP9 F1 
FABP9 R1 
5'-GAACATGGCAGGGTTAGTGA-3' 
5'-TGGTGCTCTTTACTTTCCGG-3' 
58.4°C 161 bp 
FSCN3 FSCN3 F1 
FSCN3 R1 
5'-GTGCTTTCTACTGCGTTTCC-3' 
5'-GTTTAAGCGCTCAGAAGCAG-3' 
58.4°C 598 bp 
GAGE1 GAGE1 F1 
GAGE1 R1 
5'-TAGACCAAGGCGCTATGTAC-3' 
5'-CATCAGGACCATCTTCACAC-3' 
58.4°C 245 bp 
HORMAD1 HORMAD1 F1 
HORMAD1 R1 
5'-CCAGAATGCGCTTATGGAAC-3' 
5'-CCATTCGTTCTCTCTCAGTG-3' 
58.4°C 556 bp 
KCNU1 KCNU1 F1 
KCNU1 R1 
5'-AGCCAAGACATCCTTAGGAC-3' 
5'-GTTAGGAAGGTACACAAGCC-3' 
58.4°C 642 bp 
LYRM1 LYRM1 F1 
LYRM1 R1 
5'-AGCATTTTCAGGCTTGCGAG-3' 
5'-CTCAGTTTCTCTTGGCTTCG-3' 
58.4°C 278 bp 
MAGEA1  MAGEA1 F1 
MAGEA1 R1 
5'-CCCACTACCATCAACTTCAC-3' 
5'-CTCTTGCACTGACCTTGATC-3' 
58.4°C 676 bp 
NOL4 NOL4 F1 
NOL4 R1 
5'-GATGGGAGACTCCAACAGTG-3' 
5'-CCTGCAGGACTTGAGGTAAG-3' 
58.4°C 547 bp 
NUT NUT F1 
NUT R1 
5'-CACCACCAGTTGCTCAACTG-3' 
5'-CTCCTTCACAGCTTCTGGTG-3' 
60°C 623 bp 
ODF3 ODF3 F1 
ODF3 R1 
5'-CCTGATTCCACCAACAACAG-3' 
5'-CAGAGTGTTTGATGCCGAAG-3' 
58.4°C 641 bp 
PFN3 PFN3 F1 
PFN3 R1 
5'-AACAGCTGCGTGTGGGCTTC-3' 
5'-CGTGCACCGTCTTGTTGAGG-3' 
58.4°C 298 bp 
PRDM9 PRDM9 F1 
PRDM9 R1 
5'-CAGGCTCAGAAACCAGTGTC-3' 
5'-GTTCCTGGCCGTATTCATCC-3' 
60°C 655 bp 
PRSS45 PRSS45 F1 
PRSS45 R1 
5'-GCACCAAAGAGTACTCAGTG-3' 
5'-CAACTTCACAAGCCAATGGC-3' 
58.4°C 375 bp 
Ta* - Annealing temperature   
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RAD21L RAD21L F1 
RAD21L R1 
5'-TACTTCCTTTGCGGACACAC-3' 
5'-AGCCAGCTGTTTCTTTAGGAC-3' 
58.4°C 655 bp 
REC8 REC8 F1 
REC8 R1 
5'-GAGAGTTGAAGAGATCCCTC-3' 
5'-CTGGTTTGCAGTTGTTCCTG-3' 
58.4°C 480 bp 
SLC25A41 SLC25A41 F1 
SLC25A41 R1 
5'-GGAAGTGGATAACAAGGAGG-3' 
5'-CTGGAGCATCTCATAGACAG-3' 
58.4°C 550 bp 
SMC1β SMC1β F1 
SMC1β R1 
5'-TCAAGAAATCGAGGCCCACC-3' 
5'-CTGGGGCCACACAGTTATAG-3' 
60°C 368 bp 
SSX2 SSX2 F1 
SSX2 R1 
5'-CAGAGAAGATCCAAAAGGCC-3' 
5'-CTCGTGAATCTTCTCAGAGG-3' 
58.4°C 407 bp 
SSX5 SSX5 F1 
SSX5 R1 
5'-GAGGCCATGACTAAACTAGG-3' 
5'-GCAGCTGTTTCCCATTGTTC-3' 
58.4°C 253 bp 
STAG3 STAG3 F1 
STAG3 R1 
5'-CTCTTCCATCAGGACAAGCAG-3' 
5'-CTCTTCTTCCTCGTCCTCTTC-3' 
60°C 495 bp 
STRA8 STRA8 F1 
STRA8 R1 
STRA8 F2 
5'-TGGCAGGTTCTGAATAAGGC-3' 
5'-GAAGCTTGCCACATCAAAGG-3' 
5'-GGCAAGAGGAATCACAATCC-3' 
58.4°C 
 
58.4°C 
510 bp 
 
306 bp 
SYCP1 SYCP1 F1 
SYCP1 R1 
5'-GGTACAGCAGAAAGCAAGCAAC-3' 
5'-GGCAGATGTCCACAGATAGTC-3' 
60°C 645 bp 
SYCP2 SYCP2 F1 
SYCP2 R1 
5'-CTTGGGAGACCTGGCAAAATG-3' 
5'-GATGAAGCCTCTGTTGTTCGC-3' 
60°C 354 bp 
SYCP3 SYCP3 F1 
SYCP3 R1 
5'-GTCTTCTGCAGGAGTAGTTG-3' 
5'-CACTTGCTATCTCTTGCTGC-3' 
58.4°C 509 bp 
TEX19 TEX19 F1 
TEX19 R1 
5'-GCTTCAACATGGAGATCAGC-3' 
5'-GAAGCTCCTCAAATCTCCAG-3' 
58.4°C 386 bp 
TEKT5 TEKT5 F1 
TEKT5 R1 
5'-CATTGGCTTCTGGAAGTCAG-3' 
5'-GACAAGGTCTCAAAGAGGTG-3' 
58.4°C 543 bp 
TEPP TEPP F1 
TEPP R1 
5'-CTGCTGTCCATAATAAGGGC-3' 
5'-GTGATGTCCAAACACTGCAG-3' 
58.4°C 422 bp 
TMEM225 TMEM225 F1 
TMEM225 R1 
5'-AGCCAAGATGAACCACAGTC-3' 
5'-CTGGTAGACAACTTGCACTC-3' 
58.4°C 375 bp 
TULP2 TULP2 F1 
TULP2 R1 
5'-GCAGAATTGGAGGAAGTCTC-3' 
5'-GTGAACTTGGTGCTGAAGAC-3' 
58.4°C 680 bp 
UBL4B UBL4B F1 
UBL4B R1 
5'-GGATGACAAGCACCTCTCTG-3' 
5'-CCTTCTCCTCCATGTCACAG-3' 
58.4°C 350 bp 
WDR27 WDR27 F1 
WDR27 R1 
5'-GACCAACATCAAGAGTGAGG-3' 
5'-GCCGATAAACTGGTCATGTC-3' 
58.4°C 579 bp 
ZNF558 ZNF558 F1 
ZNF558 R1 
5'-CCCAGTTGGAACAAGACAAG-3' 
5'-GAATGCTATTGTGCCCAGTG-3' 
58.4°C 579 bp 
Ta* - Annealing temperature 
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2.5.2 Gel purification of RT-PCR product for sequencing 
The gel purification was used to isolate the desired fragment. PCR products were loaded onto 
a 1% agarose gel prepared in 1x TBE buffer and 0.5 μg/ml ethidium bromide and the desired 
bands were cut out of from the gel using a sterile scalpel blade. The gel slice were then 
purified using the High Pure PCR Product Purification Kit (Roche Applied Science; 
11732676001), according to the manufacturer’s recommendations. Finally, the purified PCR 
fragment was eluted in elution buffer. The DNA concentration was determined by a 
NanoDrop (ND_1000).  
 
The DNA amounts of 5 ng/μl in a total volume of 15 μl was put in a clean Eppendorf tube and 
in other tubes, 2 pmol/μl in a minimum volume 15 μl of the forward and/or reverse primers 
were transferred. The tubes were then sent at room temperature to Eurofins MWG for DNA 
sequencing. The result sequencing of each product was subjected to blast analysis and aligned 
against the expected sequence of PCR product to compare a query sequence with the NCBI 
databases of sequences. 
 
2.6 Real time quantitative PCR (qRT-PCR)  
2.6.1 Total RNA isolation for qRT-PCR 
Total RNAs were isolated from confluence of cell cultures by means of the RNeasy Plus Mini 
Kit (Qiagen; 74134). The isolation process was done according to the manufacturer’s 
recommendation. The concentration and quality of RNA was determined using a NanoDrop 
(ND_1000) and gel electrophoresis. 1 μg of total RNA was reverse transcribed into cDNA 
using the SuperScript III First Strand synthesis system for RT-PCR (Invitrogen; 18080-051). 
The reverse transcription was done according to the manufacturer’s instructions.  
 
2.6.2 Primer design for qRT-PCR 
For efficient amplification in quantitative RT-PCR, all primers were designed manually at an 
amplicon size of < 160 bp. The length of each primer was 17-20 nucleotides, containing 40-
60% G/C, avoiding predicted internal secondary structure. The forward and reverse primers 
had no significant complementarity to each other at the 3´ends to avoid primer-dimer forming 
and had similar melting temperature. Primers were checked with blast search 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). All primers for the genes of interest were synthesised 
by Eurofins MWG (http://www.eurofinsgenomics.eu/) (see Table 2.3), while the primers for 
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housekeeping genes used in qRT-PCR were made by Qiagen (see Table 2.4). Stock primers 
were diluted with sterile distilled water to make a final concentration of 10 pmol. 
 
2.6.3 PCR setup for qRT-PCR 
To set up the real time PCR reactions, the QuantiTect SYBR Green PCR Kit (Qiagen; 
204054) was used, according to the manufacturer’s protocol. In a 96 well plate, 1.5 μl 
(containing ~100 ng/μl cDNA) cDNA and 2.5 μl from each primer were used in a total of 25 
μl. Samples were replicated three times and amplified with a pre-denaturation step at 95°C for 
5 minutes, followed by 40 cycles of a denaturation step at 95°C for 10 seconds, a primer 
annealing step at 60°C for 30 seconds and an extension step at 95°C for 10 seconds. Melt 
curve analysis was achieved after completion of the 40 cycles.  
Two negative controls were used to check for contamination. β ACT and LAMIN A were used 
as positive controls for normalisation of the qRT-PCR results. Real time PCR was carried out 
by using a BioRad CFX machine and analysis of result was achieved via the BioRad CFX 
Manager Software (version 2). 
 
Table 2.3 Primer sequences for real time RT-PCR and their expected amplicon size 
Human gene Primer name Primer sequence Ta* Amplicon size 
STRA8 STRA8 F3 
STRA8 R3 
5'-GTTCCGAGTACATCTAGCTC-3' 
5'-GAGTGTTTGCACAGCTAAGG-3' 
60°C 124 bp 
C20orf201 C20orf201 F3 
C20orf201 R3 
C20orf201 F4 
C20orf201 R4 
5'-GGCTCCTCGGCGTCCTCAAG-3' 
5'-CGGCAGGAACAGCTCCAGCC-3' 
5'-ATGCCGCCGCCAGCGAA-3' 
5'-CGGCTTGGGGGGCTCTGT-3' 
60°C 
 
60°C 
152 bp 
 
126 bp 
Ta* - Annealing temperature 
 
Table 2.4 Positive primer assay for real time RT-PCR  
Human gene Assay name Source 
β ACT  Hs_ACTB_1_SG  Qiagen; QT00095431  
LAMIN A Hs_LMNA_2_SG  Qiagen; QT01678495  
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2.7 Western blot analysis   
2.7.1 Preparation of whole cell lysate from cell culture (Technique A) 
Confluent cells were washed twice with 1x cold PBS and harvested with trypsin and then the 
cells were counted in a complete medium by a haemocytometer to determine the total number 
of cells. 5×10
5 
cells were transferred to a new Eppendorf tube and centrifuged at 5,000 xg for 
5 minutes at 4°C. The supernatant was discarded and pellet was washed again with 1x cold 
PBS. After centrifugation, the cell pellet was resuspend in lysis buffer (50 mM Tris-HCl pH 
7.4, 200 mM NaCl, 0.5% Triton X-100, 1 mM AEBSF [4-(2-aminoethyl)-benzenesulfonyl 
fluoride] (Sigma-Aldrich; A8456) with one complete, mini, EDTA-free protease inhibitor 
cocktail tablet (Roche Applied Science; 11836170001) per 10 ml of lysis buffer and an equal 
volume of 2x Laemmli buffer (Sigma-Aldrich; S3401). The protein lysates were boiled at 
95°C for 5-10 minutes. Lysate of approximately 5×10
5 
cells was loaded per well. 
 
2.7.2 Preparation of whole cell lysate from cell culture (Technique B) 
Whole cell protein lysates were isolated from 5×10
5 
cells using radio immunoprecipitation assay 
(RIPA) buffer (Sigma-Aldrich; R0278) with 1 mM AEBSF [4-(2-aminoethyl)-
benzenesulfonyl fluoride] and one complete, mini, EDTA-free protease inhibitor cocktail 
tablet was added to the 10 ml of RIPA buffer. Following, an equal volume of 2x Laemmli 
buffer was added to the lysates. The lysates were mixed gently by pipetting, and then 
incubated on ice for 30 minutes. The samples were gently vortexed and boiled at 95°C for 5-
10 minutes, followed by transferring the supernatant to a clean Eppendorf tube and discard 
the cell debris. Lysate of approximately 5×10
5 
cells was loaded per well.  
 
2.7.3 Preparation of whole cell lysate from cell culture (Technique C) 
Cells were washed with 1x cold PBS, harvested and pelleted by centrifugation at 5,000 xg for 
5 minutes at 4°C. The dry pelleted cells were weighted and re-suspended in a volume of 10 μl 
of M-PER Mammalian Extraction Reagent (Thermo; 78503) for every 1 mg of dry cell pellet. 
The cell lysate tubes were incubated at room temperature for 10 minutes, followed by 
centrifugation for 15 minutes at 14,000 xg to pellet cell debris.  The protein concentration of 
each sample was measured using the BCA protein assay kit (Thermo; 23227). Approximately 20 
μg protein was used with 2 μl Sample Reducing agent 10x (Invitrogen; NP0004) and 4 μl LDS 
Sample Buffer (4x) (Invitrogen; NP0007). The samples were then mixed by pipetting and 
boiled at 70°C for 10 minutes, followed by chilling on ice before gel loading. Approximately 
20 μg protein was loaded per well. 
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2.7.4 Source of human normal tissue lysates 
A whole cell lysates from human normal tissues were purchased and detailed in the 
accompanying table.  
 
Table 2.5 Source of normal lysates used in Western blotting 
Whole cell lysates Source Catalogue number Protein loading  
Testis Abcam AB30257 20 μg 
Testis Novus Biological NB820-59266 20 μg 
Brain: Cerebellum Abcam AB30069 20 μg 
Spinal cord Abcam AB29188 20 μg 
Brain Abcam AB29466 20 μg 
Salivary gland Abcam AB29159 20 μg 
Skeletal muscle Abcam AB29331 20 μg 
Thymus Abcam AB30146 20 μg 
Small intestine Abcam AB29276 20 μg 
Stomach Abcam AB29681 20 μg 
Ovary Abcam AB30222 20 μg 
Liver Abcam AB29889 20 μg 
 
2.7.5 Cell lysis and fractionation 
Before fractionation, cells were washed twice with cold 1xPBS, tripsinized and pelleted for 5 
minutes at 1,500 xg using centrifugation. In the cytoplasmic fraction, the cell pellet was 
resuspend in hypotonic buffer (50 mM Tris-HCl pH 7.4, 0.1 M sucrose, 1 mM AEBSF with 
one Roche complete protease inhibitor cocktail tablet/10 ml) and an equal volume of lysis 
buffer C (1% Triton-X-100, 10 mM MgCl2, 1 mM AEBSF, with one Roche complete 
protease inhibitor cocktail tablet/10 ml). The suspension were then incubated on ice for 30 
minutes and centrifuged for 2 minutes at 6,000 xg at 4°C. The pooled supernatant that 
contained cytoplasmic protein was transferred to a clean chilled Eppendorf tube.  
In contrast, in the nuclear fraction, the cell pellet was then re-suspended in lysis buffer N (50 
mM Tris-HCl pH 7.4, 100 mM KAc, 1 mM AEBSF, one Roche complete protease inhibitor 
cocktail/10 ml). The protein determination for both fractions was carried out using the BCA 
protein assay according to the recommendations of the supplier. An equal volume of 2x 
Laemmli buffer was added to cytoplasmic and nuclear tubes and then incubated at 70°C for 
10 minutes. 20 μg protein was loaded per well.  
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2.7.6 Western blotting technique 
The protein lysate for each sample was loaded onto a NuPAGE® 4-12% Bis-Tris gel 
(Invitrogen; NP0322) in 1x MOPS SDS Running Buffer (Invitrogen; NP0001) and Precision 
plus protein oral standard (BioRad; 161-0377) was also run as molecular weight markers to 
determine the protein sizes of each sample. The gels were run at 200 V for 35 minutes and 
then transferred to an Immobilon-P PVDF membrane (Millipore; IPVH00010) which was 
activated by wetting the PVDF membrane in 100% methanol.  The transfer step was carried 
out at 400 mA for 3 hour using 1x cold Towbin transfer buffer (192 mM Glycine, 25 mM Tris 
base, 10% methanol). After completing transfer, the membrane was washed in H2O five times 
to remove all traces of transfer buffer. Membranes were blocked for one hour at room 
temperature with blocking solution containing 1xPBST (1xPBS + 0.5% Tween-20, Sigma-
Aldrich; P1379) and 5% non-fat dry milk with gentle agitation followed by an overnight 
incubation on the shaker at 4°C with an appropriate dilution of primary antibody. Membranes 
were washed three times for 15 minutes using 1xPBST at RT with shaking. The secondary 
antibody was diluted in blocking solution and incubated with the membranes on the shaker at 
room temperature for 1 hour.  The primary and secondary antibodies are detailed in Tables 
2.6 and 2.7, respectively. The membranes were washed again three times for 15 minutes using 
1xPBST at RT with shaking. ECL detection using SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific; 34080) or Chemiluminescent Peroxidase Substrate-3 (Sigma-
Aldrich; CPS3100-1KT) were used in 1:1 dilution and incubated with membrane for 5 
minutes at room temperature to detect the protein. The membranes were then exposed using 
X-Ray films (Thermo Scientific; 34091) within an appropriate amount of time. 
 
Table 2.6 Primary antibodies used in Western blot (WB) and Immunofluorescence (IF)  
Primary  
antibodies 
Catalogue 
number 
Source Host Clonality Application 
Optimal 
dilution 
Anti-STRA8 AB130985 Abcam Rabbit Polyclonal WB 1/1,000 
Anti-C20orf201 
AB108142 
AB170783 
Abcam 
 
Rabbit 
 
Polyclonal 
 
WB 
IF 
1/1,000 
1/15 
Anti-6x His tag AB18184 Abcam Mouse Monoclonal WB 1/1,000 
Anti-Lamin A/C 
(636) 
Sc-7292 Santa Cruz Mouse Monoclonal WB 1/100 
Anti-Lamin B Sc-6217 Santa Cruz Goat Polyclonal WB 1/1,000 
Anti-α-Tubulin T6074 Sigma Mouse Monoclonal WB 1/5,000 
Anti-GAPDH 
(G-9) 
Sc-365062 Santa Cruz Mouse Monoclonal WB 1/2,000 
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Table 2.7 Secondary antibodies used in Western blot (WB) and Immunofluorescence (IF)  
Secondary  
antibodies 
Catalogue 
number 
Source Application 
Optimal 
dilution 
Peroxidase-conjugated AffiniPure 
donkey anti-mouse IgG (H+L) 
715-035-150 
 
Jackson ImmunoResearch 
Laboratories Inc. 
WB 1/20,000 
Peroxidase-conjugated AffiniPure 
donkey anti-rabbit IgG (H+L) 
715-035-152 
 
Jackson ImmunoResearch 
Laboratories Inc. 
WB 1/20,000 
Anti-Goat IgG (whole molecule)-
Peroxidase produced in rabbit 
A5420 Sigma WB 1/20,000 
Alexa Fluor® 568 goat anti-rabbit 
IgG (H+L) 
A11036 Invitrogen IF 1/250 
 
2.8 siRNA (small interfering RNA) Knockdown 
Confluent cells were seeded at 3×10
5 
cells per well in 6-well plates which contained fresh 
complete medium and then the cells were incubated under normal growth conditions. The 
transfection mixture for each well was prepared in a clean Eppendorf tube containing 100 μl 
of complete medium serum free, 12 μl of Hiperfect Transfection Reagent (Qiagen; 301705) 
and 1.2 μl of a 10 µM siRNA of the gene of interest or 1.2 μl of Negative Control siRNA. The 
siRNAs used in this study are summarised in Table 2.8. The mixtures were mixed and then 
incubated at room temperature for 20 minutes to allow the formation of transfection 
complexes. The complexes were added drop-wise onto the cells with gently shaking the plate 
and then the cells were incubated with the transfection complexes under their normal growth 
conditions. Untreated cells were used as controls at the same time of transfection to allow 
measurement of the expression level of the gene of interest.  
The day of transfection was considered a day 0 and two ‘hits’ was used in this study for the 
siRNA knockdown without changing the complete medium. 48 hours post-transfection the 
cells were harvested and counted as per Sections 2.7.1 and 2.7.3, and prepared for the 
Western blotting procedure (refer to Section 2.7.6). 
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Table 2.8 siRNA used for gene knockdown 
Human gene siRNA name Target sequence  
(5'to 3' direction) 
Catalogue 
number 
Source 
STRA8  Hs_STRA8_1 
Hs_STRA8_2 
Hs_LOC346673_3 
Hs_LOC346673_5 
CTCAAAGTGGCAGGTTCTGAA 
CAGGCTGTGGCAGCTTATAAT 
AAGCAGCTTAGAGGAGGTCAA 
AGGAGAAGTTTCAGCTCTATA 
Sl04251933 
Sl04317614 
Sl00505778 
Sl03145618 
Qiagen 
C20orf201 Hs_LOC198437_2 
Hs_LOC198437_5 
Hs_LOC198437_6 
Hs_LOC198437_7 
ACCGCCAAGAGGTGCAGACAA 
CCCGTGGACGCAGTCGCTCGA 
CCAGCCTCCCACATAAAGTTA 
TCCCGCGGTGACGGCGACTGA 
Sl00485135 
Sl03186386 
Sl04258772 
Sl04319574 
Qiagen 
 
 
 
NI (non- 
interfering) siRNA 
AllStars Negative 
Control siRNA  
-------------------------------------------- 1027280 Qiagen 
 
2.9 Staining of cell culture using immunofluorescence (IF) 
Cells were seeded at 5×10
4
 cells per well in 24-well plates on glass coverslips coated with 
poly-D-lysine (VitroCam; 1445-P01) and incubated under normal growth condition until 70-
80% confluence. The cells were washed twice with ice cold 1xPBS, then fixed in 4% 
paraformaldehyde (PFA) in 1xPBS pH 7.4 for 15 minutes at room temperature and washed 
gently twice with ice cold 1xPBS. The cells were permeabilized by adding 0.25% Triton X-
100 diluted in 1xPBS and incubated for 15 minutes at room temperature. The cells were then 
washed carefully three times with 1xPBS for 15 minutes and incubated with 1% BSA in 
PBST/ 0.5% Tween-20 for 30 minutes to block unspecific binding of the antibodies. The cells 
were then incubated with the primary antibody (see Table 2.6) diluted in the blocking buffer 
for one hour at room temperature or overnight at 4°C, followed by three washes for 15 
minutes using 1xPBS. The secondary antibody (see Table 2.7) was diluted in the blocking 
buffer and incubated in the dark for one hour at room temperature, followed by three washes 
for 15 minutes in the dark. The coverslips were removed carefully from each well and 
allowed to semi-air dry for about 10 minutes, before counterstaining and mounting with 7 μl 
of reagent MD (Cambio; 1124-MD-50) and incubated for 10 minutes at room temperature. 
The cover slips were placed onto glass slides and sealed with nail polish to prevent drying and 
movement under microscope. The slides were viewed by using a Zeiss Axioskop 2 
fluorescence microscope, and the pictures were performed with an AxioCam digital camera. 
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 2.10 The cloning of STRA8 and C20orf201 cDNAs genes 
2.10.1 Primers design for cloning 
The forward and reverse primers were designed in a 5'---3' orientation and contained a start 
codon (ATG) in the 5' primer and a stop codon (TTA) in the 3' primer. Restriction enzyme 
sites were added to the 5' end of the forward and reverse primers before the CDS sequence. A 
Kozak sequence was added to the 5' end of the forward primer before the initiation codon. A 
couple of bases were added to the 5' end of the primers to preserve restriction site during 
PCR. All primers for cloning were synthesised from Eurofins MWG operon and diluted to a 
concentration of 100 pmol as the manufacturer’s instructions and recommended volumes, 
followed by dilutions, from 100 pmol to 10 pmol. 
 
2.10.2 STRA8 cloning primers 
The primers used for STRA8 cloning +Kozak sequence are detailed in Table 2.9 
 
Table 2.9 Primer sequences for STRA8 cloning and their expected amplicon size 
Primer name Primer sequence Ta* 
Amplicon 
 size 
STRA8+ Kozak F4 
 
STRA8 R4 
5'-GAGCTCGAGACCATGGGGAAGATTGATGTGG-3' 
 
5'-GAGCTCGAGTTACAAATCTTCATCGTCAAAG-3' 
 
58.4°C 1212 bp 
GAG – Extra bases              CTCGAG – XhoI recognition site               ACC – Kozak sequence 
 
ATG – Start codon              TTA – Stop codon 
Ta* - Annealing temperature 
 
2.10.3 C20orf201 cloning primers 
The primers used for C20orf201 cloning +/- Kozak sequence are detailed in Table 2.10 
 
Table 2.10 Primer sequences for C20orf201 cloning and their expected amplicon size 
Primer name Primer sequence Ta* 
Amplicon 
 size 
C20orf201+ Kozak F5 
 
C20orf201- Kozak F6 
 
C20orf201 R5 
 
5'-GTGAAGCTTACCATGCCGCCGCCAGCGAA-3' 
 
5'-GTGAAGCTTATGCCGCCGCCAGCGAA-3' 
 
5'-GTGAAGCTTTTATAACTTTATGTGGGAGGCTG-3' 
 
60°C 
 
60°C 
726 bp 
 
723 bp 
GAG – Extra bases              AAGCTT – HindIII recognition site               ACC – Kozak sequence 
 
ATG – Start codon              TTA – Stop codon 
Ta* - Annealing temperature 
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2.10.4 Cloning primers for different fragments of C20orf201 
His Taq sequence was added to each reverse primer before the stop codon for cloning of 
different fragments for C20orf201 cDNAs. The primers are detailed in Table 2.11. 
 
Table 2.11 Primer sequences for 7 fragments of C20orf201 and their expected amplicon size 
Fragment Primer name Primer sequence Ta* 
Amplicon 
size 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
 
 
C20orf201 F7 
 
C20orf201 R7 
 
 
C20orf201 R8 
 
 
C20orf201 R9 
 
 
C20orf201 R10 
 
 
C20orf201 R11 
 
 
C20orf201 R12 
 
 
C20orf201 R13 
 
 
5'-GTGAAGCTTACCATGCCGCCGCCAGCGAA-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
TAACTTTATGTGGGAGGCTG-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
CGCCTCCGCTGCCGG-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
TTGGCGGTCCAGGGGGTC-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
GAGCAGCGCGATCTC-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
GTTCTGGCGCTCGGC-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
CGCCGCGCCCACGTC-3' 
 
5'-GTGAAGCTTTTAGTGGTGGTGGTGGTGGTG 
CGGCTTGGGGGGCTCTGT-3' 
 
 
 
58.4°C 
 
 
58.4°C 
 
 
58.4°C 
 
 
55°C 
 
 
55°C 
 
 
58.4°C 
 
 
58.4°C 
 
 
 
 
744 bp 
 
 
645 bp 
 
 
546 bp 
 
 
447 bp 
 
 
348 bp 
 
 
249 bp 
 
 
150 bp 
 
 
GAG – Extra bases              AAGCTT – HindIII recognition site               ACC – Kozak sequence 
 
ATG – Start codon              TTA – Stop codon               GTGGTGGTGGTGGTGGTG – His Taq sequence 
Ta* - Annealing temperature 
 
2.10.5 PCR Amplification using BioMix Red Master Mix  
Specific primers were designed for STRA8 (refer to Table 2.9) and C20orf201 cloning (refer 
to Table 2.10). The PCR reactions were carried out in a total volume of 50 μl by using 25 μl 
of BioMix red Master Mix, 1 μl of each primer (10 pmol) (refer to Tables 2.9 and 2.10), 2 μl 
of pCMV6-AC::C20orf201 vector (5 ng/μl) (Origene; SC321851) or 2 μl of pCMV6-
XL5::STRA8 vector (5 ng/μl) (Origene; SC307401) and 21 μl of water (Sigma-Aldrich; 
W3500). The PCR reaction complex was firstly predenatured at 96°C for 30 seconds, 
followed by 40 cycles of denaturation at 96°C for 30 seconds, annealing temperature 
depending on the primer site for each fragment for 30 seconds and extension at 72°C for 30 
seconds. One cycle of final extension was set up at 72°C for 5 minutes.  
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2.10.6 Loading of PCR product onto agarose gel electrophoresis 
After PCR completing, the 50 μl of PCR reactions were loaded onto 1x TBE agarose gel 
stained with ethidium bromide and run for an hour at 100 V. The right band was cut by a 
clean blade and purified by using a High Pure PCR purification kit, as per the manufacturer’s 
instructions. 1 μl of purified PCR product with gel loading blue dye (6x) (BioLabs; B7021S) 
was run on the gel to ensure that the purification has worked. HyperLadder II (BioLine; Bio-
33040) was used a marker to determine the size of the fragments. 
 
2.10.7 PCR Amplification using Phusion High Fidelity PCR Master Mix 
Specific primers were designed for different fragments of C20orf201 (refer to Table 2.11) and 
the PCR amplification were carried out in a total volume of 50 μl by using 25 μl of Phusion® 
High-Fidelity PCR Master Mix (BioLabs; M0532S), 2.5 μl of each primer (10 pmol) (refer to 
Table 2.11), 2 μl of pCMV6-AC::C20orf201 vector (5 ng/μl) and 18 μl of Sigma water. The 
PCR reaction complex was firstly predenatured at 98°C for 30 seconds, followed by 35 cycles 
of denaturation at 98°C for 10 seconds, annealing temperature depending on the primer site 
for each fragment for 30 seconds and extension at 72°C for 30 seconds. One cycle of final 
extension was set up at 72°C for 10 minutes. Following completion of PCR, the 50 μl of PCR 
reactions with gel loading dye were run on 1x TBE agarose gel (see Section 2.10.6). 
 
2.10.8 Digestion of PCR inserts by restriction endonucleases 
The restriction enzymes used for digestion of STRA8 or C20orf201 are listed in Table 2.12. 
The purified PCR product was digested in a sterile Eppendorf tube by mixing 2 μg of purified 
DNA, 5 μl of an appropriate 10x restriction enzyme buffer, 1 μl of the desired restriction 
enzyme (10 u/μl) and Sigma water was added to make up a volume of 50 μl. The mixture was 
then gently mixed by pipetting and incubated for 2 hours at 37°C.  
 
Table 2.12 Restriction enzymes used for STRA8 and C20orf201 digestions 
Gene Restriction enzyme Enzyme buffer Recognition site Catalogue No. Company 
STRA8 XhoI 10x Buffer D 5'…C▼TCGAG…3' 
3'…GAGCT▲C…5' 
R6161 Promega 
C20orf201 HindIII 10x Buffer E 5'…A▼AGCTT…3' 
3'…TTCGA▲A…5' 
R6041 Promega 
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2.10.9 Generation of STRA8 cDNA clone in pCMV6-XL5 
The pCMV6-XL5 vector was digested by NotI and 10x buffer D was used. The optimal 
digestion procedure for this is to refer to Section 2.10.8 
 
2.10.10 DNA isolation from agarose gel 
All 50 μl was separated on 1x TBE agarose gel by electrophoresis. The DNA bands were cut 
out under long wave UV light. The DNA purification was carried out using a High Pure PCR 
purification kit according to the supplier’s manual instructions.  
 
2.10.11 Digestion of pcDNA5/FRT/TO plasmid with restriction enzymes 
The mammalian expression vector, pcDNA5/FRT/TO was obtained as a gift from Dr. J. 
Müller (University of Warwick). This digestion was performed by mixing 2 μg of plasmid 
DNA, 5 μl of an appropriate 10x restriction enzyme buffer, 1 μl of the desired restriction 
enzyme (the same restriction enzymes and buffers that used in Table 2.12) and Sigma water 
was added to make up a volume of 50 μl. The mixture was then gently mixed by pipetting and 
incubated for 2 hours at 37°C. After this, 11 μl of Antartic phosphatase reaction buffer and 1 
μl of Antartic phosphatase (BioLabs; M0289S) were added to the digestion mixture and 
incubated for 15 minutes at 37°C. Thereafter, heat inactivated for five minutes at 65°C. The 
total volume were split into two well agarose gel and the plasmid DNA was purified (refer to 
Section 2.10.10). HyperLadder I (BioLine; Bio-33026) was used to determine the size of the 
migrated fragments. 
 
2.10.12 Calculation the insert and vector molar ratio for ligation 
The concentration for insert DNA and plasmid were measured by using a NanoDrop 
(ND_1000) to determine how much digested insert and plasmid are required for ligation. A 
molar ratio of pcDNA5/FRT/TO vector was used to insert DNA. The amount of insert and 
vector needed was calculated using the following formula: 
The amount of insert = [Amount of vector in ng × Length of insert in bp × molar ratio / length 
of vector in bp]  
 
 
 
 
54 
 
2.10.13 Ligation of digested PCR insert and plasmid 
The ligation of the digested insert and vector was performed using the Quick Ligation Kit 
(BioLabs; M2200S) to anneal the insert of gene of interest into the vector. Around of 50 ng of 
vector was used in one ligation reaction and combined with a 3-fold molar excess of insert. 
The volume of DNA ligation was adjusted to 10 μl with Sigma water. 10 μl of 2x Quick 
Ligation Buffer was added and mixed, followed by the addition of 1 μl of Quick T4 DNA 
Ligase. The ligation mixtures were mixed, centrifuged briefly and incubated at room 
temperature for 5 minutes. Finally, the samples were chilled on ice for 1 minute and then 
transformed into Escherichia coli. To do a self-ligation test, a control reaction containing all 
the components above except the DNA insert was set up.  
 
2.10.14 Preparation of LB and LB agar media for E. coli culture 
The LB (Luria Bertani) and LB agar media components were detailed in the following table. 
 
Table 2.13 Composition of LB and LB agar media 
LB medium (1 L) LB agar medium (1 L) 
Reagent Volume Reagent Volume 
Bacto
®
-Tryptone; 211705           10 g/L Bacto®-Tryptone          10 g/L 
Bacto
®
-Yeast Extract; 212750     5 g/L Bacto®-Yeast Extract     5 g/L 
NaCl              10 g/L NaCl              10 g/L 
  Bacto
®
-Agar; 214030                  15 g/L 
 
The above reagents (Table 2.13) for each medium was added to a sterile bottle contained 900 
ml of distilled water and stirred. Distilled water was added up to one litter, followed by 
autoclaving for 20 minutes at 120°C on the same day they were made up. The media bottles 
were cooled and Ampicillin antibiotic (Sigma-Aldrich; A9518) was added to make a final 
concentration of 100 μg/ml. 25 ml of the LB/ amp/ agar medium was poured onto each 
labelled Petri dish. The dishes were then left to solidify at room temperature in clean bench. 
The LB media and plates were stored at 4°C. 
 
2.10.15 Transformation of recombination plasmid into competent E. coli cells 
The vials of DH5α competent E. coli (BioLabs; C2987) were removed from -80°C and placed 
on ice for 5 minutes to thaw. 5 μl of the ligation mixture (refer to Section 2.10.13) was 
transferred to a chilled Eppendorf tube. The thawed competent cells were mixed by flicking 
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tube and 25 μl of the cells were taken to the previous ligation Eppendorf tube. The cells were 
then mixed with the DNA by pipetting up and down or flicking the tubes 4-5 times. The 
mixture was immediately placed on ice for 30 minutes, followed by heating shock the cells at 
42°C for 30 seconds and then the tubes were immediately placed on ice for 5 minutes. 270 μl 
of prewarmed (37°C) SOC outgrowth medium (BioLabs; B9020S) was added to each 
transformation reaction and then the tubes were incubated at 37°C for 60 minutes with 
vigorous shaking (approximately 250 xg). The Petri dishes plates (refer to Section 2.10.14) 
were warmed at 37°C for 30 minutes and 50-100 μl of the transformation reactions were 
spread out onto the required plates using a sterile spreader sealed in a flame. The plates were 
stored at room temperature until the liquid had been absorbed. The plates were then inverted 
and incubated overnight (12-16 hours) at 37°C. The tube for testing E. coli efficiency was 
carried out by taking 1 μl from undigested pcDNA5/FRT/TO (20 ng/μl) and then 
transformation was performed.  
 
2.10.16 PCR colony screening 
One colony was picked from the overnight plates by using a micropipette tip and rinsing it 
into a new Eppendorf tube containing 20 μl of LB medium with Ampicillin. PCR screening 
was directly carried out using the following reaction: 2 μl was taken from the LB/ colony 
mixture and transfer to PCR tube containing 12.5 μl of BioMix red, 0.5 μl of each primer and 
9.5 μl of distilled water. The primer sequences are listed in Table 2.14. The PCR program is 
described in Section 2.10.5. 15 μl of PCR mixture was run on 1x TBE agarose gel to 
determine the presence of the gene of interest. 
 
Table 2.14 Primers used in PCR colony screening and their amplicon size  
Human gene Primer name Primer sequence Ta* Amplicon size 
STRA8 STRA8 F1 
STRA8 R1 
5'-TGGCAGGTTCTGAATAAGGC-3' 
5'-GAAGCTTGCCACATCAAAGG-3' 
58.4°C 726 bp 
C20orf201 C20orf201 F1 
C20orf201 R1 
5'-ATCTGCCTCTTCGGCGACCTG-3' 
5'-ACACTCTCAGTCGCCGTCAC-3' 
60°C 505 bp 
Ta* - Annealing temperature 
 
2.10.17 Preparation of E. coli glycerol stock 
As a result of positive PCR screening, the remaining LB/ colony mixture (18 μl) was 
transferred to a sterile 50 ml Falcon tube containing 10 ml of LB medium containing the 
appropriate selective antibiotic. The tube was grown overnight at 37°C with vigorous shaking. 
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Next day, a glycerol stock of plasmid containing E. coli was prepared in a new cryovial by 
taking 1 ml of overnight culture of the bacteria plus 200 µl of 100% a sterile glycerol and 
mixed well by vortex. The plasmid name, cloned ID, cloning site, date and strain of bacteria 
were recorded on the vial and stored at -80°C freezer for long-term storage. The miniprep was 
prepared with 9 ml rest of bacteria culture (refer to Section 2.10.19). The purified DNA was 
stored at -20°C freezer. 
 
2.10.18 Streaking out from a glycerol stock 
To recover bacteria from the glycerol stock, the cryovial was taken from -80°C freezer and 
opened on a clean bench. A sterile loop was used to scrape off a portion from the top of the 
frozen glycerol stock. The vial was immediately returned to the -80°C freezer, while the 
bacteria streak was rinsed onto an LB agar plate containing selective marker (as required) and 
grown overnight at 37°C. On the next day, one single colony was picked up and incubated 
into 10 ml of LB medium, which contained appropriate selective antibiotic. It was incubated 
overnight at 37°C with vigorous shaking.  
 
2.10.19 Purification of plasmid DNA from E. coli 
The bacterial cells were harvested by centrifugation for 15 minutes at 6,000 xg at 4°C. The 
supernatant was discarded and the plasmid DNA was isolated from the bacterial pellet using 
QIAprep Spin Miniprep Kit (Qiagen; 27106) as per the manufacturer’s instructions. 1 μl of 
purified plasmid DNA was run onto 1x TBE agarose gel to check DNA.  
 
2.10.20 Confirming the orientation of C20orf201   
After cloning with C20orf201 fragment 1 and 2, the pcDNA5/FRT/TO was further analysed 
using the XhoI restriction enzyme to determine the right orientation of each fragment. 2 μg of 
plasmid is digested by the required restriction enzyme and then the digestion procedure was 
described in Section 2.10.8.  
 
2.10.21 Confirming the DNA sequencing of inserts 
The plasmid DNA amount of 80 ng/μl in a total volume of 15 μl was put in a clean Eppendorf 
tube. The tubes were then sent at room temperature to Eurofins MWG for DNA sequencing. 
The plasmid was sequenced with the CMV forward and BGH reverse primers to confirm that 
the gene of interest was cloned in the correct orientation for expression. The primer sequences 
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are listed in Table 2.15. The result of the correct sequencing of inserts was blasted and aligned 
against the expected sequence. 
 
Table 2.15 Primers used for checking DNA sequencing of inserts 
Primer name Primer sequence Concentration 
CMV forward  5'-CGCAAATGGGCGGTAGGCGTG-3' 10 pmol 
BGH reverse  5'-TAGAAGGCACAGTCGAGG-3' 10 pmol 
 
2.11 Flp-In T-REx-293 cell line 
2.11.1 Growth and maintenance of Flp-In T-REx-293 cell line 
The cell lines were maintained in the complete DMEM, which contained 10% heat inactivated 
FBS (refer to Section 2.1.3 for cells thawing). The thawed cells were grown in T75 cm
2 
and 
incubated in humidified incubator at 37°C and 5% CO2 for 16-24 hours, and then the media 
were aspirated off and replaced with 10 ml of fresh, complete DMEM containing 10 µg/ml of 
blasticidin S (InvivoGen; ant-bl-1) and 200 µg/ml zeocin (Invitrogen; R25001). The cells 
were incubated at 37°C and checked daily until the cells were 80-90% confluent. The 
confluent cells were routinely split 1:2 in T75 cm
2 
flasks as follows. After removal of the 
growth medium, cells were washed once with 5 ml 1xPBS to remove excess medium and 
serum. 1 ml of trypsin EDTA solution was then added to the flask and placed at 37°C for 
about 3 minutes. The cells were checked under a microscope to confirm that most of the cells 
had detached. After the cells were detached, 5 ml pre-warmed culture medium was added to 
the T75 cm
2 
flask, and the suspension was briefly pipetted up and down to break up clumps of 
cells. The cells then split into new flasks containing zeocin and blasticidin. The cells were 
frozen as soon as possible to keep stocks of the early passage number (refer to Section 2.1.4 
for cells freezing).  
 
2.11.2 Preparation of LyoVec transfection 
The cells were transfected with LyoVec (InvivoGen; lyec-12) to generate stable inducible cell 
lines. The LyoVec was prepared by adding 2 ml of deionized sterile water per vial and 
homogenized by vortexing gently for 30 seconds. The vial was placed for at least 30 minutes 
before starting transfection or stored at 4°C until required.  
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2.11.3 Preparation of transfection and DNA complexes 
The LyoVec transfection reagent was incubated at room temperature and gently vortexed to 
homogenize before used. 1 µg pcDNA5/FRT/TO::STRA8 or pcDNA5/FRT/TO::C20orf201 
plasmid DNA plus 10 µg of pOG44 at a ratio of 1:9, respectively were taken to a sterile 1.5 
ml Eppendorf tube containing 400 µl of LyoVec and then mixed gently. pOG44 plasmid was 
obtained from Dr. J. Müller (University of Warwick). pcDNA5/FRT/TO construct alone was 
prepared as a negative control. The LyoVec- DNA complexes were incubated at room 
temperature for at least 15 minutes to allow the formation of the complex. The LyoVec™- 
DNA complexes were used immediately for transfection of cells. 
 
2.11.4 Transfection of Flp-In T-REx-293  
The Flp-In T-REx-293 cells were seeded at 2×10
6
 cells culture medium containing serum in 
10 cm dishes and incubated with complete DMEM supplemented with 200 µg/ml zeocin and 
10 µg/ml blasticidin medium for 24 hours. Next day, the LyoVec and DNA complexes were 
prepared (refer to Section 2.11.3). The medium was removed from cells and replaced with 
fresh complete DMEM containing blasticidin, but without zeocin. The LyoVec -DNA 
complexes were added directly to the medium and the dish was swirled to distribute the 
complex. 24 hours after transfection the media were removed and replaced with complete 
DMEM + blasticidin. 48 hours post-transfection the cells were split directly 1:4 into medium 
supplemented with 100 µg/ml of hygromycin B (Invitrogen; 10687-010). The cells were split 
at density of less 25% confluent to increase antibiotic efficiency. The complete DMEM + 
blasticidin + hygromycin was refreshed every 2-3 days until visible foci appeared. 
 
2.11.5 Isolation of individual colonies of transfected cells 
After 7-10 days adding hygromycin to cell culture medium, few hygromycin resistance foci 
appeared. At this state, the medium was removed from the dish and cells were washed once 
with 5 ml 1xPBS. The cylinder (Sigma-Aldrich; C1059) was placed over a colony of cells by 
using a sterile curved forceps to pick up individual colony. The cylinder was pressed gently to 
seal the space between the cylinder and the dish. The cylinder was filled with the appropriate 
amount of trypsin and incubated at 37°C for 2 minutes. The cells were then checked for 
detachment under a microscope and growth media were added to resuspend the cells, and then 
the cells were transferred to a 6-well plate containing 2 ml of growth media supplemented 
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with 100 µg/ml hygromycin. The cells from one well of 6-well plates was transferred to 10 
cm dish and grown to confluence. Multiple vials were frozen.  
 
2.11.6 Isolation of genomic DNA from individual colony 
2×10
6
 cells were used for genomic DNA isolation. This was started by removing the medium 
and washed the cells once with 1xPBS. Cells were trypsinized and the cells were harvested in 
a new 1.5 ml Eppendorf tube. The cells were then centrifuged at 1,500 xg for 5 minutes to 
pellet the cells. The supernatant was removed and 500 µl 1xPBS was added to the cells pellet 
to wash the cells. The cells were spun again as previous, followed by removing the PBS and 
the pellet was kept. Wizard® SV Genomic DNA Purification System (Promega; A2361) was 
used to isolate the genomic DNA as per the manufacturer’s instructions. The genomic DNA 
was eluted in 100 µl nuclease free water. 1 µl of RNase (Promega; A797C) was added to the 
eluted genomic DNA to remove co-purified RNA, followed by incubation at room 
temperature for 15 minutes. The quality of DNA samples were tested by PCR using β ACT 
primers.  
 
2.11.7 PCR screening of different integration in Flp-In T-REx-293  
To confirm that the gene of interest, STRA8 or C20orf201, was integrated correctly into the 
genome, a PCR was carried out using primers that are listed in Table 2.16. The PCR reactions 
and program were carried out as the same as in RT-PCR reaction (refer to Section 2.5) but 
with one difference, 2 µl of genomic DNA was used instead of cDNA. 
 
Table 2.16 Primer sequences for PCR and their expected amplicon size 
Primer name Primer sequence Ta* Amplicon size 
PSV40 F1 
Hygromycin R1 
5'-CAGTTAGGGTGTGGAAAGTC-3' 
5'- GCCATGTAGTGTATTGACCG-3' 
58.4°C 805 bp 
STRA8 F5 
LacZ-Zeocin R1 
5'-CTTTGATGTGGCAAGCTTCC-3' 
5'-GCGATTAAGTTGGGTAACGC-3' 
58.4°C 900 bp 
C20orf201 F1 
LacZ-Zeocin R1 
C20orf201 F7 
5'-ATCTGCCTCTTCGGCGACCTG-3' 
5'-GCGATTAAGTTGGGTAACGC-3' 
5'-GTGAAGCTTACCATGCCGCCGCCAGCGAA-3' 
58.4°C 
 
58.4°C 
1161 bp 
 
1400 bp 
Ta* - Annealing temperature 
 
2.11.8 LacZ staining of Flp-In T-REx-293 cells 
Staining of cell lines used in this study was performed in 60 mm plates. Cells were seeded at 
3×10
6
 cells and incubated under growth condition for 24 hours. On the next day, the growth 
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medium was removed from the cells and rinsed once with 2 ml 1xPBS. The cells were then 
fixed and stained using the β-Gal Staining Kit (Invitrogen; K1465-01) according to the 
instruction of the manufacturer to detect of β galactosidase. The cells were incubated at 37°C 
for 60 minutes in staining solution and then checked under a microscope for the development 
of blue colour. The staining solution was replaced with 70% glycerol for long-term storage of 
stained plates and then kept at 4°C. 
 
2.11.9 Induction of STRA8 and C20orf201 genes in Flp-In T-REx-293  
The cells were seeded in T75 cm
2 
flask at the desired density with complete DMEM 
containing foetal bovine serum, gold (PAA, Catalogue number; A11-251, Lot A25112-7017) 
+ blasticidin + hygromycin and incubate until attached to the plastic. The cells were refreshed 
with media containing 2 µg/ml tetracycline (Sigma-Aldrich; T3383) to induce expression and 
then incubated at 37°C for 24 hours. Two flasks were used as negative controls, untransfected 
cells and a flask of cells were transfected with the pcDNA5/FRT/TO plasmid. Thereafter, the 
cells were harvested for RT-PCR (refer to Section 2.5) and Western blot (refer to Section 
2.7.3).  
The cell lines that were inserted with STRA8 were also treated with two types of inducer 
agent, all-trans retinoic acid (Sigma-Aldrich; R2625) and 9-cis retinoic acid (Sigma-Aldrich; 
R4643) at a final concentration of 5 µM and 10 µM. Thereafter, the cells were harvested for 
RT-PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
Chapter 3.0: mRNA expression profiles of 
genes identified via a bioinformatics analysis 
to detect new human CT genes  
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
3.1 Introduction  
The identification of new cancer-specific biomarkers will be a major challenge in the 
development of prognostic and diagnostic interventions for cancer (Feichtinger et al., 2012b). 
Humans possess a class of genes that expression is normally limited to adult testis; however, 
expression of these same genes is also characteristic of a wide range of cancers: these genes 
are termed cancer-testis (CT) genes (Whitehurst, 2014). The presence of the blood-testis 
barrier leads to the products of these genes not being recognised as ‘self’ by the human 
immune system when produced by cancer cells (Li et al., 2012; Mruk and Cheng, 2010). This 
feature makes CT antigens very promising targets for clinical purposes, including their use as 
diagnostic markers, in the development of vaccines and as immunotherapeutic targets (Fratta 
et al., 2011; Lim et al., 2012; Mirandola et al., 2011; Whitehurst, 2014). 
 
Different bioinformatics analysis methods have been used to identify new human CT antigen 
candidate genes (for example, see Hofmann et al., 2008). Two distinct bioinformatic tools 
were used by Feichtinger et al., (2012b; 2014) to identify potential CTA genes. The first tool 
was based on expressed sequence tag (EST) analysis data (Feichtinger et al., 2014). The 
second bioinformatic pipeline was based on cancer Microarray data (Feichtinger et al., 
2012b). Candidate CTA genes were then validated using the RT-PCR technique in the current 
study.  
 
The bioinformatic approach (Figure 3.1) was initiated by searching for mouse meiosis-
specific genes using the GermOnline database (http://www.germonline.org/), which gives 744 
mouse genes. These 744 mouse meiotic spermatocyte-specific genes were then mapped to the 
human orthologous genes and the result of this assignment was 408 human genes (Feichtinger 
et al., 2012a). These 408 orthologous human genes were then filtered using the MitoCheck 
program (Neumann et al., 2010; http://www.mitocheck.org) to eliminate genes that were 
expressed during mitotic division. The results from the MitoCheck filter left 375 human 
potential meiosis-specific genes. These human genes were then checked against two distinct 
bioinformatic programmes using previously published Microarray and EST data sets 
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(Feichtinger et al., 2012a; 2012b; 2014). The rationale for using two bioinformatic pipelines 
was to check the expression of the tissue and cancer specificity of these genes. 
 
The final number of genes that were potentially of interest from the EST and Microarray 
analysis were 177 and 40, respectively. The EST analysis produced a much greater number of 
potential candidate genes when contrasted with that of the Microarray search. The 177 
candidate genes identified through the EST pipeline were then divided into four groups based 
on the expression pattern shown in the EST analysis data. The first group comprises 9 genes, 
which are predicted to be cancer-testis-restricted genes (class 1); the second group consists of 
75 genes, which are predicted to be testis-restricted genes (class 2); the third group comprises 
21 genes, which are predicted to be cancer-testis-CNS-restricted genes (class 3) and the fourth 
group can be described as testis-CNS-restricted genes, and it contains 72 genes (class 4) 
(Feichtinger et al., 2012a; 2014; Sammut et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
Checking for mouse 
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Validation with RT-PCR in 
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Expression are classified into 
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 1) Testis-restricted 
 
 
 4) Testis-CNS-selective 
 
Validation with RT-PCR in 33 
human cancer tissues and cell lines 
Could be considered as novel candidate CT genes Excluded from candidate genes 
A 
i ii 
Figure 3.1 Method of identifying a novel CT gene candidate with the use of bioinformatics 
analyses. (A) Displays the bionformatic procedure that was used to identify CT genes. (B) Validation 
using RT-PCR with 21 human normal tissues. i) Genes expressed in several normal tissues were 
excluded from further assessement. ii) Shows the genes expressed only in the following: 1) in adult 
testis; 2) in adult testis and CNS; 3) in adult testis and selective normal tissues; or 4) in adult testis, 
CNS and selective normal tissues (one or two non-testis/CNS normal tissue). Genes from groups 1-4 
were then examined further in 33 human cancer cell lines and tissues to identify potential CT gene 
candidates. 
2) Testis-CNS-restricted  
3) Testis-selective 
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In this chapter, 21 genes were chosen at random from the 105 candidate genes in classes 1-3 
identified via the EST analysis. Another 11 genes were also chosen at random from the 40 
candidate genes identified by the Microarray analysis. RT-PCR was performed to validate the 
tissue specificity of these genes. The RT-PCR validation employed RNA from 21 normal 
tissues, including adult testis. The genes that were expressed only in the testis, or in the testis 
and CNS tissues, or in the testis and no more than two additional normal tissues, were further 
examined by RT-PCR using 33 different RNAs isolated from diverse cancer cell lines and 
tissues.  
 
3.2 Results 
3.2.1 Validation of candidate genes identified from Microarray data  
11 genes were identified from the gene expression Microarray data analysis pipeline, which 
predicted they are testis-specific. In the present study, the expression of these genes was 
analysed using RT-PCR. These predicted genes and their known functions are listed in Table 
3.1. 
 
Table 3.1 Meiosis specific-genes identified through the Microarray study and their functions  
Gene symbol Gene name Function Reference 
CCNA1 Cycline A1 Cell cycle regulator  Weiss et al., 2012 
C2orf69 
Chromosome 2 open 
reading frame 69 
Function unknown --- 
C11orf70 
Chromosome 11 open 
reading frame 70 
Function unknown --- 
C20orf195 
Chromosome 20 open 
reading frame 195 
Function unknown --- 
FSCN3 
Fascin actin-bundling 
protein 3, testicular 
Function unknown --- 
GAGE1 G antigen 1 Function unknown --- 
HORMAD1 
HORMA domain 
containing 1 (CT46) 
Essential for meiotic function 
in human spermatogenesis, 
SC formation and 
homologous alignment 
Miyamoto et al., 2012 
 
Daniel et al., 2011 
 
NOL4 Nucleolar protein 4 Function unknown --- 
SSX2 
Synovial sarcoma, X 
breakpoint 2 
Associated with 
transcriptional repressor 
activity  
Chen et al., 2012 
UBL4B Ubiquitin-like 4B 
Post-translation protein 
modification 
Yang et al., 2007 
ZNF558 Zinc finger protein 558 Function unknown --- 
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3.2.1.1 Analysis of expression in normal tissues 
In order to investigate their testis-specificity, the genes listed in Table 3.1 were subjected to 
validation by a RT-PCR analysis with a range of RNAs from 21 human normal tissues. These 
RNAs were purchased from Clontech and Ambion. RT-PCR intron-spanning primers were 
designed for every gene (refer to Table 2.2). cDNA was synthesised from the RNA. In the 
RT-PCR screening, two positive control genes were used; the expression of β-Actin was 
displayed as a positive control for the cDNA quality and MAGE-A1 was used as a positive 
control for a known CT gene (testis-specific). Triplicate PCR was performed for each gene. 
 
The RT-PCR screening of these genes on the multiple normal tissues indicated 7 genes 
(CCNA1, C2orf69, C11orf70, C20orf195, HORMAD1, NOL4 and ZNF558) were expressed in 
numerous normal tissues, including testis (Figure 3.2); therefore, these genes were all 
dismissed and were not screened for expression in the human cancer tissues or cell lines, 
because they did not display the expected expression pattern of either a meiosis-specific gene 
or a CT gene in normal tissues. The remaining 4 predicted meiosis-specific genes were 
classified into three sub-classes according to their expression profile in the normal tissues. 
The first sub-class contained 2 genes, SSX2 and UBL4B, which had expressions restricted to 
the testis in the normal tissue panel (Figure 3.3). The second sub-class was a testis-selective 
gene, GAGE1, which was expressed in the normal tissues and as a very weak expression in 
uterus (Figure 3.4). The third sub-class obtained from normal tissue analysis was a testis-
CNS-selective gene, FSCN3, which had expression limited in the testis, CNS tissues and very 
weak expression in the prostate, lung and thymus (Figure 3.5). Given the very weak signal in 
these three somatic tissues, FSCN3 was classified as ‘selective’ despite the threshold being set 
as expression in no more than two other somatic tissues. 
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Figure 3.2 RT-PCR analysis of the mRNA from normal human tissues for the genes excluded due 
to broad somatic expression. Agarose gels show the RT-PCR assays of distinct genes from the 
Microarray pipeline which were excluded due to their expressions in a range of human normal tissues. 
These genes are CCNA1, C2orf69, C11orf70, C20orf195, HORMAD1, NOL4 and ZNF558. The 
expression of all these genes was found in multiple normal cells. β ACT expression was used as a 
positive control for the cDNA samples and the expression of MAGE-A1 was used as a positive control 
for the CT antigen genes in normal tissues. The expected amplicon size of each gene is shown on the 
left between brackets. 
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Figure 3.3 RT-PCR analysis of the mRNA from normal human tissues for the testis-restricted 
genes identified from the Microarray analysis. Agarose gels show the RT-PCR assays for the 
testis–restricted genes, SSX2 and UBL4B that were identified from the microarray pipeline. cDNAs 
were isolated from the total RNA from 21 normal tissues. Both genes were expressed only in the 
normal testis. β ACT expression was used as a positive control for the cDNA samples and the 
expression of MAGE-A1 was used as a positive control for a CT antigen genes in human normal cells. 
The expected amplicon size of each gene is shown on the left between brackets. 
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Figure 3.4 RT-PCR analysis of the mRNA from normal human tissues for the testis-selective 
gene identified from the Microarray analysis. Agarose gels show the RT-PCR assays for the testis–
selective gene, GAGE1 was identified from the microarray pipeline. cDNAs were isolated from the 
total RNA from 21 normal tissues. The expression of GAGE1 was in the normal testis and uterus. β 
ACT expression was used as a positive control for the cDNA samples and the expression of MAGE-A1 
was used as a positive control for the CT antigen genes in human normal cells. The expected amplicon 
size of each gene is shown on the left between brackets. 
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Figure 3.5 RT-PCR analysis of the mRNA from normal human tissues for the testis-CNS-
selective gene identified from the Microarray analysis. Agarose gels show the RT-PCR assays for 
the testis–CNS-selective gene, FSCN3 was identified from the microarray pipeline. cDNAs were 
isolated from the total RNA from 21 normal tissues. The expression of FSCN3 was in the normal 
testis, prostate, central nervous system, lung and thymus. β ACT expression was used as a positive 
control for the cDNA samples and the expression of MAGE-A1 was used as a positive control for the 
CT antigen genes in human normal cells. The expected amplicon size of each gene is shown on the left 
between brackets. 
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3.2.1.2 Analysis of candidate gene expression profiles in cancer cells/tissues 
Expression of the testis-restricted genes SSX2 and UBL4B, the testis-selective gene GAGE1 
and the testis-CNS-selective gene FSCN3 were further investigated using cDNA from 33 
human cancer cell lines and tissues derived from different organs. The expression of β-Actin 
was displayed as a positive control for the cDNA quality, while MAGE-A1 was used as a 
positive control for a known candidate CT genes. Triplicate PCR was performed for each 
gene. 
 
SSX2 and GAGE1 were found to display expressions in two or nine cancer cells, respectively 
(Figure 3.6); this means that both genes are considered to be good candidates for the CT genes 
and were classified as CT-restricted and CT-selective genes, respectively. SSX2 displayed 
expression exclusively in the normal testis and also exhibited expression in one or more 
cancer types, whereas the expression profile for GAGE1 was observed in one of the non-
testis-CNS normal tissues in addition to the testis, but also displayed expression in one or 
more cancer samples. The RT-PCR expression profile of UBL4B was not observed in any of 
the cancer samples tested here; therefore, this gene was classified as a testis-specific gene 
(Figure 3.7). Conversely, this gene may be expressed in cancer cell lines and/or tissues not 
covered in the current study. For this reason, the UBL4B gene was not dismissed as a CT 
candidate gene. 
 
The FSCN3 gene was expressed in three cancer cell lines, including HCT116, TO14 and K-
562. However, the RT-PCR product for FSCN3 was different, because it gave the expected 
band sizes in HCT116 and K-562, but not in the TO14 cell line, when compared to the testis. 
The RT-PCR product of FSCN3 in the TO14 cell line was higher than expected 
(approximately 1000 bp). Therefore, RT-PCR products for FSCN3 in the testis and TO14 
were subjected to DNA sequencing to ensure that the correct target was being amplified (see 
Table 3.2 for sequencing results). The partial sequence obtained was virtually identical to that 
of FSCN3 indicating this higher molecular weight band could be a splice variant. The exact 
nature of this valiant was not determined. After obtaining the sequencing results, FSCN3 is 
considered as a potential CT gene and was classified as a CT-CNS-selective gene due to its 
expression profile in the normal testis, central nervous system tissues and no more than two 
additional non-testis-CNS normal tissues, but it also showed expression in at least one cancer 
tissue and/or cell line.   
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Figure 3.6 RT-PCR analysis of mRNA from human cancer cells for the potential CT antigen 
genes identified from the Microarray analysis. Agarose gels show the RT-PCR assays for the 
potential CT antigen genes identified by the Microarray pipeline. The mRNA expressions of these 
genes were positive in different cancer cell lines and tissues. The expression of SSX2 was shown in 
normal testis, COLO800 and K-562 cell lines. The expression of GAGE1 was observed in 9 cancer 
cell lines. FSCN3 expression was shown in three cancer samples, but the product size in TO14 was 
larger than expected. β ACT expression was used as a positive control for the cancer cDNA samples 
and the expression of MAGE-A1 was used as a positive control for the CT antigen genes in human 
cancer cells. The expected amplicon size of each gene is shown on the left between brackets. 
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Figure 3.7 RT-PCR analysis of mRNA from human cancer cells for the testis-restricted gene 
identified from the Microarray analysis. Agarose gels show the RT-PCR assays for the testis–
restricted gene, UBL4B, from the Microarray pipeline. cDNAs were isolated from the total RNA from 
33 cancer  tissues and cell lines.UBL4B was expressed only in the normal testis tissue and no 
expression was detected in any cancer samples tested. β ACT expression was used as a positive control 
for the cancer cDNA samples and the expression of MAGE-A1 was used as a positive control for the 
CT antigen genes in human cancer cells. The expected amplicon size of each gene is shown on the left 
between brackets. 
73 
 
3.2.1.3 Summary of the sequencing results for the Microarray identified genes  
The PCR product for the desired gene was purified and sequenced in order to amplify the 
correct sequence. The sequences recovered from the sequencing were aligned using Basic 
Local Aliment Search Tools (BLAST; NCBI http://blast.ncbi.nlm.nih.gov/Blast.cgi). The 
sequencing results of the Microarray genes are summarised in Table 3.2.  
 
Table 3.2 Summary of the sequencing results for the RT-PCR screening of the Microarray 
analysis genes  
Gene  Primer 
Expected 
size (bp) 
Sequenced in Sequence 
size (bp) 
Sequence 
identity % Normal tissues Cancer samples 
FSCN3 F1 598 
Testis 
Prostate 
Thymus 
--- 
--- 
--- 
--- 
TO14 
517 
79 
268 
837 
100 
100 
99 
100 
GAGE1 F1 245 Uterus --- 79 95 
NOL4 F1 547 
Testis (upper band) 
Testis (lower band) 
--- 
--- 
154 
154 
100 
99 
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3.2.2 Validation of candidate genes identified by EST database analysis  
177 genes were identified from the EST data analysis pipeline with predicted meiosis-
associated genes. In the present study, the mRNA expressions of 21 of these genes from class 
1-3 were analysed using the RT-PCR technique. These genes and their known functions are 
listed in Table 3.3. 
 
Table 3.3 Predicted meiosis associated-genes identified through the EST analysis and their 
functions  
Gene symbol Gene name Function Reference 
BTG4 
B-cell translocation 
gene 4 
Cell cycle regulator Auer et al., 2005 
C5orf50 
Chromosome 5 open 
reading frame 50 
Function unknown --- 
C11orf65 
Chromosome 11 open 
reading frame 65 
Function unknown --- 
C20orf201 
Chromosome 20 open 
reading frame 201 
Function unknown --- 
COX7B2 
Cytochrome c oxidase 
subunit VIIb2 
Function unknown --- 
CST8 
Cystatin 8, also known 
as CRES 
A protease inhibitor Cornwall et al., 1999 
DAZL 
Deleted in azoospermia-
like 
Encodes a germ-cell-specific 
RNA-binding protein that is 
essential in spermatogenesis 
Reynolds and Cooke, 
2005; Smorag et al., 
2014 
FABP9 
Fatty acid binding 
protein 9 
Function unknown --- 
KCNU1 
Potassium channel, 
subfamily U, member 1 
Function unknown --- 
LYRM1 LYR motif containing 1 Function unknown --- 
ODF3 
Outer dense fibre of 
sperm tails 3 
A component of sperm 
tail 
Ghafouri-Fard and 
Modarressi,  2012b 
PFN3 Profilin 3 A role in spermatogenic cells Behnen et al., 2009 
PRSS45 Protease, serine, 45 Function unknown --- 
SLC25A41 
Solute carrier family 25, 
member 41 
Transport molecule over the 
mitochondrial membrane 
Haitina et al., 2006 
SSX5 
Synovial sarcoma, X 
breakpoint 5 
May act as transcriptional 
repressor 
de Bruijn et al., 2002 
STRA8 
Stimulated by retinoic 
acid 8 
Meiosis initiation in male 
and female in mice 
Anderson et al., 2008 
TEKT5 Tektin 5 Function unknown --- 
TEPP 
Testis, prostate and 
placenta expressed 
Function unknown --- 
TMEM225 
Transmembrane protein 
225 
Function unknown --- 
TULP2 Tubby like protein 2 Function unknown --- 
WDR27 WD repeat domain 27 Function unknown --- 
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3.2.2.1 The results of RT-PCR screening of the EST genes in normal tissues  
The genes listed in Table 3.3 were validated by a RT-PCR analysis with a range of RNAs 
from 21 human normal tissues in order to investigate their potential testis-specificity. These 
RNAs were purchased from Clontech and Ambion. Intron-spanning primers were designed 
for every gene (refer to Table 2.2) and were used to perform RT-PCR using cDNA 
synthesised from the RNA preparation. Two positive control genes were used during the RT-
PCR screening; the expression of β-Actin was displayed as a positive control for the cDNAs 
quality and MAGE-A1 was used for a positive control as a known CT gene. Triplicate PCR 
was performed for each gene. 
 
The RT-PCR screening of the 21 genes predicted by the EST bioinformatic analysis on the 
multiple normal tissues demonstrated that 10 genes (BTG4, C11orf65, COX7B2, DAZL, 
LYRM1, PRSS45, SLC25A41, TEKT5, TULP2 and WDR27) were expressed in numerous 
normal tissues including testis (Figure 3.8); therefore, these genes were all dismissed and 
were not screened for expression in the human cancer tissues or cell lines because they did not 
display the expected expression pattern of either a meiosis gene or a CT gene in normal 
tissues. The remaining 11 genes were categorised into four groups according to their 
expression profile observed in the normal tissues. The first group contained 6 genes, C5orf50, 
CST8, FABP9, ODF3, STRA8 and TMEM225, and had expression restricted to the testis in the 
normal tissue panel (Figure 3.9). For the STRA8 gene, the expected PCR product size in the 
testis sample according to design of forward and reverse primers is 510 bp, but the RT-PCR 
displayed higher band of 723 bp after being confirmed by DNA sequencing (sequencing 
results are summarised in Table 3.4). The second group was made up of testis-selective genes 
such as TEPP, which was expressed in two or fewer of the somatic normal tissues; for TEPP 
there was a weak expression in the trachea (Figure 3.10). The third group obtained from 
normal tissue was composed of testis-CNS-selective genes, PFN3 and SSX5, which had 
expressions limited in the testis and central nervous system tissues and weak expression in 
uterus and thymus, respectively (Figure 3.11). The last genes were C20orf201 and KCNU1, 
which had expressions restricted to the testis and central nervous system tissues; therefore, 
these genes were classified as a testis-CNS- restricted (Figure 3.12).  
 
The expected product size for the C20orf201 gene is 505 bp; however, it was shown that the 
PCR product for this gene in the testis cDNA was smaller than 505 bp; therefore, the PCR 
product was confirmed by sequencing that showed a significant sequence similarity to 
C20orf201 (see Table 3.4 for sequencing results). Conversely, KCNUI expression in the brain 
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cerebellum and spinal cord exhibited a band of unexpected size (approximately 280 bp) 
compared to its expression in the normal testis, which was 642 bp. However, sequencing of 
this PCR product showed a significant sequence similarity to KCNU1 (see Table 3.4). The 
KCNU1 cDNA containing whole open reading frame (ORF) has a length of 3450 bp and 
consists of 27 exons. The designed primers included exons from number 8 to 14, but the 
sequence results obtained cover exons 9. These results could suggest another splice variant for 
KCNU1.  
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Figure 3.8 RT-PCR analysis of the mRNA for the genes excluded identified from the EST 
pipeline analysis. Agarose gels show the RT-PCR assays of the genes from the EST pipeline which 
were excluded because expressions were shown in a several human normal tissues and these genes 
are BTG4, C11orf65, COX7B2, DAZL, LYRM1, PRSS45, SLC25A41, TEKT5, TULP2 and WDR27. 
cDNAs were isolated from the total RNA from 33 cancer  tissues and cell lines. The expression of all 
these genes was found in multiple normal cells. β ACT expression was used as a positive control for 
the cancer cDNA samples and the expression of MAGE-A1 was used as a positive control for the CT 
antigen genes in normal tissues. The expected amplicon size of each gene is shown on the left 
between brackets. 
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Figure 3.9 RT-PCR analysis of the mRNA for the testis-restricted genes identified from the EST 
pipeline analysis in human normal tissues. Agarose gels show the RT-PCR assays for the testis–
restricted genes; C5orf50, CST8, FABP9, ODF3, STRA8 and TMEM225 were identified from the EST 
pipeline. cDNAs were isolated from the total RNA from 21 normal cells. These genes were expressed 
only in the normal testis. β ACT expression was used as a positive control for the cDNA samples and 
the expression of MAGE-A1 was used as a positive control for the CT antigen genes in human normal 
cells. The expected amplicon size of each gene is shown on the left between brackets. 
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Figure 3.10 RT-PCR analysis of the mRNA for the testis-selective gene identified from the EST 
pipeline analysis in human normal tissues. Agarose gels show the RT-PCR assays for the testis–
selective gene, TEPP that was identified from the EST pipeline. cDNAs were isolated from the total 
RNA from 21 normal cells. The expression of this gene was exclusively in the normal testis and a faint 
band indicated some expression in the trachea. β ACT expression was used as a positive control for the 
cDNA samples and the expression of MAGE-A1 was used as a positive control for the CT antigen 
genes in human normal cells. The expected amplicon size of each gene is shown on the left between 
brackets. 
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Figure 3.11 RT-PCR analysis of the mRNA for the testis-CNS-selective genes identified from the 
EST pipeline analysis in human normal tissues. Agarose gels show the RT-PCR assays for the 
testis–CNS-selective genes, PFN3 and SSX5 were identified from the EST pipeline. cDNAs were 
isolated from the total RNA from 21 normal cells. The expressions of these genes were shown in the 
testis and central nervous system tissues and also in the number of normal tissues. β ACT expression 
was used as a positive control for the cDNA samples and the expression of MAGE-A1 was used as a 
positive control for the CT antigen genes in human normal cells. The expected amplicon size of each 
gene is shown on the left between brackets. 
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Figure 3.12 RT-PCR analysis of the mRNA for the testis-CNS-restricted genes identified from 
the EST pipeline analysis in human normal tissues. Agarose gels picture illustrating the RT-PCR 
assays for the testis-CNS-restricted genes, C20orf201 and KCNU1 were identified from the EST 
pipeline. cDNAs were isolated from the total RNA from 21 normal cells. The expression of these 
genes was apparent in the testis and in central nervous system tissues.  β ACT  expression was used as 
a positive control for the cDNA samples and the expression of MAGE-A1 was used as a positive 
control for the CT antigen genes in human normal cells. The expected amplicon size of each gene is 
shown on the left between brackets. 
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3.2.2.2 The results of RT-PCR screening of the EST genes in cancer tissues and cell lines 
The testis-restricted genes C5orf50, CST8, FABP9, ODF3, STRA8 and TMEM225; the testis-
selective gene TEPP; the testis-CNS-selective genes PFN3 and SSX5 and the testis-CNS-
restricted genes C20orf201 and KCNU1 were further investigated by RT-PCR in a range of 33 
human cancer cell lines and tissues resulting from different organs. All cell lines in the current 
study were grown and RNAs were made for each cell line. The mRNAs were reverse-
transcribed to cDNAs and RT-PCR was performed. Two positive control genes were used in 
the RT-PCR screening; the expression of β-Actin was displayed as a positive control for the 
cDNAs quality, while MAGE-A1 was used as a positive control for the good candidate CT 
genes. Triplicate PCR was performed for each gene. 
 
Among the above genes identified by the EST bioinformatic analysis, three genes, CST8, 
ODF3 and TMEM225 were not found to exhibit any expression in the cancer samples used in 
the current study; therefore, they were classified as testis-specific genes, because their 
expression was restricted to the normal testis only (Figure 3.13). However, these three genes 
were not dismissed as CT gene candidates and further screening in other cancer cell line 
and/or tissues not covered in this study may express these genes. In contrast, C20orf201, 
C5orf50, FABP9, KCNU1, PFN3, SSX5, STRA8 and TEPP were expressed in different types 
of cancer cells; therefore, they are considered good candidates for CT genes (Figure 3.14). 
Furthermore, these genes according to their expression were classified into four groups. The 
first group was CT-restricted genes, which includes the following: C5orf50, FABP9 and 
STRA8. The second group was CT-selective gene and included only the TEPP gene. The third 
group was CT-CNS-selective and included two genes, PFN3 and SSX5. The last group 
included two genes, C20orf201 and KCNU1 and they were classified as CT-CNS-restricted. 
The results of DNA sequencing for the genes C20orf201, C5orf50, FABP9, KCNU1, PFN3, 
SSX5, STRA8 and TEPP were compared with the reference sequence using the NCBI’s 
BLAST software (http://blast.ncbi.nlm.nih.gov) (see Table 3.4). 
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Figure 3.13 RT-PCR analysis of the mRNA for the testis-restricted genes identified from the 
EST analysis in human cancer cell lines and tumour tissues. Agarose gels show the RT-PCR 
assays for the testis–restricted genes; CST8, ODF3 and TMEM225 from the EST pipeline. cDNAs 
were isolated from the total RNA from 33 cancer  tissues and cell lines. These genes were expressed 
only in the normal testis tissue and no expression observed in any other cancer samples. β ACT 
expression was used as a positive control for the cancer cDNA samples and the expression of MAGE-
A1 was used as a positive control for the CT antigen genes in human cancer cells. The expected 
amplicon size of each gene is shown on the left between brackets. 
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Figure 3.14 RT-PCR analysis of the mRNA for the potential CT antigen genes identified from 
the EST analysis in human cancer cell lines and tumour tissues. Agarose gels show the RT-PCR 
assays for the potential CT antigen genes identified by the EST pipeline. The mRNA expression of 
these genes was positive in different cancer cell lines and tissues.  β ACT expression was used as a 
positive control for the cancer cDNA samples and the expression of MAGE-A1 was used as a positive 
control for the CT antigen genes in human cancer cells. The expected amplicon size of each gene is 
shown on the left between brackets. 
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3.2.2.3 Summary of the sequencing results for the EST identified genes  
The PCR product for the desired gene was purified and sequenced in order to amplify the 
correct sequence. The sequences recovered from the sequencing were blasted using the 
BLAST program. The sequencing results of the EST genes are summarised in Table 3.4 
 
Table 3.4 Summary of the sequencing results for the RT-PCR screening of the EST analysis 
genes  
Gene  Primer 
Expected 
size (bp) 
Sequenced in Sequence 
size (bp) 
Sequence 
identity % Normal tissues Cancer samples 
C5orf50 F1 219 
Testis 
--- 
--- 
TO14 
111 
434 
100 
100 
C20orf201 F1 505 
Testis 
Foetal brain 
--- 
--- 
--- 
--- 
--- 
A2780 
TO14 
Jurkat 
302 
294 
456 
323 
348 
100 
100 
99 
100 
100 
FABP9 F1 161 
Testis 
Thymus 
--- 
--- 
--- 
--- 
PC-3 
A2780 
114 
113 
119 
60 
100 
100 
100 
97 
KCNU1 F1 642 
Testis 
Brain cerebellum 
--- 
--- 
--- 
--- 
NT2 
HCT116 
467 
113 
96 
61 
100 
98 
98 
98 
PFN3 F1 298 
Testis 
Foetal brain 
--- 
--- 
--- 
--- 
--- 
LoVo 
PC-3 
A2780 
257 
94 
178 
180 
166 
99 
100 
100 
100 
100 
SSX5 F1 253 
Testis 
Thymus 
--- 
--- 
--- 
--- 
Uterus tumour 
G361 
215 
212 
211 
204 
97 
98 
98 
97 
STRA8 F1 510 
Testis 
--- 
--- 
--- 
--- 
--- 
Lung tumour 
HEP-G2 
Breast tumour 
Uterus tumour 
662 
660 
408 
40 
246 
100 
99 
98 
100 
98 
TEKT5 F1 543 
Testis 
Spleen 
--- 
--- 
382 
191 
99 
99 
TEPP F1 422 
Testis (upper band) 
Testis (lower band) 
Trachea 
--- 
--- 
--- 
365 
158 
145 
99 
98 
100 
WDR27 F1 579 
Testis 
Uterus (upper band) 
Uterus (lower band) 
--- 
--- 
--- 
411 
136 
35 
100 
99 
97 
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3.3 Discussion 
3.3.1 Summary of the RT-PCR expression profiles for the Microarray and the 
EST genes  
Two bioinformatic studies were used to identify new CT gene candidates. In the current 
study, these genes were tested using a RT-PCR analysis to investigate the expression of these 
genes in a range of normal tissues or/and cancer samples. According to their expression 
profiles as assessed using RT-PCR, candidate genes were determined as potential CT genes, 
because these predicted meiosis-specific genes were observed to show expression in different 
types of cancer samples.  
 
The Microarray bioinformatic analysis identified 40 predicted meiosis-specific genes and 11 
of these genes were chosen at random for RT-PCR screening here (others were screened by 
other group members). RT-PCR analysis of 7 genes showed expression in multiple normal 
tissues, thus all 7 genes were dismissed as candidate CT genes. This screen also identified 4 
of the 11 genes as potential novel CT genes. These 4 genes were characterised after RT-PCR 
screening as the following; SSX2 is a CT-restricted gene; GAGE1 is a CT-selective gene; 
FSCN3 is a CT-CNS-selective gene and UBL4B is a testis-restricted gene. 
 
In contrast, 177 predicted meiosis-specific genes were identified via the EST pipeline and 21 
of these genes were chosen at random for RT-PCR screening here (all other genes were 
screened by other members of the group). In this test, 10 genes were excluded from the CT 
gene candidates due to their expression in different types of non-testis-CNS normal tissues. 
Furthermore, the RT-PCR screening was also identified 11 of the 21 genes as potential novel 
CT genes. These 11 genes have been characterised after RT-PCR screening as the following: 
CST8, ODF3 and TMEM225 are testis-restricted genes; C5orf50, FABP9 and STRA8 are CT-
restricted genes; PFN3 and SSX5 are CT-CNS-selective genes; C20orf201 and KCNU1 are 
CT-CNS-restricted genes and finally, TEPP was categorised as a CT-selective gene. The RT-
PCR expression profiles for the meiosis-specific genes identified by the Microarray and EST 
analysis pipelines are summarised in Figures 3.15 and 3.16 for the Microarray analysis and 
Figures 3.17 and 3.18 for the EST pipelines.  
 
According to this study, the expression of the STRA8 gene was restricted to the testis among 
normal tissues; with additional expression also being shown in three cancer tumours and one 
cell line (HEP-G2). However, RT-PCR analysis showed that the expression profile of the 
C20orf201 gene was observed in the testis and in the tissues of the CNS (brain cerebellum, 
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whole brain, foetal brain and spinal cord). Two bands of C20orf201 were detected in the CNS 
tissues; the large and small sizes of the bands were related to splice variants 1 and 2, 
respectively (see Chapter 5 for more details). The expression of C20orf201 was also found in 
various types of cancer, including MCF-7, uterus tumour and ovarian cell lines (A2780, 
PEO14 and TO14). Therefore, both genes are important and seen as good candidates to 
encode CTAs and promising for being cancer biomarkers in different cancer types. For this 
reason, these genes were chosen for further, in detail studies, described in Chapters 4 and 5, 
respectively.  
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III 
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NOL4 18                      
ZNF558 19                      
IV 
FSCN3 7                      
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Figure 3.15 Summary of the RT-PCR results for the Microarray analysis genes in different 
normal tissues. The expression patterns of individual genes are displayed by rows in the grid, with the 
column corresponding to the normal human tissues used. I. The expression profile of the control gene 
for cDNAs quality. II. The expression pattern of the positive control for CT genes. III. The expression 
pattern for seven genes from the Microarray analysis lists that showed expression in several human 
normal tissues; therefore, these genes were dismissed at this stage. IV. The expression pattern for four 
genes; FSCN3, GAGE1, SSX2 and UBL4B that might to be good CT gene candidates. The 
chromosomal location of all genes is shown in a box in front of the gene name. The dark blue boxes 
indicate the positive expression of the given genes, whereas the empty boxes indicate negative RT-
PCR results. 
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Figure 3.16 Summary of the RT-PCR results for the Microarray analysis genes in different 
cancer tissues and cell lines. The expression patterns of individual genes are displayed by rows in the 
grid, with the column corresponding to the cancer human tissues and cell lines used. I. The expression 
profile of the control gene for cDNAs quality. II. The expression pattern of the positive control for CT 
genes. III. The expression pattern for the predicted meiosis-specific gene. IV. The expression pattern 
for the potential CT antigen genes, which are the CT–CNS–selective gene, FSCN3; the CT–selective 
gene, GAGE1 and the CT–restricted gene, SSX2. The dark blue boxes indicate the positive expression 
of the given genes, whereas the empty boxes indicate negative RT-PCR results. 
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ODF3 11                      
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Figure 3.17 Summary of the RT-PCR results for the EST analysis genes in different normal 
tissues. The expression patterns of individual genes are displayed by rows in the grid, with the column 
corresponding to the normal human tissues used. I. The expression profile of the control gene for 
cDNAs quality. II. The expression pattern of the positive control for CT genes. III. The expression 
pattern for ten genes from the EST analysis lists that showed expression in multiple human normal 
tissues; therefore, these genes were dismissed at this stage. IV. The expression pattern for 11 genes: 
C5orf50, C20orf201, CST8, FABP9, KCNU1, ODF3, PFN3, SSX5, STRA8, TEPP and TMEM225 that 
might to be good CT gene candidates. The chromosomal location of all genes is shown in a box in 
front of the gene name. The dark blue boxes indicate the positive expression of the given genes, 
whereas the empty boxes indicate negative RT-PCR results. 
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Figure 3.18 Summary of the RT-PCR results for the EST analysis genes in different cancer 
tissues and cell lines. The expression patterns of individual genes are displayed by rows in the grid, 
with the column corresponding to the cancer human tissues and cell lines used. I. The expression 
profile of the control gene for cDNAs quality. II. The expression pattern of the positive control for CT 
genes. III. The expression pattern for the predicted meiosis-specific genes. IV. The expression pattern 
for the potential CT antigen genes, which are the CT–restricted genes C5orf50, FABP9 and STRA8; 
the CT–selective gene, TEPP; the CT–CNS-restricted, C20orf201 and KCNU1 and the CT–CNS-
selective, PFN3 and SSX5. The dark blue boxes indicate the positive expression of the given genes, 
whereas the empty boxes indicate negative RT-PCR results. 
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3.3.2 Dismissed genes from the EST and Microarray pipelines 
10 genes, BTG4, C11orf65, COX7B2, DAZL, LYRM1, PRSS45, SLC25A41, TEKT5, TULP2 
and WDR27 from the EST library and 7 genes, CCNA1, C2orf69, C11orf70, C20orf195, 
HORMAD1, NOL4 and ZNF558 from the Microarray library displayed expressions in various 
normal tissues, including testis. For this reason, these 17 genes were dismissed from further 
investigation, because CT genes in our strict criteria are genes whose expression were 
observed in non-more than two non-testis-CNS normal somatic tissues. Although the 
expression of the dismissed genes was observed in many normal tissues, qRT-PCR of some of 
these genes might show testis up-regulation, rather than testis specificity.  
 
In a previous study, HORMAD1 was identified as a CT gene in a screening that contained 12 
normal cells, including cells from the testis and 29 cancer cell lines. Although the RT-PCR 
expression of HORMAD1 was observed in different types of normal tissues, including brain, 
breast, colon, placenta and spleen tissues and it showed a strong expression in the testis, it is 
still considered to be a CT antigen gene (Chen et al., 2005b). However, in the present study, 
HORMAD1 is shown to exhibit an expression in 13 out of 21 normal tissues; therefore, it was 
dismissed as a CT gene candidate. The expression differences between the studies suggests 
that HORMAD1 might have been incorrectly identified as a CTA gene or the number of PCR 
cycles used in those studies was high (40 cycles), which may produce low levels of gene 
expression.   
 
Another previous study reported that LYRM1 mRNA expression was observed in distinct 
normal tissues; for example, heart, brain, placenta, lung, liver, skeletal muscle, kidney, 
adipose tissue and pancreas; however, among these nine normal tissues, adipose tissue 
expressed the highest mRNA level of LYRM1 (Qiu et al., 2009). In the present work, RT-PCR 
expression of LYRM1 was detected in all of the normal tissues tested, which confirms the 
study by Qiu et al. (2009). 
 
Hanafusa et al., (2012) study also identified the mRNA expression of TEKT5 using qRT-PCR 
analysis in various normal adult tissues, including testis and in a range of cancer types. In the 
previous study, TEKT5 was identified as a novel CT gene candidate, although the mRNA 
expression was observed in different normal cells, including brain, colon, kidney, liver, lung, 
ovary, prostate, skeletal muscles, spleen and stomach in addition to testis, which had the 
highest expression. TEKT5 mRNA expression was compared to one of the known CT genes, 
NY-ESO-1. NY-ESO-1 normally demonstrated higher expression levels of gene transcript in 
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non-testis normal tissues compared to TEKT5 expression. However, the RT-PCR analysis 
tested here revealed that the expression of TEKT5 was found in some normal 
nongametogenetic tissues and confirmed via DNA sequencing, thus TEKT5 was excluded 
from consideration as a novel CT antigen candidate.  
 
The DAZL gene was excluded from further study aimed at identifying CT gene candidates due 
to its expression in the normal tissues, but our findings support that DAZL is a testis-CNS-
selective gene. However, we followed strict criteria that led to it being excluded. Previous 
study indicated that DAZL is a germ cell marker in humans (Kerr et al., 2008) and the protein 
levels was observed in the adult human testes, but was absent in the prostate and testis 
isolated from a patient with Sertoli cells only (Ruggiu et al., 2000). A northern blot study 
showed that DAZL expression was observed in the testis, but only 17 normal tissues were 
tested (Yen et al., 1996). Another study suggested that DAZL expression was observed in both 
human male and female germ cells (Brekhman et al., 2000). 
 
3.3.3 Testis-restricted genes from the EST and Microarray pipelines 
One gene, UBL4B from the Microarray, and three genes, CST8 (CRES), ODF3 and 
TMEM225, from the EST analysis, were shown to have a testis-restricted expression pattern 
in the normal tissues and demonstrated no evidence of RT-PCR expression in the cancer 
tissues and/or cell lines. However, these genes were not dismissed from the gene screening, 
because they might be expressed in other cancer types not used in this work. A northern blot 
analysis showed that CST8 was expressed at high levels in human testis, but not in any of the 
other nine normal tissues examined, including kidney, spleen, brain, cervix, ovary, placenta, 
lung, prostate and uterus (Wassler et al., 2002), which supports the result of this work. A 
recent study reported by Dianatpour et al., (2012) revealed that the testis specific gene, ODF3 
was not expressed in breast cancer patients or breast cancer cell lines (MCF-7 and MDA-
231), but was expressed only in the testis. These results therefore provide further support to 
the results of this study. 
 
A meta-analysis was conducted on the testis-restricted genes, using the CancerMA online tool 
(http://www.cancerma.org.uk; Feichtinger et al., 2012b) to evaluate any potential gene 
expression for these genes in cancer Microarrays data sets. The meta-analysis results did not 
show any statistically significant mean upregulation for CST8, ODF3 or TMEM225 in the 
cancer array data. However, upregulation was identified for the expression of UBL4B in 
ovarian cancer array data. Therefore, this analysis identified UBL4B as a potential CT-
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restricted gene. The CTA control gene in this analysis was MAGE-A1. The meta-analysis 
indicated upregulation of the MAGE-A1 gene in head and neck cancers as well as in lung and 
brain cancers. The results from this meta-analysis are summarised in Figure 3.19. 
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in
 
Figure 3.19 The Circos plot for the testis-restricted genes. The Circos plot depicts the meta-change 
in gene expression in relation to corresponding cancer types for the testis-restricted genes and the 
control gene. One of the four genes shows a statistically significant upregulation for that type of 
cancer. The cancerMA tool was used to analyse the expression patterns of these four genes using 
cancer array data originating from a number of combined array studies for cancer tissues vs. normal 
tissue.   
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3.3.4 Genes from the EST and Microarray pipelines identified as novel CT gene 
candidates 
CT antigens represent ideal targets for cancer immunotherapy based on their restricted tissue 
expression. Here, the three Microarray genes FSCN3, GAGE1 and SSX2, and the EST 
analysis techniques of eight genes, C20orf201, C5orf50, FABP9, KCNU1, PFN3, SSX5, 
STRA8 and TEPP, were found to display possible candidate CT genes according to RT-PCR 
screening tests. According to Atanackovic et al., (2007), the mRNA expression of SSX2 and 
SSX5 were observed in different myeloma cell lines. In addition, it has previously been 
proposed that SSX2 and SSX5 showed a high positive rate of mRNA expression in patients 
with hepatocellular carcinoma (HCC) and no evidence of expression for both genes in the 
normal tissue samples adjacent to the tumour tissues (Wu et al., 2006). In one recent 
publication, GAGE1 and SSX2 have been determined as positive controls for the known X-CT 
genes. Furthermore, STRA8 and FABP9 were strongly expressed in healthy testis as well as in 
different malignant cells. It is also reported that the PFN3 and TEPP genes were classified as 
CT-CNS-selective and CT-selective, respectively (Feichtinger et al., 2012a).  
 
Meta-analysis of gene expression profiles was performed on the novel CTA gene candidates 
(11 genes), using the CancerMA online tool (http://www.cancerma.org.uk; Feichtinger et al., 
2012b), to assess any potential gene expression for these genes in cancer microarray data sets. 
The meta-analysis results did not show a statistically significant mean upregulation for 
C5orf50, FABP9, KCNU1, PFN3, STRA8 and TEPP in the cancer array data. Conversely, 
upregulation was identified for the expression of five of these genes (C20orf201, FSCN3, 
GAGE1, SSX2 and SSX5). The upregulation of C20orf201 was observed in ovarian cancer and 
FSCN3 was upregulated in ovarian and brain cancers. The upregulation of GAGE1 was 
detected in ovarian, lung, breast and brain cancers. The meta-analysis results also identified 
upregulation in ovarian, lung, brain and adrenal cancers for SSX2 and in ovarian, leukaemia 
and brain cancers for SSX5. Interestingly, in the present study, the RT-PCR results for 
GAGE1 and SSX2 did not indicate any expression in the three types of lung cancers or in the 
four types of ovarian cancers tested here, respectively. Therefore, both genes require more 
studies using more lung cancer types for GAGE1 and more ovarian cancer samples for SSX2. 
The results from this meta-analysis are summarised in Figure 3.20. 
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Figure 3.20 The Circos plot for the novel CTA genes. The Circos plot depicts the meta-change in 
gene expression in relation to corresponding cancer types for the novel CTA genes. Five of the 
eleven genes show a statistically significant upregulation for that cancer types. The cancerMA tool 
was used to analyse the expression patterns of these eleven genes using cancer array data originating 
from a number of combined array studies for cancer tissues vs. normal tissue.   
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The genes identified as novel CT genes could play a role in drug resistance; for example, a 
recent study revealed that over-expression of the testis specific gene, CYCLON, led to poor 
survival of lymphoma patients treated with a combination of CHOP chemotherapy with the 
monoclonal antibody Rituximab, but did not affect survival of patients treated with 
chemotherapy alone. These findings therefore indicated that CYCLON expression results in 
resistance to Rituximab in lymphoma patients (Knapp, 2013).  
 
Germline genes can be used as prognostic markers for cancer; for example, Rousseaux and 
his co-authors investigated the expression of testis-specific/placenta-specific (TS/PS) genes in 
1776 solid human cancers isolated from 14 different cancer types. A total of 506 tissue-
restricted genes were identified whose expression profiles were generally restricted to one 
tissue. These genes were divided into 439 testis/germline genes and 67 placenta-restricted 
genes. The expressions of hundreds of these 506 genes were aberrantly observed in all cancer 
types, indicating that these genes represent a promising source of cancer biomarkers. The 
genes were studied further to determine whether the TS/PS genes represented useful cancer 
biomarker in a specific type; lung cancer. A group of 293 patients with lung cancer at all 
stages of the disease were examined, including 152 lung cancer patients with early-stage 
cancer. The TC/PC genes were expressed to a greater extent in all 293 patients, including the 
early lung cancer patients, than in non-tumour lung (NL) samples. This study ultimately 
identified 26 of the TS/PS genes whose expression correlated with lower survival in lung 
cancer patients. Therefore, these genes are associated with poor prognosis, independent of 
cancer stage (Rousseaux et al., 2013).       
 
3.4 Conclusion 
In this work, the validation of the 32 genes using RT-PCR analysis determined that six genes 
showed a CT-restricted/selective expression pattern and five displayed CT-CNS-
restricted/selective expression patterns. These CT candidate genes were expressed in a wide 
variety of cancer cells and they were limited in the testis, or with no more than two other 
additional non-testis-CNS normal tissues. Therefore, these CT genes represent promising 
candidates due to their expression patterns in distinct types of cancer. They may be used as 
potential targets for the development of cancer vaccines and/or diagnostic markers for several 
types of cancer. However, further investigation is needed to establish the protein products of 
these excellent CT candidate genes in a range of normal and cancer tissues.  
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Chapter 4.0: Analysis of the function of the 
human STRA8 gene 
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
4.1 Introduction  
Retinoic acid (RA) is required for the switch from mitosis to meiosis. RA stimulates meiosis 
by activating the RA receptor-dependant (refer to Section 1.3.4) transcription of meiotic 
inducers, including Stra8 (Bowels and Koopman, 2007). The Stra8 gene (Stimulated by 
Retinoic Acid gene 8) was first identified by a subtractive hybridization cloning strategy that 
was used to identify retinoic acid-responsive genes in mouse P19 embryonal carcinoma (EC) 
cells in both the presence and absence of retinoic acid to identify RA-responsive genes in P19 
cells. Stra8 was one of the 50 genes identified in this screen, 40 of which were novel (Bouillet 
et al., 1995). These genes were collectively designated as those stimulated by RA (Stra) 
(Miyamoto et al., 2002; Oulad-Abdelghani et al., 1996a). It was shown that Stra8 expression 
is restricted to the early premeiotic spermatogonia, and the protein encoded by the gene is 
mostly cytoplasmic. In addition, the levels of Stra8 mRNA and protein were upregulated after 
treatment of the P19 cells by both all-trans and 9-cis retinoic acids (Oulad-Abdelghani et al. 
1996a). According to previous studies, Stra8 gene function is required for germ cells to enter 
into meiosis (Anderson et al., 2008; Baltus et al., 2006).  
 
Stra8 encodes a glutamic acid-rich protein with no homology to other known proteins. Two-
dimensional gel electrophoresis of RA-stimulated cytosolic cell extracts demonstrated that 
Stra8 has 9 different forms of phosphorylation (Oulad-Abdelghani et al., 1996b). Studies 
have suggested a possible Stra8 function in the nucleus, with shuttling of the protein between 
the nucleus and cytoplasm (Tedesco et al., 2009). Furthermore, Stra8 may play a role in 
binding double-strand DNA (Choi et al., 2010; Tedesco et al., 2009) and have a transcription 
activation function in vitro (Choi et al., 2010). In adult mice, Stra8 protein was restricted in 
spermatogonia and spermatocytes; the level of Stra8 protein was increased after the addition 
of RA to the adult spermatogonia (Zhou et al., 2008).  
 
Although the molecular function of Stra8 is still unknown, a range of studies have 
demonstrated that Stra8 is required for successful meiotic initiation in both male and female 
germ lines (Anderson et al., 2008; Mark et al., 2008) and in female embryos (Baltus et al., 
2006). Some of these studies showed that Stra8 deficiency leads to infertility in mice with no 
98 
 
evidence of mature gametes in both postnatal testes (Anderson et al., 2008; Mark et al., 2008) 
and foetal ovaries (Baltus et al., 2006). In Stra8-deficient foetal ovaries, meiosis was stalled 
just prior to prophase I entry. However, in Stra8-deficient postnatal testes, data were not 
consistent regarding whether the disruption occurs before or after initiation of meiosis (Baltus 
et al., 2006; Mark et al., 2008).  
 
Studies using Vitamin A showed that RA plays a critical role during meiosis in 
spermatogenesis in postnatal testes (Li et al., 2011) and in developing ovaries (Li and Clagett-
Dame, 2009). A recent study demonstrated that the RA is critical for spermatogenesis as well 
as for meiotic entry (Raverdeau et al., 2012). It is remarkable that there is a clear connection 
between the presence of RA and the up-regulation of Stra8 in germ cells in both adult and 
foetal meiosis (Feng et al., 2014). A previous study indicated that Dmrt1 is also a regulator of 
meiotic entry. Studies demonstrated that knockout of Dmrt1 in mice leads to the reduction of 
Stra8 expression in the foetal ovary and the number of ovarian follicles in the mature ovary is 
also decreased (Krentz et al., 2011). However, knockout of Dmrt1 in postnatal testes 
demonstrated the opposite effect with increasing Stra8 expression (Matson et al., 2011).  
 
The human STRA8 gene is localised on chromosome 7 and contains 9 exons separated by 8 
introns of different lengths. The translational start of the gene is localised in exon 1 and stop 
codon TAA in exon 9 (Figure 4.1). The STRA8 cDNA containing the whole open reading 
frame (ORF) is 993 bp (GenBank accession number AF513502), encoding a 330 amino acid 
protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 2 8 4 3 1 9 5 7 
8480 2064 469 1892 1087 5093 3244 3192 
ATG TAA 
27 60 198 76 85 286 74 112 75 
Figure 4.1 Exon and intron structure of the human STRA8 gene. Schematics show the structure of 
the STRA8 gene coding and non-coding regions. The boxes and arrows represent exons and introns, 
respectively. The lengths of each exon and intron are given above the box in the exons and below the 
arrow in the introns. Approximate positions of the start codon (ATG) and the stop codon (TAA) are 
marked in red. 
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4.2 Results 
4.2.1 Cloning of STRA8 cDNA into the pcDNA5/FRT/TO vector for over 
expression 
The purpose of cloning STRA8 cDNA was to address the protein function of this gene in 
cancer cells. The mammalian expression vector, pcDNA5/FRT/TO (Figure 4.2), was used for 
the cloning of the STRA8 ORF with and without adding the Kozak consensus sequence. The 
Kozak sequence is added to STRA8 cDNA sequences to stimulate the translation process 
(Kozak, 1991). Constructs with and without Kozak sequences were generated to potentially 
produce cell lines producing different amounts of STRA8 protein. NotI and XhoI restriction 
enzymes were used for cloning of STRA8–Kozak and STRA8+Kozak, respectively. Both 
enzymes were chosen because they are available in the cloning plasmid at the multiple 
cloning site (MCS) and do not appear in STRA8 cDNA sequences. 
 
For STRA8 cloning without the Kozak sequence, the cDNA coding clone was cut from the 
pCMV6-XL5::STRA8 vector with the NotI restriction enzyme. To evaluate vector digestion, 
gel electrophoresis was performed for both the undigested and digested pCMV6-XL5::STRA8 
vectors, which gave three molecules (Figure 4.3A left) and two bands (Figure 4.3A right), 
respectively. The two bands indicate a pCMV6-XL5 vector of about 4482 bp and a STRA8 
cDNA fragment of about 1209 bp. The insert fragment, verified by DNA sequencing, was 
subcloned into the NotI site of mammalian expression vector, pcDNA5/FRT/TO, to construct 
the plasmid termed pcDNA5/FRT/TO::STRA8–Kozak. Four molecules were observed in the 
undigested pcDNA5/FRT/TO vector (Figure 4.3B) and one band of approximately 5137 bp 
was observed, as expected, in the digested vector (Figure 4.3C left). After purification, the gel 
also displayed a STRA8–Kozak cDNA fragment within the expected size of 1209 bp (Figure 
4.3C right).  
 
In contrast, the cloning of STRA8+Kozak was initiated by amplification of STRA8 cDNA 
from the pCMV6-XL5::STRA8 vector using STRA8 F4+Kozak and R4 primers. The 
amplified fragment was 1212 bp, based on DNA sequencing, which confirms the cDNA 
sequences of the gene of interest. The purified PCR insert was subcloned into the 
pcDNA5/FRT/TO vector after digestion with the same restriction enzyme, XhoI. The vector 
was analysed on agarose gel before and after XhoI digestion in order to test the digestion 
efficiency of the vector, which yielded four molecules in the undigested vector (Figure 4.4A) 
and a single fragment of about 5137 bp in the digested vector (Figure 4.4B left). The insert 
100 
 
was also separated on the gel after digestion and purification to show a single band of about 
1212 bp, based on DNA sequencing (Figure 4.4B right).  
 
The purified STRA8 inserts (with and without Kozak) were ligated into the purified digested 
pcDNA5/FRT/TO plasmid using quick T4 DNA ligase. The recombinant plasmids were 
transformed into competent E. coli DH5α. For analysing the clones, PCR screening was 
performed on 17 randomly selected colonies. Primers internally positioned within the STRA8 
gene, STRA8 F1 and R1, were used in the PCR screening. The PCR results indicated that all 
the E. coli colonies had the gene of interest (STRA8) without Kozak (Figures 4.5) or with 
Kozak (Figure 4.6). The PCR primers were tested using testis cDNA. 
pcDNA5/FRT/TO::STRA8+Kozak and pcDNA5/FRT/TO::STRA8–Kozak plasmids were 
isolated from the E. coli. The presence of STRA8 inserts (+Kozak or –Kozak) was verified by 
restriction enzyme digestion, which cut once in the vector and once in the insert. Therefore, 6 
samples of purified DNA from the 17 pcDNA5/FRT/TO::STRA8–Kozak plasmids were 
digested with NotI, while 2 of the 17 pcDNA5/FRT/TO::STRA8+Kozak plasmids were 
digested with XhoI. Two fragments were observed in each digested plasmid. The upper 
fragment indicated the expected vector size of 5137 bp, while the lower bands indicated 
fragments of 1209 bp and 1212 bp for the STRA8–Kozak (Figure 4.7) and STRA8+Kozak, 
respectively (Figure 4.8).  
 
Two plasmids were sent for DNA sequencing using CMV forward and BGH reverse primers 
to confirm that the inserts were subcloned in the correct orientation for expression and 
contained an ATG initiation codon and a stop codon. The sequences obtained were compared 
to the original sequence through the NCB1 (BLAST). They were 100% identical to STRA8 
without mutation for the whole length of the STRA8 gene. As soon as the sequences were 
confirmed, E. coli glycerol stocks were made and stored in the -80°C freezer. 
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Figure 4.2 Map of pcDNA5/FRT/TO plasmid. pcDNA5/FRT/TO is a 5.1 kb inducible expression 
plasmid designed for use with the Flp-In T-REx system and contains the following components: A 
hybrid human cytomegalovirus (CMV)/TetO2 promoter for high-level, tetracycline-regulated 
expression of STRA8 in a Flp-In T-REx-293 cell line; multiple cloning site (MCS) that contains XhoI 
and NotI restriction sites to mediate cloning of the STRA8 gene with and without Kozak, 
respectively; an FLP Recombination Target (FRT) site for Flp recombinase to facilitate integration 
of the vector into the Flp-In T-REx-293; and a hygromycin gene to select stable Flp-In T-REx-293 
cell lines (Adapted from Invitrogen; www.invitrogen.com). 
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Figure 4.3 Generation of a STRA8 cDNA clone in the pCMV6-XL5::STRA8 vector. Agarose gel 
picture (panel (A)) showing undigested pCMV6-XL5::STRA8  mammalian expression vector (left), 
as a control to compare to the digestion vector (right), which was digested by NotI restriction 
enzyme to extract STRA8 cDNA of 1209 bp. Panel (B) shows undigested pcDNA5/FRT/TO, a 
mammalian expression vector. Panel (C) (left) shows the pcDNA5/FRT/TO vector after digestion by 
the NotI restriction enzyme and purification. The enzyme linearizes the 5137 bp plasmid into one 
single fragment. The right side of the gel (C) displays the STRA8 sequence after isolation from the 
pCMV6-XL5::STRA8 vector and purification.  
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Figure 4.4 Amplification of STRA8+Kozak from the recombinant pCMV6-XL5::STRA8 vector. 
Agarose gel picture showing undigested pcDNA5/FRT/TO, mammalian expression vector, as a 
control to compare to the digestion vector (panel (A)). Panel (B) (left) shows the pcDNA5/FRT/TO 
vector after digestion by XhoI restriction enzyme and purification. The enzyme linearizes the 5137 
bp plasmid into one single fragment. The right side of gel B displays the amplification of the STRA8 
cDNAs +Kozak sequence from the pCMV6-XL5::STRA8 vector, which was cloned with the full 
length of the open reading frame of STRA8. This band was digested with the same restriction 
enzyme, XhoI, and then underwent purification. 
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Figure 4.6 PCR screening of colonies for the cloning of STRA8. Agarose gel picture showing PCR 
screening of E. coli colonies for the cloning of STRA8+Kozak into the pcDNA5/FRT/TO using an 
internal primer for the STRA8 gene (F1, R1). Lane 1 shows the presence of STRA8 in pCMV6-
XL5::STRA8 to confirm that the primers work. The results show that all the samples in lanes 2-18 
have a STRA8 insert.  
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Figure 4.5 PCR screening of colonies for the cloning of STRA8. Agarose gel picture showing PCR 
screening of E. coli colonies for the cloning of STRA8 into the pcDNA5/FRT/TO using an internal 
primer for the STRA8 gene (F1, R1). Lane 1 shows the presence of STRA8 in the testis to confirm that 
the primers work. The results show that all the samples in lanes 2-18 contain a STRA8 insert of the 
expected size, 726 bp.  
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Figure 4.8 Digestion of recombinant plasmids. Agarose gel picture showing the digestion of 
purified recombinant plasmids (pcDNA5/FRT/TO::STRA8+Kozak) by the XhoI restriction enzyme. 
Two bands are formed for all recombinants. The upper bands show a pcDNA5/FRT/TO vector of 
approximately 5137 bp in size, while the lower bands show the full open reading frame of STRA8 
gene +Kozak at the size of 1212 bp. The plasmids in lanes 1-2 contain bands commensurate with the 
expected size for the cloning of STRA8+Kozak. 
Figure 4.7 Digestion of recombinant plasmids. Agarose gel picture showing the digestion of the 
recombinant purified pcDNA5/FRT/TO::STRA8-Kozak vectors by the NotI restriction enzyme. Two 
bands are formed for all the recombinants. The upper bands show a pcDNA5/FRT/TO vector of 
5137 bp, while the lower bands show the full open reading frame of the STRA8 gene of 1209 bp in 
size. All the minipreps in lanes 1-6 show successful cloning of STRA8 cDNA. 
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4.2.2 Integration of pcDNA5/FRT/TO containing STRA8 cDNA into the Flp-In T-
REx-293 cell line 
4.2.2.1 Generation of a stable cell line  
The Flp-In T-REx-293 cell line is derived from the HEK 293 cell (human embryonic kidney) 
and has already been transfected with two different plasmids (Figure 4.9). The first plasmid is 
pFRT/LacZeo, designed for use with the Flp-In system. This plasmid contains a single 
integrated FRT site. The FRT has been inserted just downstream of the ATG initiation codon 
of the LacZ-Zeocin fusion gene. Cell lines containing this plasmid stably express the LacZ-
Zeocin fusion gene under the control of a PSV40 promoter. Consequently, this inserted gene 
was used as a resistant marker for selection. The second plasmid, pcDNA6/TR, is designed 
for use with the T-REx system for tetracycline-regulated expression of the gene of interest. 
This plasmid expresses high levels of tetracycline (Tet) repressor under the control of human 
cytomegalovirus (CMV) promoter. The vector also contains the blasticidin resistance gene. 
Based on the insertion of the two plasmids above, the non-transfected Flp-In T-REx-293 has 
three major features: it expresses β-galactosidase activity, it confers resistance to zeocin and 
blasticidin, and it is sensitive to hygromycin. 
 
Insertion of STRA8 into the Flp-In T-REx-293 cell line also required the pOG44 vector 
(Figure 4.10), which encodes the FLP gene. The FLP gene expresses Flp recombinase which 
is required for integration of the pcDNA5/FRT/TO containing STRA8 with and without Kozak 
via the Flp recombination target (FRT) into the genome of the Flp-In T-REx-293 cell line 
(Buchholz et al., 1996). Therefore, in this study, the cell line was co-transfected with a DNA 
mixture containing STRA8 cDNA (+Kozak or –Kozak) in pcDNA5/FRT/TO and pOG44 at a 
ratio of 9:1 (pOG44: pcDNA5/FRT/TO). A negative control was set up via transfection of the 
Flp-In T-REx-293 cell line with pOG44 and pcDNA5/FRT/TO alone without the gene of 
interest. In brief, a non-transfected Flp-In T-REx-293 cell line was grown in medium 
supplemented with 200 µg/ml zeocin and 10 µg/ml blasticidin. 48 hours following 
transfection, the cells were refreshed with media containing 100 µg/ml of hygromycin instead 
of zeocin. Indeed, if the gene of interest, STRA8, integrated successfully at the FRT site of the 
cell line genome, the cells should be resistant to hygromycin, sensitive to zeocin, and lack any 
β-galactosidase activity. The majority of the cells did not survive due to the presence of 
hygromycin, which was used for the selection of a stable cell line. After pre-screening with a 
light microscope, single hygromycin resistant clones were selected for each construct (Figure 
4.11).  
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Figure 4.9 Diagram of the Flp-In T-REx-293 system. The figure above shows the major components 
of the system to generate a stable, inducible mammalian expression cell line by Flp recombinase-
mediated DNA recombination at the FRT site. Expression of the STRA8 gene from a specific genomic 
location is induced by the addition of tetracycline (Adapted from Invitrogen with some modification).  
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Figure 4.11 Examples of individual hygromycin resistant colonies. Panels (A and B) show a single 
colony still growing after hygromycin treatment; these cells were integrated with STRA8+Kozak and 
with STRA8–Kozak, respectively. Panel (C) shows cells integrated with pcDNA5/FRT/TO alone, 
without the target gene; these cells served as a negative control.  
Figure 4.10 Map of the pOG44 plasmid. pOG44 is a 5.8 kb Flp recombinase expression vector 
designed for use with the Flp-In T-REx system and contains the following components: an FLP gene 
encoding Flp recombinase to facilitate integration of the pcDNA5/FRT/TO plasmid containing 
STRA8 gene into the genome of the Flp-In T-Rex-293 cell line; a synthetic intron to enhance 
expression of the FLP gene; and a human cytomegalovirus (CMV) immediate-early 
enhancer/promoter for high-level expression of Flp recombinase (Adapted from Invitrogen; 
www.invitrogen.com). 
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4.2.2.2 Evaluation of different integrant Flp-In T-REx-293 cell lines 
Two different methods were used to analyse the successful integration of 
pcDNA5/FRT/TO::STRA8 into the genome of the Flp-In T-REx-293 cell line at the FRT site. 
The first method was screening for β-galactosidase activity. Confluent cells were analysed 
using β-Gal staining kit in media containing hygromycin or zeocin for the transfected and 
non-transfected cells, respectively. The lacZ gene product, β-galactosidase, can be visualised 
by β-Gal staining of the cell. Such activity was determined in triplicate for each cell line and 
light microscope images were obtained. In the positive control for lacZ-staining 
(untransfected Flp-In T-REx-293 cell line), all cells were blue, indicating active LacZ 
expression. In contrast, none of the cells in the clonal cell lines showed blue cells, indicating 
that the insertion of the STRA8 constructs were successful (Figure 4.12). 
 
The second method used was PCR screening of the integrant Flp-In T-REx-293. Genomic 
DNA was isolated from the non-transfected and transfected Flp-In T-REx-293 cells. β-actin 
was used as a positive control for the genomic DNA samples. PCR products were found in all 
of the transfected cells that integrated with the pcDNA5/FRT/TO::STRA8+Kozak, the 
pcDNA5/FRT/TO::STRA8–Kozak or the empty pcDNA5/FRT/TO; however, the non-
transfected cells did not display any PCR products when using primers located in the PSV40 
as a forward primer and in the hygromycin gene as a reverse primer. Primers located in the 
STRA8 gene (forward) and in the LacZ-Zeocin gene (reverse) were also used. The PCR results 
using STRA8 and LacZ-Zeocin primers showed products only for the Flp-In T-REx-293 that 
had been integrated with pcDNA5/FRT/TO::STRA8+Kozak or with 
pcDNA5/FRT/TO::STRA8–Kozak (Figure 4.13).  
The results of both methods (β-galactosidase activity and PCR screening) suggest that the 
STRA8 gene was correctly inserted into the genomic DNA of the Flp-In T-REx-293 cells. 
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Transfected Flp-In T-REx-293:: 
Figure 4.12 Assay for β-galactosidase activity. These images show the untransfected Flp-In T-REx-
293 alone exhibiting β-galactosidase (panel (B)); the transfected cells that integrated with different 
inserts (STRA8+Kozak or STRA8–Kozak or pcDNA5/FRT/TO) are not stained.  
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Figure 4.13 PCR screening of different STRA8 integrant Flp-In T-REx-293 cell lines. Panel (A) 
shows the presence of the STRA8 gene in the transfected cells when using primers located in the 
PSV40 (forward) and in the hygromycin gene (reverse). Panel (B) shows the PCR of Flp-In T-REx-
293 with the STRA8 genes when using primers in the STRA8 gene (forward) and in the LacZ-Zeocin 
gene (reverse). PCR using primers within the β-actin gene are shown as a positive control for the 
genomic DNA samples (panel (C)). The diagram in panel (D) shows the localisation of STRA8 cDNAs 
in the genome of the Flp-In T-REx-293 cell line. 
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4.2.2.3 Evaluation of the STRA8 expression level in the Flp-In T-REx-293 cell line 
Analysis of expression of the STRA8 gene was achieved using both RT-PCR and qRT- PCR 
analyses. STRA8 expression was induced by the addition of tetracycline to the culture cells (2 
µg/ml). Upon addition of tetracycline to the cell medium, tetracycline binds to the Tet 
repressor, which is expressed from the pcDNA6/TR in the Flp-In T-REx-293 cells. 
Subsequently, the STRA8 promoter initiates the transcription (Yao et al., 1998). However, 
expression of STRA8 is repressed in the absence of tetracycline (Yao et al., 1998), because the 
Tet repressor binds to the Tet operator 2 (TetO2) sequences in the pcDNA5/FRT/TO vector 
(CMV)/TetO2), which inhibit the transcription process for the STRA8 gene (refer to Figure 
4.9).  
 
 cDNAs were synthesised from the mRNAs of these cell lines. Two negative controls were 
used: untransfected cells and cells transfected with empty pcDNA5/FRT/TO. β-ACT was used 
as a positive control for the cDNA samples. RT-PCR results showed that the expression of the 
STRA8 gene (using F1 and R1 primers) was observed in the cell lines that had been integrated 
with either pcDNA5/FRT/TO::STRA8+Kozak or pcDNA5/FRT/TO::STRA8–Kozak (Figure 
4.14). However, the mRNA levels of STRA8 cDNA PCR products were higher in the cells 
treated with tetracycline compared to the same cells with no treatment. The mRNA levels of 
the STRA8 gene were not detectable in either negative control. The results in Figure 4.14 also 
show two distinct bands (18S and 28S ribosomal RNAs), which suggest good quality RNAs 
for all Flp-In T-REx-293 cell lines.  
 
qRT-PCR was carried out for the STRA8 gene in different Flp-In T-REx-293 cell lines using 
STRA8 F3 and R3 primers, while commercial positive primers were used. The STRA8 qRT-
PCR primers (F3 and R3) were tested by RT-PCR to confirm their performance using 
different cDNAs from the different Flp-In T-REx-293 cells before and after tetracycline 
treatment. The results showed that the expression of STRA8 was found in cell lines that had 
been inserted with STRA8 at the expected size of 124 bp (Figure 4.15), which suggests that 
the performance of the primers was good. Introns-intron primers and intron flanking primers 
were designed for STRA8 to prevent the amplification of potential contaminating genomic 
DNA. RT-PCR of the two sets of primer showed that the expression was observed in the cell 
lines with the integrated STRA8 gene when using intron flanking primers (STRA8 F1 and 
STRA8 R1). However, STRA8 expression was not observed in any of the cell lines when 
using intron-intron primers (STRA8 F2 and STRA8 R1) (Figure 4.16), which suggests that 
there was no genomic DNA contamination. The performance of the intron-intron primers was 
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confirmed using a serial dilution of genomic DNA isolated from Flp-In T-REx-
293::STRA8+Kozak. The expression was indicated as 306 bp in DNA amounts of 100, 10 and 
1 ng (Figure 4.17). 
 
In the STRA8 qRT-PCR results, the NRT (no reverse transcriptase) and NTC (no template 
control) negative controls did not give a Cq (quantification cycle) reading, which suggests 
that there was no non-specific background and no genomic DNA contamination (Table 4.1). 
The qRT-PCR results show a higher level of STRA8 expression in the Flp-In T-REx-
293::STRA8+Kozak and Flp-In T-REx-293::STRA8–Kozak cells compared to the Flp-In T-
REx-293::pcDNA5/FRT/TO cells after treatment with tetracycline (Figure 4.18). The RT-
PCR results shown in Figure 4.14 suggest that the Flp-In T-REx-293::pcDNA5/FRT/TO cell 
line was negative for STRA8 expression. The intensity of the STRA8 PCR band was stronger 
in cell lines that had been integrated with STRA8 after treatment with tetracycline than that 
observed in other cell lines with no treatment. Therefore, these qRT-PCR results correspond 
to the RT-PCR results previously observed (Figure 4.14). The STRA8 qRT-PCR results were 
normalised to the qRT-PCR results for Lamin A and β ACT; the results are shown in Table 4.1 
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Figure 4.14 RT-PCR expression analysis of STRA8 and β ACT in Flp-In T-REx-293 cell lines. 
The top agarose gel shows the expression of STRA8 in Flp-In T-REx-293 integrated with three 
different insertions (STRA8+Kozak or STRA8–Kozak or pcDNA5/FRT/TO) with and without 
tetracycline treatment. The middle agarose gel displays the expression profile for β-actin as a positive 
control for the cDNA samples. The bottom agarose gel shows the quality of the total RNAs for the 
different Flp-In T-REx-293 cell lines. Three bands of ribosomal RNAs appear in each sample. The 
28S and 18S ribosomal RNA bands are clearly visible in the RNA samples at the ratio of 
approximately 2:1. The RNAs were isolated using the RNeasy Plus Mini Kit. 
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Figure 4.15 RT-PCR analysis of STRA8 expression using qRT-PCR primers in different Flp-In 
T-REx-293 cell lines. The top agarose gel shows the expression of STRA8 in Flp-In T-REx-293 
integrated with three different insertions (STRA8+Kozak or STRA8–Kozak or pcDNA5/FRT/TO) 
with and without tetracycline treatment. The bottom agarose gel displays the expression profile for 
β-actin as a positive control for the cDNA samples.  
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Figure 4.16 RT-PCR analysis of STRA8 expression in different Flp-In T-REx-293 cells using 
intron-intron and intron flanking primers. The agarose gel on panels (A and B) show the 
expression of STRA8 in Flp-In T-REx-293 integrated with three different insertions (STRA8+Kozak or 
STRA8–Kozak or pcDNA5/FRT/TO) with and without tetracycline treatment. In panel (A), no 
amplification is apparent in any of the cells, whereas in gel (B), there are strong expressions in the 
cells that had been integrated with STRA8, with or without Kozak. The bottom agarose gel on panel 
(C) displays the expression profile for β-actin as a positive control for the cDNA samples.  
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Figure 4.17 Serial dilution of genomic DNA from Flp-In T-REx-293:: STRA8+Kozak cells. The 
agarose gel shows the PCR analysis of STRA8 in different dilutions of genomic DNA of Flp-In T-
REx-293::STRA8+Kozak to confirm the performance of the intron-intron primers.  
Figure 4.18 qRT-PCR analysis of STRA8 expression in Flp-In T-REx-293 cells. The bar chart 
displays the gene expression results for STRA8 with and without Kozak consensus in Flp-In T-REx-
293 cell lines before (-) and after (+) adding tetracycline to the cell culture, compared to the cells 
with the integrated pcDNA5/FRT/TO vector alone (negative). Expression data were normalised to 
the β ACT and Lamin A reference genes. The error bars represent the standard error of the mean 
(SEM) for three repeats. 
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Table 4.1 Real-time qRT-PCR analysis for STRA8 expression in Flp-In T-REx-293 cells. The 
table displays the mean of three repeats of the quantification cycle (Cq) and the standard deviation 
(SD) for STRA8 expression with and without Kozak consensus in Flp-In T-REx-293 cell lines before 
(-) and after (+) tetracycline treatment. These results were normalised by β ACT and Lamin A 
expression. Also shown in the table are the Cq readings for the no reverse transcriptase (NRT) and no 
template control (NTC). 
 
Target name Sample name Wells Cq Mean Cq SD 
STRA8 Flp-In T-Rex-293: pcDNA5/FRT/TO+ 3 31.26 0.079 
β ACT Flp-In T-Rex-293: pcDNA5/FRT/TO+ 3 16.65 0.024 
Lamin A Flp-In T-Rex-293: pcDNA5/FRT/TO+ 3 21.99 0.127 
STRA8 Flp-In T-Rex-293: pcDNA5/FRT/TO- 3 31.02 0.125 
β ACT Flp-In T-Rex-293: pcDNA5/FRT/TO- 3 16.74 0.068 
Lamin A Flp-In T-Rex-293: pcDNA5/FRT/TO- 3 22.00 0.121 
STRA8 Flp-In T-Rex-293: STRA8+Kozak+ 3 18.09 0.022 
β ACT Flp-In T-Rex-293: STRA8+Kozak+ 3 16.95 0.110 
Lamin A Flp-In T-Rex-293: STRA8+Kozak+ 3 22.17 0.042 
STRA8 Flp-In T-Rex-293: STRA8+Kozak- 3 22.64 0.073 
β ACT Flp-In T-Rex-293: STRA8+Kozak- 3 16.89 0.052 
Lamin A Flp-In T-Rex-293: STRA8+Kozak- 3 21.95 0.090 
STRA8 Flp-In T-Rex-293: STRA8-Kozak+ 3 18.68 0.074 
β ACT Flp-In T-Rex-293: STRA8-Kozak+ 3 17.00 0.057 
Lamin A Flp-In T-Rex-293: STRA8-Kozak+ 3 22.18 0.047 
STRA8 Flp-In T-Rex-293: STRA8-Kozak- 3 22.75 0.036 
β ACT Flp-In T-Rex-293: STRA8-Kozak- 3 16.95 0.046 
Lamin A Flp-In T-Rex-293: STRA8-Kozak- 3 22.05 0.046 
STRA8 Flp-In T-Rex-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-Rex-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-Rex-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
STRA8 Flp-In T-Rex-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
β ACT Flp-In T-Rex-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-Rex-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
STRA8 Flp-In T-Rex-293: STRA8+Kozak+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-Rex-293: STRA8+Kozak+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-Rex-293: STRA8+Kozak+ (NRT) 1 0.00 0.000 
STRA8 Flp-In T-Rex-293: STRA8+Kozak- (NRT) 1 0.00 0.000 
β ACT Flp-In T-Rex-293: STRA8+Kozak- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-Rex-293: STRA8+Kozak- (NRT) 1 0.00 0.000 
STRA8 Flp-In T-Rex-293: STRA8-Kozak+ (NRT)  1 0.00 0.000 
β ACT Flp-In T-Rex-293: STRA8-Kozak+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-Rex-293: STRA8-Kozak+ (NRT) 1 0.00 0.000 
STRA8 Flp-In T-Rex-293: STRA8-Kozak- (NRT) 1 0.00 0.000 
β ACT Flp-In T-Rex-293: STRA8-Kozak- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-Rex-293: STRA8-Kozak- (NRT) 1 0.00 0.000 
STRA8 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
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4.2.3 siRNA knockdown of STRA8 in HEP-G2 and NT2 
Knockdown of STRA8 levels was attempted using four types of STRA8-specific siRNAs in 
both HEP-G2 and NT2 cell lines to determine any effect that knockdown of this protein may 
have on these cells and to test the specificity of the anti-STRA8 antibody. Whole cell extracts 
were collected from the cells after siRNA treatment and analysed using Western blotting. 
 
The predicted size of the STRA8 cDNA according to the NCBI, is 993 bp, which gives a 
molecular weight of about 37 KDa. However, the DNA sequencing for RT-PCR products 
confirms that the entire open reading frame of STRA8 is 1209 bp (see Section 4.2.5). 
Therefore, the expected molecular weight of STRA8 is approximately 44 KDa. However, the 
band observed in HEP-G2 and NTERA2 producing a molecular weight of about 48 KDa. The 
band thought to correspond to STRA8 appears fainter in HEP-G2 after 48 hours treatment (2 
“hits”) with all siRNAs, especially siRNAs 3, 5 and a combination of four STRA8-specific 
siRNAs compared to the negative controls (untreated cells and cells treated with non-
interfering siRNA). α-Tubulin levels were shown as a loading control. Therefore, the Western 
blot results for the two negative controls and α-Tubulin suggest that there was significant 
STRA8 knockdown in the HEP-G2 cells (Figure 4.19). 
 
Although NT2 did not show any detectable expression of the STRA8 gene (refer to Figure 
3.14), Western blot analysis showed significant protein levels at a molecular weight of ~48 
KDa. The intensity of the band corresponding to STRA8 in the NT2 cells treated for 48 hours 
(2 “hits”) with 5 nM siRNA appears to be reduced compared to the untreated cells and the 
cells treated with non-interfering siRNA. The α-Tubulin signal appears to be relatively 
uniform, which suggests that this difference is due to successful STRA8 knockdown, 
especially in cells transfected with siRNA number 5 (Figure 4.19).  
 
4.2.4 Evaluation of the protein levels of STRA8 in Flp-In T-REx-293 cell lines 
STRA8 protein levels were assessed in different integrants of Flp-In T-REx-293 cell lines 
before and after tetracycline treatment. The molecular weight for STRA8 protein is ~48 KDa, 
according to Western blotting (Figure 4.19). Western blots using the anti-STRA8 antibody 
showed different bands, especially in cell lines treated with tetracycline. This may suggest 
that tetracycline treatment could give a nonspecific background. However, the Flp-In T-REx-
293 cell line inserted with STRA8+Kozak and treated with tetracycline showed a strong band 
at a molecular weight of ~48 KDa. This suggests that the band is related to STRA8 protein 
(Figure 4.20). The protein loading for each clone was indicated by α-Tubulin. 
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Figure 4.19 Western blot analysis for siRNA knockdown of STRA8 in HEP-G2 and NT2 cancer 
cells. Two negative controls for the siRNA knockdown were used: cells with no transfection 
(untreated), and cells treated with non-interfering siRNA. Cells were transfected with 5 nM 
concentrations of four independent STRA8-specific siRNAs, a combination of the four siRNAs 
(siRNAs 1+2+3+5) or with 5 nM of non-interfering siRNA. The transfection reagent and siRNAs 
were added to the cell cultures at seeding. The cells were collected 48 hours after siRNA transfection. 
α-Tubulin protein levels were used as controls for protein loading. 
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Figure 4.20 Western blot analysis showing STRA8 induction using tetracycline in the Flp-In T-
REx-293 cell lines. Four of these cultures were subjected to 2 µg/ml of tetracycline and four were 
not. Positive signals are seen in cells containing the STRA8 gene with Kozak sequencing after 
treatment with tetracycline. The cells were harvested 24 hours after induction. The lysates were 
separated on a 10% SDS-PAGE gel. α-Tubulin protein levels were used as controls for protein 
loading. 
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4.2.5 Comparison between human STRA8 cDNA and amino acid sequences from 
the GenBank and those obtained from RT-PCR 
The RT-PCR analysis of the STRA8 gene in the testis cDNA gave a band 216 bp, larger than 
expected, when we used internal primers; the forward primer located in exon 3 and the 
reverse primer located in exon 7. These extra base pairs were confirmed by DNA sequencing. 
Therefore, other primers were designed for cloning to cover the whole open reading frame of 
STRA8 and to confirm the final results. A forward primer was designed and located in exon 1 
starting at a start codon (ATG) and a reverse primer was located in exon 9, which starts by 
sequences complementary to a stop codon (TAA). RT-PCR results for the STRA8 gene using 
both primers and testis as a template for amplification was 1209 bp, according to the DNA 
sequence; although the whole cDNA length identified in the GenBank is 993 bp. Indeed, in 
this study, 216 bp were detected by RT-PCR analysis and the majority of these sequences 
were translated to glutamic acid (Figure 4.21). Previous studies showed that the STRA8 
human protein does not have a glutamic acid-rich domain. However, Stra8 mouse protein is 
rich in glutamic acid, which confers a high acidity to the Stra8 protein (Miyamoto et al., 
2002; Oulad-Abdelghani et al., 1996b). Some proteins of the cytoskeleton, such as 
neurofilaments are composed of glutamic acid (Levy et al., 1987). Figure 4.21 shows the 
differences between both sequences.  
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atggggaagattgatgtggacaagatcctctttttcaatcaagaaatcaggctgtggcag 
 M  G  K  I  D  V  D  K  I  L  F  F  N  Q  E  I  R  L  W  Q  
cttataatggcaacccctgaagaaaacagcaatccccatgacagagcaacaccccagctg 
 L  I  M  A  T  P  E  E  N  S  N  P  H  D  R  A  T  P  Q  L  
ccagcacagctgcaggagcttgagcatcgggtggcccggagacggctgtcccaggcccgc 
 P  A  Q  L  Q  E  L  E  H  R  V  A  R  R  R  L  S  Q  A  R  
caccgagccaccctggcagcgctcttcaacaacctcaggaagacagtgtactctcagtct 
 H  R  A  T  L  A  A  L  F  N  N  L  R  K  T  V  Y  S  Q  S  
gatctcatagcctcaaagtggcaggttctgaataaggcaaagagtcatattccagaactg 
 D  L  I  A  S  K  W  Q  V  L  N  K  A  K  S  H  I  P  E  L  
gagcaaaccctggataatttgctgaagctgaaagcatccttcaacctggaagatgggcat 
 E  Q  T  L  D  N  L  L  K  L  K  A  S  F  N  L  E  D  G  H  
gcaagcagcttagaggaggtcaagaaagaatatgccagcatgtattctggaaatgacagc 
 A  S  S  L  E  E  V  K  K  E  Y  A  S  M  Y  S  G  N  D  S  
ctgctttcaaacagttttcctcagaatggttcctccccttggtgcccaactgaggcagtc 
 L  L  S  N  S  F  P  Q  N  G  S  S  P  W  C  P  T  E  A  V  
aggaaggatgctgaggaggaggaagatgaggaagaggaagatcaagaagaagaggaggag 
 R  K  D  A  E  E  E  E  D  E  E  E  E  D  Q  E  E  E  E  E  
gaagaagaagaggaggaggaggaggaagaggaggaagaggaagaggaggaggaggaagag 
 E  E  E  E  E  E  E  E  E  E  E  E  E  E  E  E  E  E  E  E  
gagaaaaaagtgatcttatactccccaggaactttgtcgcctgacctcatggaatttgaa 
 E  K  K  V  I  L  Y  S  P  G  T  L  S  P  D  L  M  E  F  E  
cggtatctcaacttttacaaacagacgatggaccttctgactggcagcgggatcattacc 
 R  Y  L  N  F  Y  K  Q  T  M  D  L  L  T  G  S  G  I  I  T  
ccgcaggaggcggcgctgcccatcgtctccgcggccatctcccacctgtggcagaacctc 
 P  Q  E  A  A  L  P  I  V  S  A  A  I  S  H  L  W  Q  N  L  
tcggaggagaggaaggccagcctccggcaggcctgggcgcagaagcaccgcggccctgcg 
 S  E  E  R  K  A  S  L  R  Q  A  W  A  Q  K  H  R  G  P  A  
accctggcggaggcctgccgagagccggcctgtgccgagggcagcgtgaaggacagcggc 
 T  L  A  E  A  C  R  E  P  A  C  A  E  G  S  V  K  D  S  G  
gtggacagccagggggccagctgctcgctggtctccacgcccgaggagatcctttttgag 
 V  D  S  Q  G  A  S  C  S  L  V  S  T  P  E  E  I  L  F  E  
gatgcctttgatgtggcaagcttcctggacaaaagtgaggttccgagtacatctagctcc 
 D  A  F  D  V  A  S  F  L  D  K  S  E  V  P  S  T  S  S  S  
agttcagtgcttgccagctgcaacccagaaaacccagaggagaagtttcagctctatatg 
 S  S  V  L  A  S  C  N  P  E  N  P  E  E  K  F  Q  L  Y  M  
cagatcatcaacttttttaaaggccttagctgtgcaaacactcaagtaaagcaggaagca 
 Q  I  I  N  F  F  K  G  L  S  C  A  N  T  Q  V  K  Q  E  A  
tcctttcccgttgatgaagagatgatcatgttgcagtgcacagagacctttgacgatgaa 
 S  F  P  V  D  E  E  M  I  M  L  Q  C  T  E  T  F  D  D  E  
gatttgtaa 
  D  L  - 
Figure 4.21 Nucleotide and deduced amino acid sequence of human STRA8 cDNA. The ATG 
codon and the TAA terminating codon are bold and coloured in red. The STRA8 cDNA sequence 
was detected using testis cDNA, forward and reverse primers. The positions of the two primers 
used for expression analysis are underlined. The nucleotides marked in black letters indicate 
identical sequences between the STRA8 cDNA in the GenBank and those obtained via RT-PCR 
analysis. The extra bases identified by RT-PCR are marked in green. The STRA8 nucleotide 
sequence was translated to amino acid using the Expasy program; http://www.expasy.org/tools/. 
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4.2.6 Analysis of meiotic gene expressions in different Flp-In T-REx-293 cell lines 
treated with retinoic acids 
It has been demonstrated that RA induces STRA8 gene expression in germ cells (Feng et al., 
2014). Therefore, our hypothesis asks: Does the STRA8 gene lead to the induction of any 
other meiosis-specific gene when treating cell lines that have the STRA8 gene with RAs? The 
Flp-In T-REx-293 cell lines were treated with two types of RAs, all-trans and 9-cis retinoic 
acids, for 24 hours. These RAs were used at a final concentration of 5 µM and 10 µM. 12 
meiosis-specific/CTA genes were randomly selected to perform this experiment: GAGE1, 
MAGE-A1, NUT, PRDM9, RAD21L, REC8, SMC1β, STAG3, SYCP1, SYCP2, SYCP3 and 
TEX19.  
 
The experiment was initiated by treating the Flp-In T-REx-293 cells inserted with 
STRA8+Kozak, STRA8–Kozak or empty pcDNA5/FRT/TO with two different concentrations 
of two types of RAs, 5 or 10 µM all-trans and 5 or 10 µM 9-cis retinoic acids. cDNAs were 
synthesised from the mRNA for these cells. Two negative controls were used to detect the 
absence of the STRA8 gene in the cells, untransfected Flp-In T-REx-293 cells and cells 
transfected with pcDNA5/FRT/TO plasmid only. Testis cDNA was used to validate the 
primer for each gene. β ACT gene served as a positive control to validate the quality of the 
cDNA, and the STRA8 gene was used as a positive control for analysis of the induction of the 
12 meiosis-specific genes (Figure 4.22). RAs were prepared in DMSO. Therefore, cells were 
subjected to DMSO, which itself may induce cell differentiation; therefore, a control culture 
was made. 
 
RT-PCR expression was performed for 9 meiosis-specific genes including GAGE1, MAGE-
A1, NUT, PRDM9, RAD21L, SMC1β, SYCP1, SYCP3 and TEX19. The aim of this analysis 
was to establish which of these genes become overexpressing when the STRA8 gene was 
activated in the cells. RT-PCR showed that there was no induction of mRNA expression for 
these genes (Figures 4.23 and 4.24), except for MAGE-A1 (Figure 4.23), but a strong band 
appeared in cells that had been integrated with plasmid (pcDNA5/FRT/TO) alone. This could 
be due to the effect of DMSO. The expressions of these genes were compared to negative and 
positive controls. 
 
After obtaining the results of the previous RT-PCR, another experiment was designed using 
10 µM all-trans RA and 15 different Flp-In T-REx-293 clones: 5 different clones from Flp-In 
T-REx-293::STRA8+Kozak; 5 different clones from Flp-In T-REx-293::STRA8–Kozak; and 5 
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different clones from Flp-In T-REx-293::pcDNA5/FRT/TO. Cells containing STRA8+Kozak 
or STRA8–Kozak were used as the positive controls for the RT-PCR of the STRA8 gene. In 
contrast, untransfected Flp-In T-REx-293 cells and cells transfected with pcDNA5/FRT/TO 
were used as the negative controls for the RT-PCR. The RT-PCR for the STRA8 gene did not 
show any expression, as expected, in the untransfected cells and in all 5 clones of Flp-In T-
REx-293::pcDNA5/FRT/TO (Figure 4.25). The results of the RT-PCR expression in Flp-In T-
REx-293::pcDNA5/FRT/TO for GAGE1, MAGE-A1, NUT, PRDM9, RAD21L and REC8 are 
shown in Figure 4.25. The SMC1β, STAG3, SYCP1, SYCP2, SYCP3 and TEX19 results are 
shown in Figure 4.26. 
 
The RT-PCR for the STRA8 gene showed strong expression in all 5 clones of Flp-In T-REx-
293::STRA8+Kozak (Figure 4.27), but there was no significant overexpression of the other 
meiosis genes tested here. The results of the RT-PCR expression in Flp-In T-REx-
293::STRA8+Kozak for GAGE1, MAGE-A1, NUT, PRDM9, RAD21L and REC8 are shown in 
Figure 4.27. The results for SMC1β, STAG3, SYCP1, SYCP2, SYCP3 and TEX19 are shown in 
Figure 4.28. In contrast, The RT-PCR results for the 12 selected meiosis genes in the 5 
different clones from Flp-In T-REx-293::STRA8–Kozak showed results identical to those 
obtained from Flp-In T-REx-293::STRA8+Kozak. The RT-PCR expression results for the 
selected meiosis genes in Flp-In T-REx-293::STRA8–Kozak are shown in Figures 4.29 and 
4.30.  
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Figure 4.22 Analysis of the induction of STRA8 gene expression in different Flp-In T-REx-293 
cell lines treated with retinoic acid. RT-PCR analysis of STRA8 mRNA expression in different Flp-
In T-REx-293 cells. Prior to RNA extraction, the cells were treated with all-trans or 9-cis retinoic 
acids at different concentrations, or with the DMSO vehicle alone for 24 hours. β ACT expression was 
used as a positive control for the cDNA samples. The expected amplicon size of each gene is shown 
on the left between brackets. 
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Figure 4.23 Analysis of induction of meiotic genes expression in different Flp-In T-REx-293 cell 
lines treated with retinoic acid. RT-PCR analysis of GAGE1, MAGE-A1, NUT and PRDM9 mRNA 
expression in different Flp-In T-REx-293 cells. Prior to RNA extraction, the cells were treated with 
all-trans or 9-cis retinoic acids at different concentrations or with the DMSO vehicle alone for 24 
hours. The expected amplicon size of each gene is shown on the left between brackets. 
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Figure 4.24 Analysis of meiotic genes expression in different Flp-In T-REx-293 cell lines treated 
with retinoic acid. RT-PCR analysis of RAD21L, SMC1β, SYCP1, SYCP3 and TEX19 mRNA 
expression in different Flp-In T-REx-293 cells. Prior to RNA extraction, the cells were treated with 
all-trans or 9-cis retinoic acids at different concentrations or with the DMSO vehicle alone for 24 
hours. The expected amplicon size of each gene is shown on the left between brackets. 
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Figure 4.25 Analysis of meiotic genes expression in different Flp-In T-REx-293:: 
pcDNA5/FRT/TO cell lines treated with all-trans retinoic acid. RT-PCR analysis for STRA8, 
GAGE1, MAGE-A1, NUT, PRDM9, RAD21L and REC8 mRNA expression in five different colonies 
(1-5) of Flp-In T-REx-293 cells that had been transfected with the pcDNA5/FRT/TO vector alone. 
Prior to RNA extraction, the cells were treated with 10 µM all-trans retinoic acids or with the DMSO 
vehicle alone for 24 hours. β ACT expression was used as a positive control for the cDNA samples. 
The expected amplicon size of each gene is shown on the left between brackets.  
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Figure 4.26 Analysis of meiotic genes expression in different Flp-In T-REx-293:: 
pcDNA5/FRT/TO cell lines treated with all-trans retinoic acid. RT-PCR analysis for STRA8, 
SMC1β, STAG3, SYCP1, SYCP2, SYCP3 and TEX19 mRNA expression in five different colonies (1-
5) of Flp-In T-REx-293 cells that had been transfected with the pcDNA5/FRT/TO vector alone. Prior 
to RNA extraction, the cells were treated with 10 µM all-trans retinoic acids or with the DMSO 
vehicle alone for 24 hours. β ACT expression was used as a positive control for the cDNA samples. 
The expected amplicon size of each gene is shown on the left between brackets.  
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Figure 4.27 Analysis of meiotic genes expression in different Flp-In T-REx-293::STRA8+Kozak 
cell lines treated with all-trans retinoic acid. RT-PCR analysis for GAGE1, MAGE-A1, NUT, 
PRDM9, RAD21L and REC8 mRNA expression in five different colonies (1-5) of Flp-In T-REx-293 
cells that had been transfected with STRA8 cDNA +Kozak. Prior to RNA extraction, the cells were 
treated with 10 µM all-trans retinoic acids or with the DMSO vehicle alone for 24 hours. STRA8 
expression was used as a positive control for the transfected cells with STRA8+Kozak. β ACT 
expression was used as a positive control for the cDNA samples. The expected amplicon size of each 
gene is shown on the left between brackets.  
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Figure 4.28 Analysis of meiotic genes expression in different Flp-In T-REx-293::STRA8+Kozak 
cell lines treated with all-trans retinoic acid. RT-PCR analysis for SMC1β, STAG3, SYCP1, SYCP2, 
SYCP3 and TEX19 mRNA expression in five different colonies (1-5) of Flp-In T-REx-293 cells that 
had been transfected with STRA8 cDNA +Kozak. Prior to RNA extraction, the cells were treated with 
10 µM all-trans retinoic acids or with the DMSO vehicle alone for 24 hours. STRA8 expression was 
used as a positive control for the transfected cells with STRA8+Kozak. β ACT expression was used as 
a positive control for the cDNA samples. The expected amplicon size of each gene is shown on the left 
between brackets.  
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Figure 4.29 Analysis of meiotic genes expression in different Flp-In T-REx-293::STRA8–Kozak 
cell lines treated with all-trans retinoic acid. RT-PCR analysis for GAGE1, MAGE-A1, NUT, 
PRDM9, RAD21L and REC8 mRNA expression in five different colonies (1-5) of Flp-In T-REx-293 
cells that had been transfected with STRA8 cDNA –Kozak. Prior to RNA extraction, the cells were 
treated with 10 µM all-trans retinoic acids or with the DMSO vehicle alone for 24 hours. STRA8 
expression was used as a positive control for the transfected cells with STRA8–Kozak. β ACT 
expression was used as a positive control for the cDNA samples. The expected amplicon size of each 
gene is shown on the left between brackets.  
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Figure 4.30 Analysis of meiotic genes expression in different Flp-In T-REx-293::STRA8–Kozak 
cell lines treated with all-trans retinoic acid. RT-PCR analysis for SMC1β, STAG3, SYCP1, SYCP2, 
SYCP3 and TEX19 mRNA expression in five different colonies (1-5) of Flp-In T-REx-293 cells that 
had been transfected with STRA8 cDNA –Kozak. Prior to RNA extraction, the cells were treated with 
10 µM all-trans retinoic acids or with the DMSO vehicle alone for 24 hours. STRA8 expression was 
used as a positive control for the transfected cells with STRA8–Kozak. β ACT expression was used as 
a positive control for the cDNA samples. The expected amplicon size of each gene is shown on the 
left between brackets.  
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4.3 Discussion 
4.3.1 Integration of the human STRA8 gene into Flp-In T-REx-293 cells 
The STRA8 gene is a mammalian regulator of meiotic progression in both females and males 
(Anderson et al., 2008). STRA8 is required for transcriptional activation of REC8 and DMC1 
(Anderson et al., 2008). To study the function of the human STRA8, we considered the 
integration of STRA8 in a cell line that does not already express it to determine if the 
overexpression of STRA8 in a human cell line leads to the induction of REC8 or DMC1 or the 
upregulation of other meiotic genes. The STRA8+Kozak and STRA8–Kozak cDNA inserts 
were subcloned into the mammalian expression vector, pcDNA5/FRT/TO. The reason for 
choosing this vector was because it comprises an important element for integration of the 
STRA8 gene into the Flp-In T-REx-293 cell line. This element is hybrid human 
cytomegalovirus (CMV)/TetO2 promoter for high level tetracycline-regulated expression of 
any gene of interest in most mammalian cells (Andersson et al., 1989; Hillen and Berens, 
1994).  
 
All the cells that were transfected with pcDNA5/FRT/TO containing STRA8+Kozak or 
STRA8–Kozak were grown in medium containing hygromycin and β-galactosidase was 
examined in the cells before and after inserting pcDNA5/FRT/TO. The cells expressed β-
galactosidase before inserting the pcDNA5/FRT/TO, whereas they did not express it after 
pcDNA5/FRT/TO insertion, which suggests successful STRA8 integration. 
 
4.3.2 Induction of STRA8 expression by retinoic acid 
The expression of Stra8 in mice is related to the availability of RA in both sexes (Zhou et al., 
2008). In the present study, the Flp-In T-REx-293 cell lines that had been integrated with the 
STRA8 gene were treated with 5 µM or 10 µM RA to induce other genes that could induce the 
expression of STRA8. GAGE1, MAGE-A1, NUT, PRDM9, RAD21L, REC8, SMC1β, STAG3, 
SYCP1, SYCP2, SYCP3 and TEX19 meiosis genes were investigated in these cells that were 
treated with all-trans and 9-cis retinoic acids. The purpose of the investigation was to 
determine which of these meiosis genes, if any, were upregulated. The RT-PCR results did 
not indicate any overexpression among these genes. This result could be due to the 
concentration of RA, to the duration of treatment or to the possibility that STRA8 could play 
other roles in Flp-In T-REx-293 cells. It might also indicate that STRA8 expression alone is 
not sufficient to induce meiotic genes and could demonstrate that other factors are required.  
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A previous study investigated the expression of Stra8 in adult mice testes after subcutaneous 
injection with 100 µl of 7.5 mg/ml all-trans retinoic acid for 24 hours; the Stra8 transcript 
levels increased three-fold (Zhou et al., 2008). Another study implied that mRNA expression 
of STRA8 was induced in human foetal testes subjected to 1 µM all-trans retinoic acid for 24 
hours, but based on qRT-PCR, expression in other meiosis-associated genes, SYCP3 and 
DMC1, there was no subsequent downstream gene activation (Childs et al., 2011). This could 
indicate that the role of STRA8 in meiotic gene activation is not identical in humans and 
mouse. Indeed, recent work showing REC8 expression in human non-testis tissue supports 
this (Feichtinger et al., 2012a). 
 
In Stra8-deficient spermatogenic cells, the meiotic specific cohesin (Rec8) and synaptonemal 
complex protein (Sycp3) are not properly localised to the chromosomes when examined by 
immunohistochemical staining, compared to Rec8 and Sycp3 proteins in wild-type 
spermatogenic cells (Anderson et al., 2008; Baltus et al., 2006). This indicates that Stra8 may 
be required in the formation of meiotic cohesin and synaptonemal complexes in mouse. 
Neither up-regulation of Spo11 and Dmc1 nor the proteins were detected in Stra8-deficient 
testes (Anderson et al., 2008). Furthermore, DNA DSBs are marked by γ-H2AX and were not 
observed by immunostaining in Stra8-deficient testes; whereas, γ-H2AX staining was 
detected in several cells of wild-type testes showing that DNA DSBs are formed. Results for 
Spo11, Dmc1 and γ-H2AX strongly indicate that DSBs are not formed and there is a lack of 
meiotic recombination in spermatogenic cells of Stra8-deficient testes (Anderson et al., 2008). 
Lack of Stra8 in females gives rise to the repression of many events in meiosis, including 
DNA replication, sister chromosome cohesion, synapsis and meiotic recombination (Baltus et 
al., 2006).  
 
Overexpression of 12 meiosis genes tested here was not observed by RT-PCR analysis using 
F1 and R1 primers and Flp-In T-REx-293 cell lines, which contained STRA8 cDNA with and 
without Kozak sequences. These results could potentially indicate that the RT-PCR analysis 
used was not adequate for studying whether STRA8 can induce a meiosis gene. In this chapter, 
the 12 meiosis genes were investigated in cell lines inserted with the STRA8 cDNA and 
treated with retinoic acids; these genes were chosen at random. Many genes inside the cells 
can play fundamental roles in meiosis. Consequently, the STRA8 gene could induce other 
meiosis genes that were not tested here or expression of STRA8 alone was not sufficient to 
initiate a meiotic gene expression programme. Further analysis can be performed to study 
whether  STRA8 can induce any other meiosis genes; for example, STRA8 gene was expressed 
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at low levels in the HEP-G2 cell line and we thought that treatment of these cells with retinoic 
acid might induce a STRA8 transcript that could be detected using different techniques, such 
as RT-PCR, qRT-PCR and Western blotting. Furthermore, this experiment can be carried out 
using genes other than the 12 meiosis genes, including other CTA genes, like NY-ESO-1 
(Whitehurst, 2014). 
 
In total, 7 of the 36 CTA genes identified by Feichtinger et al. (2012a) were expressed in 
HEP-G2 cells. These genes are: C19orf67, C22orf33, ODF4, STRA8, TEX19, CXorf27 and 
ZCCHC13. We speculate that knockdown of the STRA8 gene with siRNA might 
downregulate these genes in the HEP-G2 cell line after siRNAs treatment. This remains to be 
tested thoroughly. 
 
No detectable levels of STRA8 mRNA were observed in the NTERA2 cell line by RT-PCR 
analysis; however, Western blotting results indicated a clear band for the STRA8 protein 
product in this cell. The NTERA2 cell has the ability to differentiate into neurons as well as 
other cell types following exposure to retinoic acid (Andrews, 1984). Therefore, both 
NTERA2 and the STRA8 gene are responsive to retinoic acid. The RT-PCR results indicated 
that the undifferentiated NTERA2 cells did not show mRNA expression for STRA8. 
Therefore, treatment of the NTERA2 cell line with retinoic acid followed by analysis of 
STRA8 expression/protein levels would be informative.     
 
4.4 Conclusion 
Based on the RT-PCR screening performed in Chapter 3, the STRA8 gene is considered to be 
a good CT gene, because its expression profile is clearly restricted to the normal testis among 
the normal tissues and in different type of cancers. The STRA8 protein plays a role in the 
progression of meiosis. In this chapter, STRA8 was inserted into the human cell line to 
establish a stable cell line expressing the STRA8 gene. The target of this insertion was to 
investigate the role of STRA8 in a stable cell line. We demonstrated that the STRA8 gene can 
be overexpressed in the human Flp-In T-REx-293 cell line, but the expression of other 
meiosis-specific genes did not increase after stimulation by retinoic acids. Therefore, further 
investigation is needed to study the function of this gene in the normal human testis and in 
cancer cells. 
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Chapter 5.0: Functional analysis of the 
human C20orf201 gene 
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
5.1 Introduction  
Cancer is a serious disease that can lead to substantially increased mortality. This occurs not 
only due to the limited effectiveness of available treatments, but also because diagnosis 
usually takes place late in the tumour development (Abramovitz and Leyland-Jones, 2006; 
Miturski et al., 2002). For this reason, the identification of new cancer-specific biomarkers is 
essential to improve patient diagnosis (Baulande et al., 2014). The detection of cancer 
biomarkers will play a fundamental role in the early detection/screening of diseases, but also 
in other aspects such as the classification and staging of cancer development, prognosis 
assessment and assessment of patient responses to treatment. Diagnosis at the early and 
asymptomatic stage is considered to be the key to effective cancer treatment (Yang and 
Sweedler, 2014).  
 
A recent study has suggested that cancer-testis (CT) genes might be useful biomarkers of 
cancer cells (van Duin et al., 2011). The profile of CTA gene expression has significance for 
the early detection and immunotherapy of cancer (Ghafouri-Fard and Modarressi, 2009). One 
CTA gene that shows potential as a good candidate cancer biomarker is the human C20orf201 
gene, based on the findings presented in Chapter 3 (see Figures 3.12 and 3.14); however, its 
actual function is not known. 
 
Cancer cells naturally present antigenic peptides termed human leukocyte antigen (HLA) 
molecules on their surfaces; these peptides are normally recognised by specific cytotoxic T-
lymphocytes. These cancer-associated antigens are potentially promising tools for the 
production of peptide vaccines against cancer (Kamata et al., 2013). For example, Kamata 
and his colleagues identified HLA class-I-binding peptides that originated from cancer-
associated proteins expressed in human prostate cancer cells. This identification was 
performed by immunoproteomics and indicated that these isolated peptides could possibly be 
used for the generation of vaccines against prostate cancer. The 5- or 6-mer peptides (TKLSA 
and RLRYT) were selected among these peptides isolated from the HLA molecule located on 
the prostate cancer cells. However, an uncharacterised protein C20orf201 was observed to be 
the source protein of the RLRYT peptide. A qRT-PCR analysis of C20orf201 gene expression 
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revealed that this gene was significantly expressed in different cancer cell types, whereas no 
expression was found in non-cancerous tissues, except for the testis and brain (whole or 
cerebellum) (Kamata et al., 2013).    
 
The human C20orf201 gene is localised on chromosome 20 and has two different splice 
variants. The first splice variant contains 2 exons separated by one intron of 112 bp in length. 
However, the second splice variant comprises 3 exons separated by 2 introns of different 
lengths (Figure 5.1). The translational start of the gene is localised in exon 1 and stop codon 
TAA is in exon 2 or 3 for splice variant 1 or 2, respectively. The C20orf201 cDNA containing 
the whole open reading frame (ORF) is 723 bp for splice variant 1 or 585 bp for splice variant 
2 (GenBank accession number BC036837). The splice variants 1 and 2 encode 240 and 194 
amino acid proteins, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 1 
112 
 
ATG TAA 
402 321 
2 1 
112 
 
ATG TAA 
402 60 
3 
 
88 
123 
Splice variant 1 Splice variant 2 
Figure 5.1 Exon and intron structure of the human C20orf201 gene. Schematics show the 
structure of the C20orf201 gene coding and non-coding regions for two different splice 
variants. The boxes and arrows represent exons and introns, respectively. The lengths of each 
exon and intron are given above the box in the exons and below the arrow in the introns. 
Approximate positions of start codon (ATG) and stop codon (TAA) are marked with red. 
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5.2 Results 
5.2.1 Analysis of expression of the C20orf201 gene, variant 2, in normal and 
cancer tissues 
RT-PCR analysis was performed for C20orf201 gene splice variant number 2 in a range of 
RNAs obtained from 21 human normal tissues and 33 cancer tissues and cell lines. RT-PCR 
intron-spanning primers were designed for C20orf201 gene splice variant 2 (refer to Table 
2.2). The cDNAs were synthesised from the RNAs and β-Actin was used in the RT-PCR 
screening as a positive control for the cDNA quality. 
 
Two transcript variants have been identified for C20orf201 gene. The RT-PCR screening of 
the splice variant 1 was previously described in Chapter 3 (see Figures 3.12 and 3.14). The 
expression of C20orf201, variant 2, is analysed in this chapter. The expression of C20orf201 
was observed in normal testis, CNS tissues and trachea (Figure 5.2), which suggests that this 
variant is testis-CNS-selective, based on its expression pattern. This variant was investigated 
further in multiple cancer tissues/cell lines, and importantly, it was detailed in 13 different 
cancers (Figure 5.3).  
 
5.2.2 Cloning of C20orf201 cDNA into the mammalian pcDNA5/FRT/TO vector 
for over expression 
The aim of cloning C20orf201 cDNA is to address the function of this gene in cancer cells. 
The mammalian expression vector, pcDNA5/FRT/TO (refer to Figure 4.2), was used for the 
cloning of the C20orf201 variant 1 with and without addition of the Kozak consensus 
sequence. The Kozak sequence is added to the C20orf201 cDNA sequences to stimulate the 
translation process (Kozak, 1991). Constructs with and without Kozak sequences were 
generated to potentially produce cell lines that differed in the amounts of C20orf201 protein 
produced. The HindIII restriction enzyme was used for cloning of C20orf201–Kozak and 
C20orf201+Kozak, since it does not appear in C20orf201 cDNA sequences and is found at 
the multiple cloning site (MCS) of the pcDNA5/FRT/TO vector. 
 
The cloning of C20orf201+Kozak was initiated by amplification of C20orf201 cDNA from 
the pCMV6-AC::C20orf201 vector using C20orf201 F5+Kozak and R5 primers. The 
amplified fragment was 726 bp, based on DNA sequencing, which confirmed the cDNA 
sequences of the gene. The purified PCR insert was subcloned into the pcDNA5/FRT/TO 
vector after digestion with the same restriction enzyme, HindIII. The vector was analysed on 
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agarose gel before and after HindIII digestion in order to confirm the digestion efficiency of 
the vector, which yielded four molecules with the undigested vector (Figure 5.4A) and a 
single fragment of about 5137 bp with the digested vector (Figure 5.4B left). The insert was 
separated on a gel after digestion and purified to confirm the presence of a single band of 
about 726 bp, as predicted by DNA sequencing (Figure 5.4B right).  
 
In contrast, C20orf201 cloning without the Kozak sequence was initiated by amplification of 
C20orf201 cDNA from the pCMV6-AC::C20orf201 vector using C20orf201 F6 and R5 
primers. The amplified fragment was subcloned into the pcDNA5/FRT/TO vector after 
digestion with HindIII restriction enzyme and purification. The vector was analysed on 
agarose gel before and after HindIII digestion in order to confirm the digestion efficiency of 
the vector, which produced four molecules with the undigested vector (Figure 5.5A) and one 
fragment of about 5137 bp with the digested vector (Figure 5.5B left). Conversely, the 
C20orf201 insert was loaded onto an agarose gel following digestion and purification and 
displayed a single band of about 723 bp, as predicted by DNA sequencing (Figure 5.5B right).  
 
The purified C20orf201 inserts (with and without Kozak) were ligated into the purified 
digested pcDNA5/FRT/TO plasmid using quick T4 DNA ligase. The recombinant plasmids 
were transformed into competent E. coli DH5α. The clones were analysed by PCR screening 
performed on 20 randomly selected colonies. Primers internally positioned within the 
C20orf201 gene, namely C20orf201 F1 and R1, were used in the PCR screening. The PCR 
results indicated that 8 of the E. coli colonies had the gene of interest (C20orf201) with Kozak 
(Figure 5.6) and 6 colonies without Kozak (Figure 5.7). The PCR primers were tested using 
testis cDNA, which gave a band lower than the expected size, with about 88 bp missing, 
which was confirmed by DNA sequencing. 
 
The pcDNA5/FRT/TO::C20orf201+Kozak and pcDNA5/FRT/TO::C20orf201–Kozak 
plasmids were isolated from E. coli. The presence of C20orf201 inserts (+Kozak or –Kozak) 
was verified by restriction enzyme digestion, which cut once in the vector and once in the 
insert. Therefore, 8 samples of purified DNA from the pcDNA5/FRT/TO::C20orf201+Kozak 
plasmids and 6 samples of purified DNA from the pcDNA5/FRT/TO::C20orf201–Kozak 
plasmids were digested with HindIII. Two fragments were observed for each digested 
plasmid. The upper fragments gave the expected vector size of 5137 bp, while the lower 
bands gave fragments of 726 bp and 723 bp for the C20orf201+Kozak (Figure 5.8) and 
C20orf201–Kozak, respectively (Figure 5.9).  
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Two purified plasmids (pcDNA5/FRT/TO::C20orf201+Kozak and 
pcDNA5/FRT/TO::C20orf201–Kozak) were sent for DNA sequencing using two sets of 
primers, CMV (forward) and BGH (reverse) to confirm that the C20orf201 inserts were 
subcloned in the correct orientation for expression and contained an ATG start codon and a 
TAA stop codon. The sequences obtained from the DNA sequencing were compared with the 
original sequence via the NCB1 (BLAST). They were 100% identical to C20orf201, without 
any mutation evident in the whole length of the C20orf201 gene.  
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Figure 5.2 RT-PCR analysis of the messenger RNA for C20orf201 gene splice variant 2 with normal 
human tissues. Agarose gel image illustrating the RT-PCR assays for the C20orf201 gene. cDNAs were 
isolated from the total RNA from 21 normal tissues. The expression of C20orf201 was observed in the 
normal testis, central nervous system tissues and trachea. β ACT expression was used as a positive control 
for the cDNA samples. The expected amplicon size of each PCR product is shown on the left between 
brackets. 
Figure 5.3 RT-PCR analysis of the messenger RNA for C20orf201 gene splice variant 2 with 
human cancer cell lines and tumour tissues. Agarose gel image illustrating the RT-PCR assays for 
the C20orf201. cDNAs were isolated from the total RNA from 33 cancer tissues and cell lines. This 
gene was expressed in the normal testis tissue and in different cancer samples. β ACT expression was 
used as a positive control for the cancer cDNA samples. The expected amplicon size of PCR product is 
shown on the left between brackets.  
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Figure 5.4 Amplification of C20orf201+Kozak from recombinant pCMV6-AC::C20orf201 
vector. Agarose gel image shown in panel (A) is undigested pcDNA5/FRT/TO, mammalian 
expression vector, used as a control to compare to the digestion vector. In contrast, the left side of 
panel (B) shows the pcDNA5/FRT/TO vector after digestion by HindIII restriction enzyme and 
purification. The enzyme linearizes the 5137 bp plasmid into one single fragment. The right side of 
gel B displays the amplification of C20orf201 cDNAs +Kozak sequence from pCMV6-
AC::C20orf201 vector, which was already cloned with the full length open reading frame of 
C20orf201 by using F5 and R5 primers. This band was digested with the same restriction enzyme, 
HindIII, and then underwent purification.   
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Figure 5.5 Amplification of C20orf201–Kozak from recombinant pCMV6-AC::C20orf201 
vector. Agarose gel image shown in panel (A) is undigested pcDNA5/FRT/TO, mammalian 
expression vector used as a control to compare to the digestion vector. In contrast, the left side of the 
panel (B) shows the pcDNA5/FRT/TO vector after digestion by HindIII restriction enzyme and 
purification. The enzyme linearizes the 5137 bp plasmid into one single fragment. The right side of 
gel B displays the amplification of C20orf201 cDNAs –Kozak sequence from pCMV6-
AC::C20orf201 vector, which was already cloned with the full length open reading frame of 
C20orf201 by using F6 and R5 primers. This band was also digested with the same restriction 
enzyme, HindIII, and then underwent purification.  
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Figure 5.6 PCR screening of colonies for cloning of C20orf201. Agarose gel image showing PCR 
screening of E. coli colonies for cloning of C20orf201+Kozak into pcDNA5/FRT/TO using an 
internal primer for the C20orf201 gene (F1,R1). The first band (lane 1) displays the presence of 
C20orf201 in the testis cDNA to confirm that the primers worked. The samples in lanes 4-6 and 13-
15 have an insert of the expected size of 505 bp for C20orf201.  
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Figure 5.7 PCR screening of colonies for cloning of C20orf201. Agarose gel image showing PCR 
screening of E. coli colonies for cloning of C20orf201–Kozak into pcDNA5/FRT/TO using an 
internal primer of C20orf201 gene (F1,R1). The first band (lane 1) displays the presence of 
C20orf201 in the testis cDNA to confirm that the primers worked. The samples in lanes 3, 5, 8, 11 
and 14 have an insert of the expected size of 505 bp for C20orf201.  
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Figure 5.8 Digestion of recombinant plasmids. Agarose gel image showing digestion of the 
recombinant purified pcDNA5/FRT/TO vectors by the HindIII restriction enzyme. Two bands are 
formed for all recombinants. The upper bands demonstrate a pcDNA5/FRT/TO vector of 5137 bp, 
while the lower bands demonstrate the full open reading frame of C20orf201 gene +Kozak with a 
size of 726 bp. All the minipreps in lanes 1-8 show successful cloning of C20orf201 cDNA. 
Figure 5.9 Digestion of recombinant plasmids. Agarose gel image showing the digestion of 
recombinant purified pcDNA5/FRT/TO vectors by the HindIII restriction enzyme. Two bands are 
formed for all recombinants. The upper bands demonstrate a pcDNA5/FRT/TO vector of 5137 bp, 
while the lower bands demonstrate the full open reading frame of C20orf201 gene –Kozak with a 
size of 723 bp. The minipreps in lanes 1-6 are all successful clones of C20orf201 cDNA. 
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5.2.3 Integration of pcDNA5/FRT/TO containing C20orf201 cDNA into the Flp-In 
T-REx-293 cell line 
5.2.3.1 Generation of a stable cell line  
Insertion of C20orf201 into the genome of the Flp-In T-REx-293 requires pOG44 vector 
(refer to Figure 4.10). In this study, the Flp-In T-REx-293 was co-transfected with a DNA 
mixture containing C20orf201 cDNA (+Kozak or –Kozak) in pcDNA5/FRT/TO and pOG44 
at a ratio of 9:1 (pOG44: pcDNA5/FRT/TO). A negative control was set up via transfection of 
the Flp-In T-REx-293 cell line with pOG44 and pcDNA5/FRT/TO alone without the gene of 
interest. In brief, a non-transfected Flp-In T-REx-293 cell line was grown in medium 
supplemented with 200 µg/ml zeocin and 10 µg/ml blasticidin. 48 hours following 
transfection, the cells were refreshed with media containing 100 µg/ml of hygromycin instead 
of zeocin.  
 
Insertion of pcDNA5/FRT/TO containing the C20orf201 gene with or without the Kozak 
sequence or the vector alone into the genome of the Flp-In T-REx-293 cell line at the FRT 
site brings the PSV40 promoter and the start codon (ATG) (from pFRT/lacZeo plasmid) frame 
with the hygromycin gene. Therefore, the hygromycin gene becomes active and the lacZ-
Zeocin gene is inactivated (see Figure 4.9). Stable cell lines can be selected for hygromycin 
resistance, zeocin sensitivity and lack of β-galactosidase activity. Following integration, the 
C20orf201 gene is expressed under the control of the (CMV)/TetO2 promoter. The majority 
of the cells did not survive due to the presence of hygromycin, which was used for the 
selection of a stable cell line. After pre-screening by viewing with a light microscope, single 
hygromycin resistant clones were selected for each construct (Figure 5.10).  
 
5.2.3.2 Evaluation of different integrant Flp-In T-REx-293 cell lines 
Two different methods were used to analyse the successful integration of 
pcDNA5/FRT/TO::C20orf201 into the genome of the Flp-In T-REx-293 cell line at the FRT 
site. The first method involved screening for β-galactosidase activity. Confluent cells were 
analysed using a β-Gal staining kit in media containing hygromycin or zeocin for the 
transfected and non-transfected cells, respectively. The lacZ gene product, β-galactosidase, 
can be visualized by β-Gal staining of the cell. This activity was determined in triplicate for 
each cell line and light microscope images were obtained. The positive control for lacZ-
staining (untransfected Flp-In T-REx-293 cell line) contained only blue cells, indicating 
active LacZ expression. In contrast, none of the cells in the clonal cell lines were blue, 
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indicating that the insertion of the C20orf201 constructs was successful (Figure 5.11). 
 
The second method used was PCR screening of the integrant Flp-In T-REx-293. Genomic 
DNA was isolated from the non-transfected and transfected Flp-In T-REx-293 cells. β-actin 
was used as a positive control for the genomic DNA samples. PCR products were found in all 
transfected cells that integrated with the pcDNA5/FRT/TO::C20orf201+Kozak, the 
pcDNA5/FRT/TO::C20orf201–Kozak or the empty pcDNA5/FRT/TO; however, the non-
transfected cells did not display any PCR products when using primers located in the PSV40 as 
a forward primer and the hygromycin gene as a reverse primer. Primers located in the 
C20orf201 gene (forward) and in the LacZ-Zeocin gene (reverse) were also used. The PCR 
results using C20orf201 and LacZ-Zeocin primers showed products only for the Flp-In T-
REx-293 that had been integrated with pcDNA5/FRT/TO::C20orf201+Kozak or with 
pcDNA5/FRT/TO::C20orf201–Kozak (Figure 5.12).  
 
The results of both methods (β-galactosidase activity and PCR screening) suggest that the 
C20orf201 gene was correctly inserted into the genomic DNA of the Flp-In T-REx-293 cells. 
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Figure 5.10 Examples of individual hygromycin resistance colonies. These images (panels (A) and 
(B)) show examples of a single colony still growing after hygromycin treatment,  suggesting these 
cells have integrated with C20orf201+Kozak and C20orf201–Kozak, respectively. Panel (C) shows 
an example of cells that have integrated with pcDNA5/FRT/TO alone, without the target gene, and 
these cells served as a negative control.   
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before staining  
After staining 
C
2
0
o
rf
2
0
1
+
 K
o
za
k
 
C
2
0
o
rf
2
0
1
–
 K
o
za
k
 
p
cD
N
A
5
/F
R
T
/T
O
 
U
n
tr
an
sf
ec
te
d
 F
lp
-I
n
 T
-R
E
x
- 
2
9
3
 
Transfected Flp-In T-REx-293:: 
Figure 5.11 Assay for β-galactosidase Activity. These images show the untransfected cells of Flp-In 
T-REx-293 cells only produce β-galactosidase, but the transfected cells that integrated with different 
inserts of C20orf201+Kozak or C20orf201–Kozak or pcDNA5/FRT/TO do not produce β-
galactosidase, as assessed by the colour of the cells following staining. 
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Figure 5.12 PCR screening of different C20orf201 integrations into Flp-In T-REx-293 cell lines. 
Panel (A) shows the presence of the C20orf201 gene in the transfected cells when using PSV40 as a 
forward primer and hygromycin as a reverse primer. Panel (B) shows PCR products of Flp-In T-REx-
293 with the C20orf201 genes when using primers in the C20orf201 gene (forward) and in the LacZ-
Zeocin gene (reverse). PCR using primers within the β-actin gene are shown as a positive control for 
the genomic DNA samples (panel (C)). The diagram in panel (D) shows the localisation of C20orf201 
cDNAs in the genome of Flp-In T-REx-293 cell line. 
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5.2.3.3 Evaluation of the C20orf201 expression level in the Flp-In T-REx-293 cell line 
The expression of the C20orf201 gene was analysed using both RT-PCR and qRT-PCR. 
C20orf201 expression was induced by the addition of tetracycline to the culture cells (2 
µg/ml) and cDNAs were synthesised from the mRNAs of these cell lines. Two negative 
controls were used: untransfected cells and cells transfected with empty pcDNA5/FRT/TO. β-
actin was used as a positive control for the cDNA samples. RT-PCR results confirmed the 
expression of the C20orf201 gene (using F1 and R1 primers) in the cell lines that had been 
integrated with either pcDNA5/FRT/TO::C20orf201+Kozak or 
pcDNA5/FRT/TO::C20orf201–Kozak (Figure 5.13). However, higher levels of PCR products 
were observed for C20orf201 in the cells treated with tetracycline relative to the same cells 
with no treatment. The mRNA levels of the C20orf201 gene were detectable, indicating weak 
expression, in both negative controls using the same primers. The results in Figure 5.13 also 
show two distinct bands (18S and 28S ribosomal RNAs), which suggest good quality RNAs 
for all Flp-In T-REx-293 cell lines.  
 
qRT-PCR was carried out for the C20orf201 gene in different Flp-In T-REx-293 cell lines 
using C20orf201 F3 and R3 primers, while commercial positive primers were used. The NRT 
(no reverse transcriptase) and NTC (no template control) negative controls did not give a Cq 
(quantification cycle) reading, which suggests no non-specific background and no genomic 
DNA contamination (Table 5.1). The qRT-PCR results show a higher level of C20orf201 
expression in the Flp-In T-REx-293::C20orf201+Kozak and Flp-In T-REx-293::C20orf201–
Kozak cells with tetracycline than in the Flp-In T-REx-293::pcDNA5/FRT/TO cells before 
treatment with tetracycline (Figure 5.14). In contrast, the mRNA levels were distinguished 
between cells containing C20orf201+Kozak or C20orf201–Kozak in the absence of 
tetracycline and the negative control with and without addition of tetracycline (Figure 5.15). 
This demonstrated that the expression was higher in cells containing the C20orf201 gene, 
even though no tetracycline was added, compared to negative control (Figure 5.15). The RT-
PCR results shown in Figure 5.13 suggest that the Flp-In T-REx-293::pcDNA5/FRT/TO cell 
line was negative for C20orf201 expression. The intensity of the C20orf201 PCR band was 
stronger in cell lines that had been integrated with C20orf201 after treatment with tetracycline 
than in the other cell lines with no treatment. Therefore, these qRT-PCR results corresponded 
to the RT-PCR results previously observed (Figure 5.13). The C20orf201 qRT-PCR results 
were normalised to the qRT-PCR results for Lamin A and β ACT; the results are shown in 
Table 5.1. 
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Figure 5.13 RT-PCR expression of C20orf201 and β ACT in Flp-In T-REx-293 cell lines. The top 
agarose gel shows the expression of C20orf201 in cells with three different insertions (C20orf201 
+Kozak or C20orf201–Kozak or pcDNA5/FRT/TO) with and without tetracycline treatment. The 
middle agarose gel displays the expression profile for β-actin as a positive control for the cDNA 
samples. The bottom agarose gel shows the quality of the total RNAs for different cell lines. Three 
bands of ribosomal RNAs appear in each sample. The 28S and 18S ribosomal RNA bands are clearly 
visible in the RNA samples at the ratio of approximately 2:1. 
155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 5.14 Real-time quantitative RT-PCR analysis for C20orf201 expression in Flp-InT-
REx-293 cells. The bar chart displays the gene expression results for C20orf201 with and without 
Kozak consensus in Flp-In T-REx-293 cell lines before (-) or after (+) adding tetracycline to the 
cell culture, compared to the cells which contain the pcDNA5/FRT/TO vector alone (negative). 
Expression data were normalised to the β-ACT and Lamin A reference genes. The error bars 
represent the standard error of the mean (SEM) for three repeats. 
Figure 5.15 Real-time quantitative RT-PCR analysis for C20orf201 expression in Flp-In T-
REx-293 cells. The bar chart displays the gene expression results for C20orf201 with and without 
Kozak sequence in Flp-In T-REx-293 cell lines before (-) adding tetracycline to the cell culture, 
compared to the cells which contain the pcDNA5/FRT/TO vector alone, with and without 
tetracycline treatment (negative). Expression data were normalised to the β-ACT and Lamin A 
reference genes. The error bars represent the standard error of the mean (SEM) for three repeats. 
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Table 5.1 Real-time qRT-PCR analysis for C20orf201 expression in Flp-In T-REx-293 cells. The 
table displays the mean of three repeats of quantification cycle (Cq) and standard deviation (SD) for 
analysis of C20orf201 expression with and without Kozak consensus in Flp-In T-REx-293 cell lines 
before (-) or after (+) adding tetracycline treatment. These results were normalised against β-ACT and 
Lamin A expression. The Cq readings for the no reverse transcriptase (NRT) and no template controls 
(NTC) are also shown. 
 
Target name Sample name Wells Cq Mean Cq SD 
C20orf201 Flp-In T- REx-293: pcDNA5/FRT/TO+ 3 23.62 0.184 
β ACT Flp-In T- REx-293: pcDNA5/FRT/TO+ 3 16.70 0.035 
Lamin A Flp-In T- REx-293: pcDNA5/FRT/TO+ 3 21.83 0.137 
C20orf201 Flp-In T- REx-293: pcDNA5/FRT/TO- 3 23.47 0.090 
β ACT Flp-In T- REx-293: pcDNA5/FRT/TO- 3 16.83 0.104 
Lamin A Flp-In T- REx-293: pcDNA5/FRT/TO- 3 21.94 0.164 
C20orf201 Flp-In T- REx-293: C20orf201+Kozak+ 3 18.07 0.053 
β ACT Flp-In T- REx-293: C20orf201+Kozak+ 3 17.53 0.063 
Lamin A Flp-In T- REx-293: C20orf201+Kozak+ 3 22.70 0.047 
C20orf201 Flp-In T- REx-293: C20orf201+Kozak- 3 22.58 0.162 
β ACT Flp-In T- REx-293: C20orf201+Kozak- 3 16.88 0.040 
Lamin A Flp-In T- REx-293: C20orf201+Kozak- 3 22.13 0.062 
C20orf201 Flp-In T- REx-293: C20orf201-Kozak+ 3 17.61 0.048 
β ACT Flp-In T- REx-293: C20orf201-Kozak+ 3 17.18 0.071 
Lamin A Flp-In T- REx-293: C20orf201-Kozak+ 3 22.44 0.111 
C20orf201 Flp-In T- REx-293: C20orf201-Kozak- 3 22.48 0.056 
β ACT Flp-In T- REx-293: C20orf201-Kozak- 3 17.13 0.026 
Lamin A Flp-In T- REx-293: C20orf201-Kozak- 3 22.25 0.022 
C20orf201 Flp-In T- REx-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
β ACT Flp-In T- REx-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T- REx-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T- REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
β ACT Flp-In T- REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
Lamin A Flp-In T- REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T- REx-293: C20orf201+Kozak+ (NRT) 1 0.00 0.000 
β ACT Flp-In T- REx-293: C20orf201+Kozak+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T- REx-293: C20orf201+Kozak+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T- REx-293: C20orf201+Kozak- (NRT) 1 0.00 0.000 
β ACT Flp-In T- REx-293: C20orf201+Kozak- (NRT) 1 0.00 0.000 
Lamin A Flp-In T- REx-293: C20orf201+Kozak- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T- REx-293: C20orf201-Kozak+ (NRT)  1 0.00 0.000 
β ACT Flp-In T- REx-293: C20orf201-Kozak+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T- REx-293: C20orf201-Kozak+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T- REx-293: C20orf201-Kozak- (NRT) 1 0.00 0.000 
β ACT Flp-In T- REx-293: C20orf201-Kozak- (NRT) 1 0.00 0.000 
Lamin A Flp-In T- REx-293: C20orf201-Kozak- (NRT) 1 0.00 0.000 
C20orf201 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
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5.2.4 Evaluation of the C20orf201 protein levels in the Flp-In T-REx-293 cell lines 
The C20orf201 protein levels were assessed in different integrants of Flp-In T-REx-293 cell 
lines before and after tetracycline treatment using anti-C20orf201 antibody (Abcam; 
AB108142). The molecular weight of C20orf201 protein is ~26 KDa, according to Western 
blotting (Figure 5.16). Western blots indicated that the levels of C20orf201 protein were 
clearly strong in the Flp-In T-REx-293 cell lines inserted with either C20orf201+Kozak or 
C20orf201–Kozak following treatment with tetracycline, when compared to the two negative 
controls (untransfected cells and cells transfected with pcDNA5/FRT/TO only) (Figure 5.16). 
The mRNA of C20orf201 gene was expressed in cells with C20orf201+Kozak or C20orf201–
Kozak without tetracycline treatment (refer to Figure 5.13); however, no proteins were 
detectable in either sample. Therefore, the Western blotting results suggest that some 
mechanism might operate that inhibits translation in the absence of tetracycline (high mRNA 
levels). Appropriate protein loading was confirmed for each clone by the GAPDH control. 
 
5.2.5 Protein analysis of the C20orf201 gene in the normal and cancer tissues 
Western blotting was performed to investigate protein levels of C20orf201 in 11 different 
normal tissues and 6 different cancer cell lines. Two types of testis lysate were used, obtained 
from different companies. Normal tissues showed C20orf201 protein levels in both testis 
lysates and central nervous system tissues (brain, brain-cerebellum and spinal cord) (Figure 
5.17), in agreement with the RT-PCR results obtained for C20orf201 gene in non-cancer cells 
(refer to Figure 3.12). In contrast, the presence of the C20orf201 protein was validated in 4 
cell lines that showed previously RT-PCR expression in Chapter 3, while NTERA2 and HEP-
G2 cell lysates were used as negative controls for the C20orf201, because no PCR product 
was detected. Interestingly, The C20orf201 protein was detected in breast cancer (MCF-7) at 
a high level and in ovarian cancer (TO14) at low levels (Figure 5.18). Neither negative 
control displayed any levels of protein for C20orf201, which corresponded with the RT-PCR 
results (refer to Figure 3.14). 
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Figure 5.16 Western blot analysis showing C20orf201 induction using tetracycline in the Flp-In T-
REx-293 cell lines.  Four cultures were subjected to 2 µg/ml of tetracycline and four were not. Positive 
signals are seen in cells containing the C20orf201 gene with and without Kozak sequencing after treatment 
with tetracycline. The cells were harvested 24 hours after induction. The lysates were separated on a 10% 
SDS-PAGE gel. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) was used as the loading control. 
159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
anti-GAPDH –37 KDa 
P
E
O
1
4
 
A
2
7
8
0
 
M
C
F
-7
 
N
T
E
R
A
2
 
H
E
P
-G
2
 
T
O
1
4
 
M
ar
k
er
s 
50 KDa 
37 KDa 
25 KDa 
50 KDa 
37 KDa 
anti-C20orf201 –26 KDa 
Figure 5.17 Western blot analysis showing C20orf201 protein in distinct normal lysates. Positive 
signals are seen in testes and central nervous tissues (top). The lysates were separated on a 10% SDS-
PAGE gel.  GAPDH was used as the loading control (bottom). 
Figure 5.18 Western blot analysis for C20orf201 protein levels in distinct cancer cell line 
lysates. Western blot analysis showing a strong signal in the MCF-7 cell line compared to other cell 
lines (top). The NTERA2 and HEP-G2 lysates were used as negative controls as RT-PCR of these 
cell lines showed no expression of C20orf201. The lysates were separated on a 10% SDS-PAGE gel. 
GAPDH was used as the loading control (bottom). 
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5.2.6 RT-PCR and protein analyses of the C20orf201 gene in cancer cell lines 
MCF-7, A2780, PEO14 and TO14 cell lines were grown; RNAs and whole lysates were 
extracted from them for RT-PCR and Western blotting analyses, respectively. The cDNAs 
were also made from these cells, with and without adding reverse transcriptase. Expression of 
C20orf201 was observed in all cell lines tested here, but with some differences in mRNAs 
levels. The intensity of the C20orf201 PCR band was significantly fainter in the breast cancer 
(MCF-7) cell line than in the other cell lines tested (Figure 5.19, top left). Samples containing 
no reverse transcriptase were used as negative controls and C20orf201 expression was not 
detectable in any of the cell lines under this condition, indicating no genomic DNA 
contamination (Figure 5.19, top right). Testis cDNA was used in RT-PCR to confirm the 
performance of primers. β ACT gene was used as well to assess the cDNA quality synthesised 
from these cell lines. 
 
Post-transcriptional mechanisms may affect the association between gene expression and 
protein levels (Tan et al., 2009). Consequently, C20orf201 expression in four cancer cell lines 
does not guarantee that the C20orf201 protein is produced. Therefore, Western blotting 
analysis was used to investigate the protein abundance for the C20orf201 protein in one breast 
cancer and three ovarian cancer cell lines. The GAPDH results suggest that the gel loading 
was relatively equal, so differences in protein level intensities are likely to be due to 
variations in protein abundance in the four cell lines. Western blot analysis using anti-
C20orf201 identified two bands at approximately 50 KDa (upper band) and at 26 KDa (lower 
band) in all cell lines. These Western blot analysis results showed a fainter band for 
C20orf201 in the A2780 cells compared to the other cells. Importantly, the strongest band for 
C20orf201 was found in the MCF-7 (Figure 5.20), although the gene expression shown in 
Figure 5.19 was extremely faint.  
 
qRT-PCR was carried out to compare the mRNA expression for the C20orf201 gene in the 
MCF-7, A2780, PEO14 and TO14 cell lines (Figure 5.21). The RT-PCR (Figure 5.19) and the 
qRT-PCR (Figure 5.21) results indicated a lower level of C20orf201 gene expression in the 
MCF-7 cells, but the protein level was high in this cell line compared to the three ovarian 
cancer cells (Figure 5.20). Therefore, these Western blot results did not appear to correspond 
with the gene expression results. The C20orf201 qRT-PCR results were normalised to the 
qRT-PCR results for Lamin A and β ACT. The qRT-PCR results are shown in Figure 5.21.  
 
RT-PCR and Western blotting results for the C20orf201 gene in 11 normal tissues and 4 
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cancer cell lines confirmed that the C20orf201 gene is potentially a good CTA gene 
candidate.   
 
The band that appeared in the testis protein lysate through Western blot analysis using anti-
C20orf201 antibody was confirmed to have the same molecular weight in the MCF-7, Flp-In 
T-REx-293::C20orf201+Kozak and Flp-In T-REx-293::C20orf201–Kozak by running these 
cell lysates again, side by side, to identify any differences in the molecular weight of 
C20orf201 protein among them. The Western blotting results for the C20orf201 gene are 
shown in Figure 5.22. These results indicated that the molecular weight for C20orf201 protein 
is approximately 26 KDa.  
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Figure 5.19 RT-PCR analysis for C20orf201 gene expression in different human cancer cells. 
Agarose gel image illustrating the RT-PCR analysis for C20orf201 expression in normal testis, three 
ovarian cancer cell lines (A2780, PEO14 and TO14) and a breast cancer cell line (MCF-7). cDNAs 
were isolated for these cells with (+) and without (-) adding reverse transcriptase. The C20orf201 
gene was expressed in all cells, but with some differences. β ACT expression was used as a positive 
control for the cDNA samples. The expected amplicon size of each gene is shown on the left between 
brackets. 
Figure 5.20 Western blot analysis for C20orf201 protein levels in distinct cancer cell line 
lysates. Western blot analysis showed a strong signal in the MCF-7 cell line compared to other cell 
lines (top). The lysates were separated on a 10% SDS-PAGE gel. GAPDH was used as the loading 
control (bottom). 
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Target name Sample name Wells Cq Mean Cq SD 
C20orf201 MCF7 3 23.49 0.053 
β ACT MCF7 3 14.41 0.315 
Lamin A MCF7 3 18.89 0.081 
C20orf201 A2780 3 23.63 0.101 
β ACT A2780 3 15.91 0.033 
Lamin A A2780 3 21.90 0.138 
C20orf201 PEO14 3 24.39 0.045 
β ACT PEO14 3 17.91 0.078 
Lamin A PEO14 3 21.10 0.076 
C20orf201 TO14 3 23.60 0.073 
β ACT TO14 3 15.72 0.061 
Lamin A TO14 3 18.65 0.033 
C20orf201 MCF7 (NRT) 1 0.00 0.000 
β ACT MCF7 (NRT) 1 0.00 0.000 
Lamin A MCF7 (NRT) 1 0.00 0.000 
C20orf201 A2780 (NRT) 1 0.00 0.000 
β ACT A2780 (NRT) 1 0.00 0.000 
Lamin A A2780 (NRT) 1 0.00 0.000 
C20orf201 PEO14 (NRT) 1 0.00 0.000 
β ACT PEO14 (NRT) 1 0.00 0.000 
Lamin A PEO14 (NRT) 1 0.00 0.000 
C20orf201 TO14 (NRT) 1 0.00 0.000 
β ACT TO14 (NRT) 1 0.00 0.000 
Lamin A TO14 (NRT) 1 0.00 0.000 
C20orf201 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
 
 
 
 
 
 
 
 
A 
B 
Figure 5.21 Real-time quantitative RT-PCR analysis for C20orf201 expression in different 
cells. The bar chart in panel (A) displays the gene expression results for C20orf201 in MCF-7, 
A2780, PEO14 and TO14 cancer cell lines. The error bars represent the standard error of the mean 
(SEM) for 3 repeats. The table in panel (B) displays the mean of three repeats of quantification cycle 
(Cq) and standard deviation (SD) for C20orf201. Expression data were normalised to the β ACT and 
Lamin A reference genes. Also shown in the table are the Cq readings for the no reverse transcriptase 
(NRT) and no template controls (NTC).  
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5.2.7 Cellular localisation of C20orf201  
The cellular location of C20orf201 was analysed in MCF-7 (a breast cancer cell line) cells 
using Western blot analysis and Immunofluorescent staining of fixed cells.  
 
5.2.7.1 Western blot analysis  
The nuclear and cytoplasmic protein fractions were prepared alongside whole cell extracts for 
the MCF-7 cell line, to identify the cellular location of C20orf201 gene using anti-C20orf201 
antibody (Abcam; AB108142). Nuclear, cytoplasmic and whole protein lysates were prepared 
for MCF-7 to localise the protein for the C20orf201 gene. These lysates were then analysed 
using Western blot analysis, as shown in Figure 5.23. Antibodies against GAPDH and lamin 
B were used as the positive controls for the cytoplasmic and nuclear fractions, respectively. 
The predicted band size for C20orf201 using anti-C20orf201 is approximately 26 KDa. 
Interestingly, the C20orf201 protein was detected in the MCF-7 cells as a stronger band in 
both the cytoplasm at 26 KDa and the nucleus at 50 KDa.  
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Figure 5.22 Western blot analyses for C20orf201 protein levels in normal and cancer cell 
lysates. Western blot analysis showed strong signals in all cells for a protein with molecular weight 
of about 26 KDa (top). The lysates were separated on a 10% SDS-PAGE gel. GAPDH was used as 
the loading control (bottom). 
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5.2.7.2 Immunofluorescent staining of fixed cells  
Immunofluorescent staining was also performed for C20orf201 in fixed MCF-7 cells using 
anti-C20orf201 antibody (Abcam; AB170783). Two images are shown for anti-C20orf201 
staining of MCF-7 cells; the upper and lower rows show cells magnified with a 60x objective 
lens. Both stained images suggest that C20orf201 is found in the nucleus and the cytoplasm of 
the MCF-7 cells (Figure 5.24). Therefore, the immunostaining results appear to correspond 
with the Western blotting results.  
 
The anti-mouse secondary antibody was used as a negative control and to check the level of 
non-specific background in the MCF-7 cells. However, the non-specific background produced 
through the secondary antibody was not significant compared with the staining observed with 
the primary antibody. Therefore, this indicates that the staining detected for anti-C20orf201 
resulted from staining of the primary antibody.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 Western blot analysis of C20orf201 sub-cellular localisation in MCF-7 cancer cell 
line. Western blot analysis showing the cellular localisation of C20orf201 protein in the MCF-7 cell 
line using a whole cell extract (W), a cytoplasmic lysate fraction (C) and a nuclear lysate fraction 
(N). Antibodies against lamin B (Nuclear) and GAPDH (Cytoplasmic) were used as the positive 
controls, to confirm the fractionation efficiency and the loading of the gel. 
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5.2.8 siRNA knockdown of C20orf201 in MCF-7 cell line 
Knockdown of C20orf201 levels was attempted using four types of C20orf201-specific 
siRNAs in the MCF-7 cell line to determine any effect that knockdown of this protein may 
have on these cells and to test the specificity of the anti-C20orf201 antibody. The predicted 
molecular weight of the C20orf201 gene is approximately 26 KDa. Whole cell extracts were 
collected from the cells following siRNA treatment and analysed using Western blot and 
qRT-PCR analyses. The number of siRNA treatments (‘hits’) was increased to optimise any 
knockdown in C20orf201 protein levels or gene expression. 
 
The band thought to correspond to C20orf201 showed only a slight decrease after 48 hours 
treatment (2 ‘hits’) with siRNA 7 and a combination of four C20orf201-specific siRNAs 
compared to the negative control (cells treated with non-interfering siRNA). Furthermore, 
faint but clear protein bands were also observed at approximately 50 KDa in cells treated with 
siRNA 7 and mixed siRNAs (2, 5, 6 and 7) compared to transfected cells (Figure 5.25). 
However, this band was also observed as well as a faint band in a few protein lysates in 
anti-C20orf201 
anti-C20orf201 
anti-mouse alone 
DAPI 
DAPI 
DAPI 
C20orf201 
Anti-mouse 
DAPI/C20orf201 
DAPI/C20orf201 
DAPI/anti-mouse 
C20orf201 
Figure 5.24 Immunofluorescent staining of fixed MCF-7 cells with antibody against C20orf201. 
Images for immunofluorescent staining for C20orf201 (red) in MCF-7 cells, viewed using a Zeiss 
Axioskop 2 fluorescence microscope (60x lens). Staining with the secondary antibodies (anti-mouse) 
only was used as the negative control. Nuclei are stained blue with DAPI. 
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normal tissues (refer to Figure 5.17) and in the NTERA2 and HEP-G2 cell lines that were 
negative for RT-PCR expression of the C20orf201 gene (refer to Figure 5.18). These results 
suggest that this band may be specific to C20orf201. GAPDH levels were used as a loading 
control.  
 
Gene expression was also examined using qRT-PCR to determine whether expression of 
C20orf201 decreases after siRNA knockdown after 48 hours (two ‘hits’) treatment with 
different types of siRNAs. Importantly, the qRT-PCR results show significant C20orf201 
expression knockdown in the MCF-7 cells. The knockdown was observed in siRNAs 5, 6, 7 
and a combination of four C20orf201-specific siRNAs compared to the non-interfering 
siRNA control (Figure 5.26). The C20orf201 qRT-PCR results were normalised to the qRT-
PCR for Lamin A and β ACT; the results are shown in Table 5.2. Neither negative control, 
NRT and NTC, gave a Cq reading, which indicated the absence of genomic contamination 
and non-specific background (Table 5.2).  
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Figure 5.25 Western blot analysis for two hits of siRNA depletion of C20orf201 in the MCF-7 
cell line. Negative control for the siRNA knockdown was used: cell treated with non-interfering 
siRNA. Cells were transfected with 5 nM concentrations of four independent C20orf201 siRNAs and 
also a combination of the four siRNAs (siRNAs 2+5+6+7) or with 5 nM of non-interference siRNA. 
The transfection reagent and siRNAs were added to the cells culture upon seeding. The cells were 
collected at 48 hours after siRNA transfection. GAPDH protein levels were used as a control for 
protein loading. 
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Figure 5.26 Real-time quantitative RT-PCR analysis for two hits of siRNA knockdown of 
C20orf201 expression in MCF-7 cells. The bar chart displays the gene expression results for 
C20orf201 in the presence of four types of siRNAs for C20orf201 in the MCF-7 cell line compared to 
the cells treated with non-interfering siRNA (negative control). Expression data were normalised to 
the β-ACT and Lamin A reference genes. The error bars represent the standard error of the mean 
(SEM) for three repeats. 
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Table 5.2 Real-time qRT-PCR analysis for siRNA knockdown (2 ‘hits’) of C20orf201 in MCF-7 
cells. The table displays the mean of three repeats of quantification cycle (Cq) and standard deviation 
(SD) for C20orf201. These results were normalised by β ACT and Lamin A expression. Also shown in 
the table are the Cq readings for the no reverse transcriptase (NRT) and no template controls (NTC). 
 
Target name Sample name Wells Cq Mean Cq SD 
C20orf201 Non-interference 3 29.41 0.059 
β ACT Non-interference 3 16.67 0.006 
Lamin A Non-interference 3 21.40 0.093 
C20orf201 siRNA-2 3 27.62 0.062 
β ACT siRNA-2 3 16.60 0.080 
Lamin A siRNA-2 3 21.45 0.048 
C20orf201 siRNA-5 3 23.20 0.018 
β ACT siRNA-5 3 16.46 0.023 
Lamin A siRNA-5 3 21.23 0.044 
C20orf201 siRNA-6 3 30.11 0.051 
β ACT siRNA-6 3 16.25 0.038 
Lamin A siRNA-6 3 21.10 0.043 
C20orf201 siRNA-7 3 29.86 0.177 
β ACT siRNA-7 3 16.19 0.055 
Lamin A siRNA-7 3 21.06 0.036 
C20orf201 Mixed siRNAs 3 29.95 0.202 
β ACT Mixed siRNAs 3 16.48 0.083 
Lamin A Mixed siRNAs 3 21.43 0.024 
C20orf201 Non-interference (NRT) 1 0.00 0.000 
β ACT Non-interference (NRT) 1 0.00 0.000 
Lamin A Non-interference (NRT) 1 0.00 0.000 
C20orf201 siRNA-2 (NRT) 1 0.00 0.000 
β ACT siRNA-2 (NRT) 1 0.00 0.000 
Lamin A siRNA-2 (NRT) 1 0.00 0.000 
C20orf201 siRNA-5 (NRT) 1 0.00 0.000 
β ACT siRNA-5 (NRT) 1 0.00 0.000 
Lamin A siRNA-5 (NRT) 1 0.00 0.000 
C20orf201 siRNA-6 (NRT) 1 0.00 0.000 
β ACT siRNA-6 (NRT) 1 0.00 0.000 
Lamin A siRNA-6 (NRT) 1 0.00 0.000 
C20orf201 siRNA-7 (NRT) 1 0.00 0.000 
β ACT siRNA-7 (NRT) 1 0.00 0.000 
Lamin A siRNA-7 (NRT) 1 0.00 0.000 
C20orf201 Mixed siRNAs (NRT) 1 0.00 0.000 
β ACT Mixed siRNAs (NRT) 1 0.00 0.000 
Lamin A Mixed siRNAs (NRT) 1 0.00 0.000 
C20orf201 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
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5.3 Discussion 
5.3.1 Expression of the human C20orf201 gene in normal and cancer tissues  
The C20orf201 gene splice variant 1 was expressed in different normal tissues, including 
testis, brain (whole or cerebellum), foetal brain and spinal cord, while splice variant 2 was 
expressed in the same tissues as well as in the trachea. During the course of our work another 
study indicated that C20orf201 was expressed only in the testis and brain (whole or 
cerebellum) (Kamata et al., 2013). Both studies confirm the results presented in Chapter 3 for 
C20orf201 splice variant 1 and in Chapter 5 for splice variant 2.  
 
RT-PCR for the C20orf201 gene in various cancer tissues and cell lines indicated expression 
of variants 1 and 2 in 8 and 13 cancer cell lines, respectively. Feichtinger et al. (2012a) 
reported detectable C20orf201 expression in 8 cancer cell lines, including MCF-7, A2780, 
PEO14, TO14, HL-60, Jurkat, and uterus and ovarian tumours. Another previous study using 
qRT-PCR analysis revealed that the expression of C20orf201 was detected in 13 cancer types 
derived from different organs (Kamata et al., 2013). The results obtained in this chapter by 
RT-PCR and Western blotting and the previous studies described above confirm that 
C20orf201 is a good example of a cancer testis antigen and may be useful as a cancer 
biomarker. Subsequent work within the group has now demonstrated immunohistochemistry 
staining of C20orf201 in ovarian cancer tissue, but not healthy tissues. 
 
5.3.2 Regulation of meiosis-specific transcripts 
The Western blot and RT-PCR analyses using anti-C20orf201 antibody and primers (F1, R1), 
respectively, showed strong bands for C20orf201 protein and expression in the presence of 
tetracycline in both Flp-In T-REx-293::C20orf201+Kozak and Flp-In T-REx-
293::C20orf201–Kozak cell lines. Conversely, in the absence of tetracycline, the C20orf201 
gene was expressed in the same cell lines, but no protein at the expected size was detected. 
Therefore, the Western blotting results obtained in the presence and absence of tetracycline 
indicated that there might be some mechanism that represses translation of the C20orf201 
mRNA in these cell lines in the absence of tetracycline treatment (such as system exists in 
fission yeast). 
 
Meiosis leads to a reduction in the genetic material of the cell. The meiotic program among 
eukaryotes is tightly regulated, although much of the mechanism regulating meiosis remains 
unknown (Holm and Thon, 2012). In fission yeast, Saccharomyces pombe meiosis takes place 
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in zygote diploid cells that are heterozygous for the mating-type genes and are exposed to 
nitrogen starvation. These cells arrest in the G1 phase of the mitotic cell cycle, initiate DNA 
synthesis, and then perform two different consecutive nuclear divisions, the first and second 
meiotic divisions (Borgen et al., 2002). The fission yeast utilises a RNA degradation system 
that selectively eliminates meiosis-specific mRNA during the mitotic cell cycle. Mmi1, a 
novel RNA binding protein of the YTH-family, is critical for this process (Yamamoto, 2010). 
When fission yeast cells undergo meiosis, the expression of hundreds genes is newly induced 
or significantly up-regulated by the function of specific transcription factors, such as Ste11, 
which are activated by nitrogen starvation (Yamamoto, 2010). 
 
The Mmi1 RNA elimination system is a type of RNA interference (RNAi) pathway found in 
fission yeast and used for degradation of meiotic transcripts (Harigaya et al., 2006). In this 
pathway, the RNA binds a specific region on the mRNA, termed the DSR (determinant of 
selective removal), with the aid of multiple factors (Sugiyama and Sugioka- Sugiyama, 2011). 
During meiotic progression, Mmi1 is sequestered by the master regulator of meiosis, Mei2 
nuclear dot, in meiotic prophase, which results in the failure of the mRNAs to be destroyed by 
Mmi1. As a result, meiosis-specific mRNAs are stably expressed (Holm and Thon, 2012). 
However, in mitosis, repression of meiotic-specific transcripts occurs through Mmi1. Mmi1 
functions by binding to the DSR sequences in a meiotic mRNAs. Therefore, the function of 
Mmi1 is to mediate elimination of meiotic mRNAs during mitosis (Harigaya et al., 2006).   
 
5.3.3 A possible ubiquitinated variant? 
Ubiquitination is an important post-translational modification (PTM) and plays a fundamental 
role in the regulating of protein functions and it involves the covalent attachment of the 
ubiquitin (Ub) peptide to lysine residues on substrate proteins, which control all aspects of 
cellular functioning (Xu and Jaffrey, 2013). The binding between the Ub and substrate protein 
can lead to protein monoubiquitination or polyubiquitination (Sadowski et al., 2012). Protein 
may be ubiquitinated on one or multiple lysines, resulting in a modification called either 
monoubiquitination or multiubiquitination, respectively (Petroski and Deshaies, 2005). 
Ubiquitination can change protein-protein interactions or alter protein localisation 
(Mukhopadhyay and Riezman, 2007). Many human diseases, such as cancer, are caused by 
the alteration of protein ubiquitination (Xu and Jaffrey, 2013). Protein ubiquitination is 
catalysed by Ub-conjugating and Ub-ligase enzymes, which are recognised a specific type of 
Ub modification on protein substrates; however, how these enzymes operate is still poorly 
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understood (Sadowski et al., 2012). In order to understand the biological function of 
ubiquitination and its role in cancer, it is important to identify protein ubiquitination sites 
(Hoeller and Dikic, 2009). However, the identification of ubiquitination sites is a major 
challenge for two reasons. First, the number of ubiquitinated proteins in cells is very low 
under normal physiological conditions (Mann and Jensen, 2003). Second, only one or a few 
lysine residues are modified in an ubiquitinated protein (Jadhav and Wooten, 2009). 
 
In this chapter, we do not know if the C20orf201 protein is ubiquitinated in the MCF-7 cell 
line; however, we noted that the patterns of three high-molecular-weight bands are consistent 
with ubiquitination patterns the largest being a 50 KDa species. Interestingly, it is 50 KDa 
species which shows a nuclear localisation suggesting this has functional relevance (refer to 
Figures 5.20 and 5.22). One way to prove this notion is the immunoprecipitation and 
purification of C20orf201 protein before running the pure C20orf201 protein on the gel. We 
can probe the Western blot with an antibody to ubiquitin to determine if the C20orf201 is 
ubiquitinated. To confirm such a result, another experiment should be run, but in reverse, 
using an antibody against ubiquitin and purifying all ubiquitinated proteins. This should be 
followed by running them on the gel and probing the Western blot with an antibody against 
C20orf201. If the results are still the same, we would then have strong evidence that the 
protein is ubiquitinated. 
 
5.3.4 C20orf201 function 
Only one paper has been published about the human C20orf201 gene. In this study, 
C20orf201 ORF was integrated into Flp-In T-REx-293 to ask the question “Does the 
overexpression of C20orf201 in the Flp-In T-REx-293 cell lines lead to changes in the 
morphology of the cells or affect the cells ability to survive? These cells were grown in a 
medium containing tetracycline to induce the gene expression of C20orf201; however, no 
abnormal observations were observed and cells apparent to grow normally, without any 
obvious phenotypic changes, although to date this analysis was limited due to time 
constraints. 
 
5.4 Conclusion 
The C20orf201 gene variant 2 can be considered a good CT candidate gene because its 
expression patterns are clearly restricted to the normal testis and in central nervous tissues. 
Importantly, it is also expressed in different types of cancer tissues and cell lines, which could 
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present cancer biomarkers. The results from the Western blots correspond to the RT-PCR 
results in both the normal and cancer tissues tested here. To study the C20orf201 function, it 
was inserted into a human cell line to establish a stable cell line expressing the C20orf201 
gene. We originally thought that translation of C20orf201 mRNA was inhibited in the Flp-In 
T-REx-293::C20orf201 (+Kozak or –Kozak) cells that were not treated with tetracycline. 
However, the subsequent proposal that the 50 KDa species could in fact be a modified 
(ubiquitinate) form of C20orf201 lead us to moderate this hypothesis, although the question of 
a translational inhibition mechanism is addressed in Chapter 6. Therefore, further studies are 
required to study this protein. As a first step, the hypothesis that C20orf201 is ubiquitinated in 
cancer cells should be tested. Importantly, Western blotting of C20orf201 on normal testis 
detected a faint band of 50 KDa species, but in a breast cancer was a strong band in the 
nucleus. This could be a cancer-specific mechanism.  
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Chapter 6.0: Functional analysis of different 
fragments of the human C20orf201 gene 
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
6.1 Introduction  
The Western blots presented in Chapter 5 showed no detectable protein levels of C20orf201 at 
26 KDa in Flp-In T-REx-293 cells, which had been inserted with C20orf201 cDNA with and 
without the Kozak sequences, unless the cells were supplemented with tetracycline (refer to 
Figure 5.16). Nevertheless, RT-PCR results showed evidence of significant gene expression in 
all cells, regardless of the presence or absence of tetracycline treatment (refer to Figure 5.13). 
This indicated the possible presence of a mechanism that allows transcription but inhibits 
translation of the C20orf201 gene in these cell lines in the absence of tetracycline. The 
question addressed in this chapter is to determine whether C20orf201 mRNA sequences serve 
to inhibit translation. The fact that further induction of gene expression by addition of 
tetracycline permits translation might suggest an inhibitory mechanism becomes saturated by 
excessive mRNA thus triggering translation. Such a translational inhibition mechanism exists 
in yeast for meiotic mRNAs that are produced during the mitotic cell cycle. This mechanism 
involves the Mmi1 protein which is a YTH family protein. Members of this family of proteins 
are also found in humans indicating such a mechanism could exist. To test this hypothesis that 
a similar mechanism is operating here, we divided the entire open reading frame of the 
C20orf201 gene into 7 fragments to determine which fragment/s might act as a binding site to 
stop the translation of the C20orf201 mRNA.  
 
6.2 Results 
6.2.1 Cloning of C20orf201 fragments 1 to 7 cDNAs into the pcDNA5/FRT/TO 
vector 
A mammalian expression plasmid (pcDNA5/FRT/TO) was used in the cloning application to 
clone each fragment of C20orf201 into individual vector. The cloning of the C20orf201 
fragments was performed by adding the Kozak consensus sequence to the 5' end of each 
fragment. The reason for this addition was because this sequence plays a fundamental role in 
stimulating protein translation (Kozak, 1991). Each C20orf201 cDNA fragment differs from 
the others by 99 bp (33 amino acids). The full length size of C20orf201 amino acids is 240. 
The anti-C20orf201 antibody used in Chapter 5 recognises 51 amino acids from the entire 
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C20orf201 amino acids, so a His Tag sequence (CACCACCACCACCACCAC) was added to 
the 3' end of C20orf201 of each fragment before the stop codon to ensure Western blot 
monitoring of translation using anti-His monoclonal antibody. The HindIII restriction enzyme 
was used in cloning each of the 7 fragments of the C20orf201 gene. A HindIII recognition 
sequence is present at the multiple cloning site (MCS) of the pcDNA5/FRT/TO vector but 
does not exist in the C20orf201 cDNA sequences; for this reason, the HindIII was chosen 
from the 10 unique restriction enzymes appearing at the MCS of the vector. 
 
The cloning of individual C20orf201 fragments was initiated by amplification of C20orf201 
cDNA from the pCMV6-AC::C20orf201 vector using C20orf201 F7 and R7 primers for 
fragment 1; C20orf201 F7 and R8 primers for fragment 2; C20orf201 F7 and R9 primers for 
fragment 3; C20orf201 F7 and R10 primers for fragment 4; C20orf201 F7 and R11 primers 
for fragment 5; C20orf201 F7 and R12 primers for fragment 6; or C20orf201 F7 and R13 
primers for fragment 7. The amplification of C20orf201 fragments 1 and 2 were performed 
using the Phusion High Fidelity PCR Master Mix (BioLabs; M0532S), while other C20orf201 
fragments were amplified using the BioMix Red Master Mix (BioLine; BIO-25006). The 
amplified PCR products for fragments 1, 2, 3, 4, 5, 6 and 7 were 744 bp, 645 bp, 546 bp, 447 
bp, 348 bp, 249 bp and 150 bp, respectively. The sequence of each fragment was confirmed 
by sequencing.  
 
Each fragment of C20orf201 was cloned into the pcDNA5/FRT/TO plasmid using HindIII. 
The vector was analysed on agarose gel before and after HindIII digestion to verify the 
digestion efficiency of the vector, which yielded three molecules in the undigested vector 
(Figure 6.1A left) and a single fragment of about 5137 bp in the digested vector (Figure 6.1A 
right). Each fragment (PCR insert) was separated on a gel after digestion, purification and 
showed the expected single bands, based on DNA sequencing of all fragments (Figure 6.1B).  
 
Each purified C20orf201 inserts for every fragment was ligated into the purified digested 
pcDNA5/FRT/TO plasmid. The recombinant plasmids were transformed into competent E. 
coli DH5α. The clones for each fragment were analysed by PCR screening of 14, 29, and 17 
randomly selected colonies for fragments 1, 2 and 3, respectively. A random selection of 15 
colonies was screened by PCR for fragments 4, 5, 6 and 7. The set of primers used in the PCR 
amplification for each fragment was also used in the PCR screening. The PCR analysis results 
indicated that: 12 of the 14 E. coli colonies had C20orf201 fragment 1 (Figure 6.2); 13 of the 
29 E. coli colonies had C20orf201 fragment 2 (Figure 6.3); 16 of the 17 E. coli colonies had 
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C20orf201 fragment 3 (Figure 6.4); all of the E. coli colonies had C20orf201 fragment 4 
(Figure 6.5); 2 of the 15 E. coli colonies had C20orf201 fragment 5 (Figure 6.6); 14 of the 15 
E. coli colonies had C20orf201 fragment 6 (Figure 6.7) and 10 of the 15 E. coli colonies had 
C20orf201 fragment 7 (Figure 6.8). All the PCR primers for each C20orf201 fragment were 
validated using pCMV6-AC::C20orf201 cDNA. 
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Figure 6.1 Amplification of C20orf201 cDNA fragments from recombinant pCMV6- 
AC::C20orf201 vector. Agarose gel showing on panel (A) the pcDNA5/FRT/TO vector before (left) 
and after (right) digestion with HindIII restriction enzyme and purification. The enzyme linearizes the 
5137 bp plasmid into one single fragment. Panel (B) shows the PCR amplification for seven 
fragments for C20orf201 from pCMV6- AC::C20orf201 vector using the same forward and different 
reverse primers. These fragments were digested with HindIII and then purified. 
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Figure 6.2 PCR screening of colonies for cloning of C20orf201 fragment 1. Agarose gel showing 
the PCR expression of different E. coli colonies using cloning primers of the C20orf201 fragment 1 
(F7, R7). The first band on the left (lane 1) shows the presence of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate that the primers were working. The samples in lanes 2-6, 8-13 and 
15 have an insert of the expected size of 744 bp. 
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Figure 6.3 PCR screening of colonies for cloning of C20orf201 fragment 2. Agarose gel showing 
the PCR expression of different E. coli colonies by using cloning primers of C20orf201 fragment 2 
(F7, R8). The first band on the left (lane 1) shows the presence of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate the primers. The samples in lanes 7-9, 13 and 15-16 have an insert of 
the expected size of 645 bp. 
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Figure 6.4 PCR screening of colonies for cloning of C20orf201 fragment 3. Agarose gel showing 
the PCR products from different E. coli colonies using cloning primers of C20orf201 fragment 3 (F7, 
R9). The first band on the left (lane 1) shows the presence of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate the primers. The samples in lanes 2-18, except lane 14, have an 
insert of the expected size of 546 bp. 
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Figure 6.5 PCR screening of colonies for cloning of C20orf201 fragment 4. Agarose gel showing 
the PCR products from different E. coli colonies using cloning primers of C20orf201 fragment 4 (F7, 
R10). The first band on the left (lane 1) shows the presence of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate the primers. All samples in lanes 2-16 have an insert of the expected 
size of 447 bp. 
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Figure 6.6 PCR screening of colonies for cloning of C20orf201 fragment 5. Agarose gel showing 
the PCR products from different E. coli colonies using cloning primers of C20orf201 fragment 5 (F7, 
R11). The first band on the left (lane 1) shows the presence of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate the primers. The samples in lanes 2 and 13 have an insert of the 
expected size of 348 bp. 
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Figure 6.7 PCR screening of colonies for cloning of C20orf201 fragment 6. Agarose gel showing 
the PCR products from different E. coli colonies using cloning primers of C20orf201 fragment 6 (F7, 
R12). The first band on the left (lane 1) shows the expression of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate the primers. All samples in lanes 2-16, except lane 10, have an 
insert of the expected size of 249 bp. 
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Figure 6.8 PCR screening of colonies for cloning of C20orf201 fragment 7. Agarose gel showing 
the PCR products from different E. coli colonies using cloning primers of C20orf201 fragment 7 (F7, 
R13). The first band on the left (lane 1) shows the presence of C20orf201 in the pCMV6-
AC::C20orf201 vector to validate the primers. The samples in lanes 2-3, 6-11 and 13-14 have an insert 
of the expected size of 150 bp. 
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6.2.2 Screening of successfully cloned inserts by restriction enzyme digestion 
A total of 7 pcDNA5/FRT/TO::C20orf201 plasmids containing different C20orf201 
fragments were isolated from the E. coli cells. The presence of each C20orf201 fragment was 
verified by a HindIII digestion. This digestion confirmed that all the digested recombinant 
plasmids for both fragments 1 and 2 contained the desired fragments (Figures 6.9 and 6.10, 
respectively). Figures 6.11 to 6.15 show the number of successful cloning for fragment 3 to 7, 
respectively. The successful cloning of each fragment of C20orf201 revealed two fragments 
(bands) in each digested plasmid. The larger fragments showed the expected vector size of 
5137 bp, whereas the smaller bands showed C20orf201 fragments of different sizes, 
according to the insert length.  
 
6.2.3 Confirming the orientation of C20orf201 fragments 1 and 2 by restriction 
enzyme digestion  
Two different methods were used to validate the insert (C20orf201 fragments) orientations: 
restriction enzyme digestion for C20orf201 fragments 1 and 2 and DNA sequencing for other 
fragments. Insertion of distinct fragments of C20orf201 cDNA into the pcDNA5/FRT/TO 
vector using a single restriction enzyme leads to either correct or incorrect orientations. For 
this reason, digestion of another restriction enzyme is also required to compare between the 
correct and the opposite orientations of these inserts. XhoI restriction enzyme was chosen to 
check the insert orientation subcloned into the pcDNA5/FRT/TO. This is because XhoI can 
cut only once within the insert, but significantly off centre (close the 5'end), and also cuts 
nearby in the pcDNA5/FRT/TO backbone. Therefore, XhoI gave different size fragments 
depending on the orientation of the fragment.   
 
Digestion of pcDNA5/FRT/TO::C20orf201 fragment 1 plasmids with XhoI gave two bands; 
the 524 bp insert and the 5357 bp backbone for the correct orientation or the 386 bp insert and 
the 5495 bp backbone for the incorrect orientation of C20orf201 fragment 1. A total of 5 of 
the 11 purified plasmids contained only the right orientation of fragment 1 (Figure 6.16). By 
contrast, digestion of pcDNA5/FRT/TO::C20orf201 fragment 2 plasmids with XhoI 
restriction enzyme gave two bands, but of different sizes. These bands are the 425 bp insert 
and the 5357 bp backbone for the right direction or the 386 bp insert and the 5396 bp 
backbone for the opposite direction for C20orf201 fragment 2. A total of 4 of the 13 purified 
plasmids contained only the correct orientation of fragment 2 (Figure 6.17). One plasmid that 
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contained the correct orientation for each fragment was sent for DNA sequencing to check the 
entire cDNA fragment. 
 
To confirm the orientation of other C20orf201 inserts (fragments 3-7), two plasmids of each 
C20orf201 fragment were sent for DNA sequencing using two sets of uniform primers, 
including CMV forward and BGH reverse primers to verify that the fragments were 
subcloned in the correct orientation for expression and contained an ATG initiation codon and 
a stop codon. The sequences obtained were compared to the original sequence through the 
NCB1 (BLAST). These sequences were 100% identical to C20orf201 without any mutation 
for the entire length of each C20orf201 fragment. 
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Figure 6.9 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 1 digested by HindIII. Two bands are formed for all the recombinants. 
The upper bands show the pcDNA5/FRT/TO vector of 5137 bp in size, while the lower bands are 
fragment 1 of the C20orf201 gene with a size of 744 bp. All minipreps in lanes 1-11 show successful 
cloning of the C20orf201 fragment 1 cDNA. 
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Figure 6.10 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 2 digested by HindIII. Two bands are formed for all the recombinants. 
The upper bands demonstrate the pcDNA5/FRT/TO vector of 5137 bp in size, while the lower bands 
demonstrate fragment 2 of C20orf201 gene with a size of 645 bp. All minipreps in lanes 1-13 have the 
C20orf201 fragment 2 cDNA cloned. 
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Figure 6.11 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 3 digested by HindIII. Two bands are formed for only one 
recombinant. The upper band demonstrates the pcDNA5/FRT/TO vector of 5137 bp in size, while the 
lower band demonstrates fragment 3 of the C20orf201 gene with a size of 546 bp. The miniprep in 
lane 1 has the only successful cloning of the C20orf201 fragment 3 cDNA. 
Figure 6.12 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 4 digested by HindIII. Two bands are formed for three recombinants. 
The upper bands demonstrate the pcDNA5/FRT/TO vector of 5137 bp in size, while the lower bands 
demonstrate fragment 4 of the C20orf201 gene with a size of 447 bp. The minipreps in lanes 5, 9 and 
10 show successful cloning of the C20orf201 fragment 4 cDNA. 
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Figure 6.13 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 5 digested by HindIII. Two bands are formed for all the 
recombinants. The upper bands demonstrate the pcDNA5/FRT/TO vector of 5137 bp in size, while 
the lower bands demonstrate fragment 5 of the C20orf201 gene with a size of 348 bp. All minipreps 
in lanes 1-5 have successful cloning of the C20orf201 fragment 5 cDNA. 
Figure 6.14 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 6 digested by HindIII. Two bands are formed for 5 recombinants. The 
upper bands demonstrate the pcDNA5/FRT/TO vector of 5137 bp in size, while the lower bands 
demonstrate fragment 6 of the C20orf201 gene with a size of 249 bp. Minipreps in lanes 1, 2, 4, 5 and 
7 show successful cloning of the C20orf201 fragment 6 cDNA. 
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Figure 6.15 Digestion of recombinant plasmids. Agarose gel showing recombinant plasmids 
containing C20orf201 fragment 7 digested by HindIII. Two bands are formed for all the recombinants. 
The upper bands demonstrate the pcDNA5/FRT/TO vector of 5137 bp in size, while the lower bands 
demonstrate fragment 7 of the C20orf201 gene with a size of 150 bp. All the minipreps in lanes 1-10 
show successful cloning of the C20orf201 fragment 7 cDNA. 
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Figure 6.16 Verifying fragment 1 orientation by restriction digest. Agarose gel showing digestion 
by XhoI of recombinant plasmids containing fragment 1 to determine the correct orientation of the 
inserts. Depending on which way the C20orf201 fragment 1 is inserted, the XhoI enzyme will produce 
fragments of 524 + 5357 bp, or 386 + 5495 bp; this is because the inserts are oriented in two different 
directions in the vector. Minipreps 1, 3, 4, 6 and 11 all contain inserts with the right direction, while 
minipreps 2, 5, 7, 8, 9 and 10 have the fragment inserted in the opposite direction. 
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Figure 6.17 Verifying fragment 2 orientation by restriction digest. Agarose gel showing digestion 
by XhoI of recombinant plasmids containing C20orf201 fragment 2 to determine the correct 
orientation of the inserts. Depending on which way the C20orf201 fragment 2 is inserted, the XhoI 
enzyme will produce fragments of 425 + 5357 bp, or 386 + 5396 bp; this is because the inserts are 
oriented in two different directions in the vector. Minipreps 1, 3, 7 and 11 all contain inserts with the 
right direction, while minipreps 2, 4, 5, 6, 8, 9, 10, 12 and 13 have the fragment inserted in the 
opposite direction.  
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6.2.4 Insertion of pcDNA5/FRT/TO containing different fragments of C20orf201 
cDNA into the human Flp-In T-REx-293 cell line 
6.2.4.1 Generation and selection of a stable expression cell line  
Since different fragments were inserted into different pcDNA5/FRT/TO plasmids, the 
different recombinant plasmids required digestion to make sure the plasmid that contained the 
desired C20orf201 fragment was chosen correctly. The digestion was carried out prior to 
insertion of the fragment of interest into the Flp-In T-REx-293 cells. The results of this 
digestion gave two bands for each recombinant plasmid; the larger bands showed the size of 
the plasmid DNA, while the smaller bands were related to the different sizes of inserts, which 
depended on the fragment size (Figure 6.18) 
 
Integration of different fragments of C20orf201 cDNA into the entire genome of the Flp-In T-
REx-293 cell lines was dependent on the pOG44 vector (refer to Figure 4.10). The insertion 
occurred by co-transfection of the Flp-In T-REx-293 with a mixed DNA containing the 
following: pcDNA5/FRT/TO::C20orf201 cDNA (fragments 1-7) and pOG44 vector at a ratio 
of 1:9 (pcDNA5/FRT/TO: pOG44). The Flp-In T-REx-293 cell line transfected with pOG44 
and pcDNA5/FRT/TO alone (without the fragment of interest) was used as a negative control. 
In brief, an untransfected Flp-In T-REx-293 cell line was grown in media containing 200 
µg/ml zeocin and 10 µg/ml blasticidin. 48 hours after transfection; the media of cells were 
supplemented with 100 µg/ml of hygromycin instead of zeocin antibiotic to select of stable 
cell lines.  
 
Stable cell lines can be selected for hygromycin resistance, zeocin sensitivity, lack of β-
galactosidase activity and tetracycline-regulated gene expression. The expression of the 
C20orf201 gene following insertion is controlled by the (CMV)/TetO2 promoter. When the 
cell was refreshed with medium containing hygromycin, the majority of the cells did not 
survive. After hygromycin selection and pre-screening under a light microscope, single 
hygromycin resistant clones were isolated and expanded for each construct to generate 
individual clonal cell lines (Figure 6.19A). Examples of picked cells after growing in 6 well 
plates for 24 hours and selecting for hygromycin are shown in Figure 6.19B. 
  
6.2.4.2 Analysis of the successful integrant Flp-In T-REx-293 cell lines 
The correct integration of the pcDNA5/FRT/TO construct containing C20orf201 into the FRT 
site of the Flp-In T-REx-293 cell line genome was evaluated by PCR screening performed 
using genomic DNA as a template. The genomic DNA was extracted from the untransfected 
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and transfected Flp-In T-REx-293 cells. PCR products were found in all transfected cells that 
were integrated with the pcDNA5/FRT/TO::C20orf201 (fragments 1-7), or the empty 
pcDNA5/FRT/TO when using primers located in the PSV40 (forward) and located in the 
hygromycin gene (reverse); however, the untransfected cells did not show any PCR products 
when using the same set of primers (Figure 6.20A). By contrast, PCR results using primers 
located in the C20orf201 gene (forward (F7)) and in the LacZ-Zeocin gene (reverse) gave 
products only in the Flp-In T-REx-293 that had been integrated with 
pcDNA5/FRT/TO::C20orf201 fragments 1-7 (Figure 6.20B). β-actin was used in PCR 
analysis to test the genomic DNA quality in each sample (Figure 6.20C). Therefore, the 
results of PCR screening suggest that the different fragments of the C20orf201 gene were 
correctly integrated into the genomic DNA of the Flp-In T-REx-293 cells. 
 
6.2.4.3 PCR amplification of different integrated C20orf201 fragments for DNA 
sequencing  
The analysis described in Section 6.2.4.2 suggested that all pcDNA5/FRT/TO constructs 
containing distinct fragments of C20orf201 cDNA were inserted successfully into the 
genome. However, the integration of these fragments could lead to deletions in any of these 
fragments. Therefore, PCR analysis was conducted using genomic DNA isolated from these 
cell lines and tetracycline operator 2 (TetO2), and BGH as forward and reverse primers, 
respectively. The PCR results indicated that every cell line contained different fragments of 
C20orf201 that gave the expected size of the PCR product when using TetO2 and BGH 
primers (Figure 6.21A). β-actin was used to validate the genomic DNA quality (Figure 
6.21B). Genomic DNA for each sample was sent for DNA sequencing using TetO2 and BGH 
primers to confirm that the fragments integrated into the Flp-In T-REx-293 did not have 
mutations along the entire length of each C20orf201 fragment. The sequences obtained were 
compared to the original sequence through the NCB1 (BLAST). These results showed that the 
sequences were 100% identical to each fragment of C20orf201, with no mutations found. 
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Figure 6.18 Confirmation of the digestion of different recombinant plasmids. Agarose gel 
showing digestion by HindIII of recombinant plasmids containing different fragments of C20orf201 
cDNAs (1, 2, 3, 4, 5, 6 and 7). Two bands are formed for all recombinants. The upper bands show the 
pcDNA5/FRT/TO vector of approximately 5137 bp in size, while the lower bands show different 
fragments of C20orf201 cDNAs with different sizes of base pairs. The expected sizes for fragments 1, 
2, 3, 4, 5, 6 and 7 are 744 bp, 645 bp, 546 bp, 447 bp, 348 bp, 249 bp and 150 bp, respectively. 
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Figure 6.19 Examples of individual hygromycin resistance colonies. Panel A shows different 
resistance Flp-In T-REx-293:C20orf201 colonies 2 days after adding an antibiotic marker, 
hygromycin (fragments from 1-7). Panel B shows the colonies 24 hours after picking and transfer to 6 
well plates. 
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Figure 6.20 PCR screening of different C20orf201 integrations in Flp-In T-REx-293 cell lines. 
Panel (A) shows the PCR analysis of the vector in the transfected cells with distinct fragments of 
C20orf201 cDNA (lanes 1-7) or with a pcDNA5/FRT/TO vector alone (penultimate lane on the right) 
when using PSV40 as a forward primer and hygromycin as a reverse primer. Panel (B) shows the 
PCR products for C20orf201 fragments when using the C20orf201 as forward primer and LacZ-
Zeocin gene as a reverse primer. The expression profile for Beta-actin is shown as a positive control 
for the genomic DNA samples (Panel (C)). Panel (D) shows the localisation of C20orf201 cDNAs in 
the genome of Flp-In T-REx-293 cell line. 
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Figure 6.21 Amplification of different fragments of C20orf201 for genomic DNA sequencing. 
Panel (A) shows the PCR products of distinct fragments of C20orf201 in Flp-In T-Rex-293 cell lines 
(lanes 1-7) using tetracycline operator 2 as a forward primer and BGH gene as a reverse primer. The 
PCR profile for β ACT is shown as a positive control for the genomic DNA samples (Panel (B)). Panel 
(C) shows the localisation of C20orf201 cDNAs in the genome of Flp-In T-Rex-293 cell line.  
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6.2.4.4 Investigation of the expression level of each C20orf201 fragment in the human 
Flp-In T-REx-293 cell line 
The expression of the C20orf201 fragments 1 to 7 cDNA was investigated through RT-PCR 
and qRT- PCR analyses. Tetracycline was used at a final concentration of 2 µg/ml to induce 
transcription of the C20orf201 from the pcDNA5/FRT/TO expression vector. The cDNAs 
were synthesised from the mRNAs from these cell lines. Cells transfected with empty 
pcDNA5/FRT/TO was used as a negative control. β-actin was used as a positive control for 
the cDNA samples. RT-PCR results showed that the expression of each C20orf201 fragment 
was strongly observed in cell lines treated with or without tetracycline except fragment two in 
the absence of tetracycline. The primers used in RT-PCR analysis were the same forward and 
reverse primers used in cloning (refer to Section 6.2.1). However, neither untransfected cells 
nor transfected cells with empty pcDNA5/FRT/TO produced any RT-PCR products (Figure 
6.22).   
 
Another analysis used here to validate the C20orf201 expression of each fragment gene was 
the qRT-PCR study. C20orf201 F4 and R4 primers were used in this investigation for 
C20orf201 fragments 1 to 7 in different Flp-In T-REx-293 cell lines. In contrast, β ACT and 
Lamin A commercial positive primers were used. The NRT (no reverse transcriptase) and 
NTC (no template control) negative controls did not give Cq (quantification cycle) readings, 
which suggested no non-specific background and no genomic DNA contamination (Tables 
6.1, 6.2 and 6.3). In the absence of tetracycline, the qRT-PCR results show a higher level of 
expression in the Flp-In T-REx-293::C20orf201, fragment 3 compared to other fragments  
and no expression was detected in the negative control tested here (Figure 6.23). However, in 
the presence of tetracycline, the qRT-PCR results displayed a higher expression levels in all 
C20orf201 fragments compared to the cells not treated with tetracycline. Among the treated 
cells, the expression of C20orf201 gene was highest for fragment 6, followed by 3, 5, 4, 7, 1 
and 2 (Figures 6.24 and 6.25). The C20orf201 qRT-PCR results were normalised to the qRT-
PCR results for Lamin A and β ACT; the results are shown in Tables 6.1, 6.2 and 6.3. 
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Flp-In T-REx-293::C20orf201, fragment  
Untransfected Flp-In T-REx-293  Flp-In T-REx-293::pcDNA5/FRT/TO  
C20orf201 
β ACT 
(553 bp) 
— 1000 bp 
— 600 bp 
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— 200 bp 
+/- Tetracycline 
Figure 6.22 RT-PCR analysis of expression of C20orf201 and β ACT in integrated Flp-In T-REx-
293 cell lines. The top agarose gel shows the expression of different fragments of C20orf201 in Flp-In 
T-REx-293 cell lines with and without tetracycline treatment for each fragment (lanes 1-7). The upper 
gel also shows the analysis of expression of C20orf201 in the untransfected cells (the first two lanes 
on the left after the markers) and cells transfected with the vector alone (the last two wells on the right 
before the markers) in Flp-In T-REx-293 cell lines. The bottom agarose gel displays the expression 
profile for β-actin as a positive control for the cDNA samples.  
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Figure 6.23 Real-time quantitative RT-PCR analysis of distinct fragments of C20orf201 in Flp-
In T-REx-293 cells. The bar chart displays the gene expression results for different fragments (1-7) 
of C20orf201 in the Flp-In T-REx-293 cell lines without (-) adding tetracycline to the cell culture, 
compared to the cells cloned with the pcDNA5/FRT/TO vector alone (negative). Expression data 
were normalised to the β ACT and Lamin A reference genes. The error bars represent the standard 
error of the mean (SEM) for 3 repeats. 
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Table 6.1 Real-time qRT-PCR analysis of distinct fragments of C20orf201 in Flp-In T-REx-293 
cells. The table displays the mean of three repeats of the quantification cycle (Cq) and standard 
deviation (SD) for seven fragments (1-7) of C20orf201 before (-) adding tetracycline. These results 
were normalised by β ACT and Lamin A expressions. The table also shows the Cq reading for the no 
reverse transcriptase (NRT) and no template control (NTC). 
 
Target name Sample name Wells Cq Mean Cq SD 
C20orf201 Flp-In T-REx-293: pcDNA5/FRT/TO- 3 90.03 0.190 
β ACT Flp-In T-REx-293: pcDNA5/FRT/TO- 3 17.71 0.003 
Lamin A Flp-In T-REx-293: pcDNA5/FRT/TO- 3 88.27 0.171 
C20orf201 Flp-In T-REx-293: C20orf201 F1- 3 84.01 0.041 
β ACT Flp-In T-REx-293: C20orf201 F1- 3 17.90 0.040 
Lamin A Flp-In T-REx-293: C20orf201 F1- 3 88.21 0.109 
C20orf201 Flp-In T-REx-293: C20orf201 F2- 3 80.31 0.102 
β ACT Flp-In T-REx-293: C20orf201 F2- 3 17.84 0.018 
Lamin A Flp-In T-REx-293: C20orf201 F2- 3 88.11 0.079 
C20orf201 Flp-In T-REx-293: C20orf201 F3- 3 89.41 0.810 
β ACT Flp-In T-REx-293: C20orf201 F3- 3 17.91 0.093 
Lamin A Flp-In T-REx-293: C20orf201 F3- 3 88.44 0.103 
C20orf201 Flp-In T-REx-293: C20orf201 F4- 3 84.12 0.021 
β ACT Flp-In T-REx-293: C20orf201 F4- 3 17.08 0.074 
Lamin A Flp-In T-REx-293: C20orf201 F4- 3 88.74 0.031 
C20orf201 Flp-In T-REx-293: C20orf201 F5- 3 84.01 0.029 
β ACT Flp-In T-REx-293: C20orf201 F5- 3 17.81 0.044 
Lamin A Flp-In T-REx-293: C20orf201 F5- 3 88.00 0.073 
C20orf201 Flp-In T-REx-293: C20orf201 F6- 3 80.87 0.042 
β ACT Flp-In T-REx-293: C20orf201 F6- 3 17.94 0.107 
Lamin A Flp-In T-REx-293: C20orf201 F6- 3 88.20 0.029 
C20orf201 Flp-In T-REx-293: C20orf201 F7- 3 80.11 0.084 
β ACT Flp-In T-REx-293: C20orf201 F7- 3 17.07 0.049 
Lamin A Flp-In T-REx-293: C20orf201 F7- 3 88.07 0.108 
C20orf201 Flp-In T-REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F1- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F1- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F1- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F2- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F2- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F2- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F3- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F3- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F3- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F4-(NRT)  1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F4- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F4- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F5- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F5- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F5- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F6- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F6- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F6- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F7- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F7- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F7- (NRT) 1 0.00 0.000 
C20orf201 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
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Figure 6.24 Real-time quantitative RT-PCR analysis of distinct fragments of C20orf201 in Flp-
In T-REx-293 cells. The bar chart displays the gene expression results for three fragments (1-3) of 
C20orf201 in the Flp-In T-REx-293 cell lines with (+) and without (-) adding tetracycline to the cell 
culture, compared to the cells cloned with the pcDNA5/FRT/TO vector alone (negative). Expression 
data were normalised to the β ACT and Lamin A reference genes. The error bars represent the 
standard error of the mean (SEM) for 3 repeats. 
Figure 6.25 Real-time quantitative RT-PCR analysis of distinct fragments of C20orf201 in Flp-
In T-REx-293 cells. The bar chart displays the gene expression results for four fragments (4-7) of 
C20orf201 in the Flp-In T-REx-293 cell lines with (+) and without (-) adding tetracycline to the cell 
culture, compared to the cells integrated with the pcDNA5/FRT/TO vector alone (negative). 
Expression data were normalised to the β ACT and Lamin A reference genes. The error bars 
represent the standard error of the mean (SEM) for 3 repeats. 
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Table 6.2 Real-time qRT-PCR analysis of distinct fragments of C20orf201 in Flp-In T-Rex-293 
cells. The table displays the mean of three repeats of the quantification cycle (Cq) and standard 
deviation (SD) for three fragments (1-3) of C20orf201 before (-) and after (+) adding tetracycline. 
These results were normalised by β ACT and Lamin A expressions. The table also shows the Cq 
reading for the no reverse transcriptase (NRT) and no template control (NTC). 
 
Target name Sample name Wells Cq Mean Cq SD 
C20orf201 Flp-In T-REx-293: pcDNA5/FRT/TO+ 3 90.01 0.101 
β ACT Flp-In T-REx-293: pcDNA5/FRT/TO+ 3 11.39 0.077 
Lamin A Flp-In T-REx-293: pcDNA5/FRT/TO+ 3 88.01 0.070 
C20orf201 Flp-In T-REx-293: pcDNA5/FRT/TO- 3 90.43 0.109 
β ACT Flp-In T-REx-293: pcDNA5/FRT/TO- 3 17.11 0.013 
Lamin A Flp-In T-REx-293: pcDNA5/FRT/TO- 3 88.30 0.109 
C20orf201 Flp-In T-REx-293: C20orf201 F1+ 3 13.37 0.890 
β ACT Flp-In T-REx-293: C20orf201 F1+ 3 17.00 0.070 
Lamin A Flp-In T-REx-293: C20orf201 F1+ 3 88.30 0.100 
C20orf201 Flp-In T-REx-293: C20orf201 F1- 3 81.03 0.804 
β ACT Flp-In T-REx-293: C20orf201 F1- 3 17.99 0.007 
Lamin A Flp-In T-REx-293: C20orf201 F1- 3 89.00 0.040 
C20orf201 Flp-In T-REx-293: C20orf201 F2+ 3 13.92 0.041 
β ACT Flp-In T-REx-293: C20orf201 F2+ 3 11.13 0.011 
Lamin A Flp-In T-REx-293: C20orf201 F2+ 3 88.93 0.023 
C20orf201 Flp-In T-REx-293: C20orf201 F2- 3 80.33 0.010 
β ACT Flp-In T-REx-293: C20orf201 F2- 3 11.23 0.010 
Lamin A Flp-In T-REx-293: C20orf201 F2- 3 88.41 0.108 
C20orf201 Flp-In T-REx-293: C20orf201 F3+ 3 12.03 0.120 
β ACT Flp-In T-REx-293: C20orf201 F3+ 3 17.90 0.191 
Lamin A Flp-In T-REx-293: C20orf201 F3+ 3 88.74 0.012 
C20orf201 Flp-In T-REx-293: C20orf201 F3- 3 89.12 0.113 
β ACT Flp-In T-REx-293: C20orf201 F3- 3 11.27 0.044 
Lamin A Flp-In T-REx-293: C20orf201 F3- 3 88.90 0.007 
C20orf201 Flp-In T-REx-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: pcDNA5/FRT/TO+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: pcDNA5/FRT/TO- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F1+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F1+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F1+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F1- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F1- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F1- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F2+ (NRT)  1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F2+ (NRT)  1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F2+ (NRT)  1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F2- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F2- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F2- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F3+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F3+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F3+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F3- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F3- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F3- (NRT) 1 0.00 0.000 
C20orf201 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
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Table 6.3 Real-time qRT-PCR analysis of distinct fragments of C20orf201 in Flp-In T-Rex-293 
cells. The table displays the mean of three repeats of the quantification cycle (Cq) and standard 
deviation (SD) for four fragments (4-7) of C20orf201 before (-) and after (+) adding tetracycline. 
These results were normalised by β ACT and Lamin A expressions. The table also shows the Cq 
reading for the no reverse transcriptase (NRT) and no template control (NTC). 
 
Target name Sample name Wells Cq Mean Cq SD 
C20orf201 Flp-In T-REx-293: C20orf201 F4+ 3 80.29 0.840 
β ACT Flp-In T-REx-293: C20orf201 F4+ 3 17.70 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F4+ 3 89.89 0.107 
C20orf201 Flp-In T-REx-293: C20orf201 F4- 3 84.31 0.037 
β ACT Flp-In T-REx-293: C20orf201 F4- 3 17.10 0.002 
Lamin A Flp-In T-REx-293: C20orf201 F4- 3 89.81 0.038 
C20orf201 Flp-In T-REx-293: C20orf201 F5+ 3 80.01 0.022 
β ACT Flp-In T-REx-293: C20orf201 F5+ 3 17.23 0.031 
Lamin A Flp-In T-REx-293: C20orf201 F5+ 3 89.80 0.001 
C20orf201 Flp-In T-REx-293: C20orf201 F5- 3 81.00 0.109 
β ACT Flp-In T-REx-293: C20orf201 F5- 3 17.78 0.001 
Lamin A Flp-In T-REx-293: C20orf201 F5- 3 89.14 0.011 
C20orf201 Flp-In T-REx-293: C20orf201 F6+ 3 81.10 0.148 
β ACT Flp-In T-REx-293: C20orf201 F6+ 3 12.70 0.028 
Lamin A Flp-In T-REx-293: C20orf201 F6+ 3 80.19 0.017 
C20orf201 Flp-In T-REx-293: C20orf201 F6- 3 84.03 0.020 
β ACT Flp-In T-REx-293: C20orf201 F6- 3 12.01 0.078 
Lamin A Flp-In T-REx-293: C20orf201 F6- 3 89.40 0.070 
C20orf201 Flp-In T-REx-293: C20orf201 F7+ 3 80.43 0.073 
β ACT Flp-In T-REx-293: C20orf201 F7+ 3 17.04 0.189 
Lamin A Flp-In T-REx-293: C20orf201 F7+ 3 89.13 0.082 
C20orf201 Flp-In T-REx-293: C20orf201 F7- 3 84.01 0.093 
β ACT Flp-In T-REx-293: C20orf201 F7- 3 17.81 0.040 
Lamin A Flp-In T-REx-293: C20orf201 F7- 3 88.20 0.182 
C20orf201 Flp-In T-REx-293: C20orf201 F4+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F4+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F4+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F4- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F4- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F4- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F5+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F5+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F5+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F5- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F5- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F5- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F6+ (NRT)  1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F6+ (NRT)  1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F6+ (NRT)  1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F6- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F6- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F6- (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F7+ (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F7+ (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F7+ (NRT) 1 0.00 0.000 
C20orf201 Flp-In T-REx-293: C20orf201 F7- (NRT) 1 0.00 0.000 
β ACT Flp-In T-REx-293: C20orf201 F7- (NRT) 1 0.00 0.000 
Lamin A Flp-In T-REx-293: C20orf201 F7- (NRT) 1 0.00 0.000 
C20orf201 NTC 1 0.00 0.000 
β ACT NTC 1 0.00 0.000 
Lamin A NTC 1 0.00 0.000 
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6.2.4.5 Investigation of the presence of C20orf201 protein in the human Flp-In T-
REx-293 cell lines 
A monoclonal antibody against the 6X His tag (Abcam; AB18184) was used to study the 
protein levels of C20orf201 for distinct integrants of Flp-In T-REx-293 cell lines containing 
different fragments of C20orf201 cDNA. The protein for each C20orf201 fragment was 
evaluated in cultured cells in the presence and absence of tetracycline treatment. Western 
blots indicated that C20orf201 protein fragments were clearly observed in the Flp-In T-REx-
293 cell line inserted with only C20orf201 fragments 1, 2 or 3 when the membrane was 
exposed for 10 minutes using the X-ray film and Chemiluminescent Peroxidase Substrate-3 
(Sigma-Aldrich; CPS3100-1KT) (Figure 6.26 upper film); whereas no protein was detected 
for fragment 3 when the membrane was exposed for 2 minutes (Figure 6.26 lower film). 
These proteins for the fragments 1 to 3 were detected after treating the cells with tetracycline. 
Appropriate protein loading was confirmed for each clone by the GAPDH control. The 
molecular weights for each fragment of C20orf201 gene are shown in Table 6.4. 
 
Table 6.4 Calculation of the molecular weights (MW) of each C20orf201 fragment 
Fragment Size (bp) Number of amino 
 acids 
C20orf201 MW (KDa) Histidine 
MW (KDa) 
Expected 
MW (KDa) 
1 720 720/3= 240 240×110/1000= 26.4 0.66 27.06 
2 621 621/3= 207 207×110/1000= 22.77 0.66 23.43 
3 522 522/3= 174 174×110/1000= 19.14 0.66 19.8 
4 423 423/3= 141 141×110/1000= 15.51 0.66 16.17 
5 324 324/3= 108 108×110/1000= 11.88 0.66 12.54 
6 225 225/3= 75 225×110/1000= 8.25 0.66 8.91 
7 126 126/3= 42 126×110/1000= 4.62 0.66 5.28 
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Figure 6.26 Western blot analysis showing different fragments of C20orf201 induced by 
tetracycline in the Flp-In T-REx-293 system. One group of 7 cell lines with distinct fragments of 
the C20orf201 gene inserted into the Flp-In T-REx-293 cells were subjected to 2 µg/ml of 
tetracycline and another group of 7 were not. Positive signals are seen in cells containing the 
C20orf201 fragment 1, 2 and 3 after treatment with tetracycline. The cells were harvested 24 hours 
after induction. The lysates were separated on a 10% SDS-PAGE gel. GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase) was used as the loading control (bottom). The upper membrane for anti-
6X His tag was exposed for 10 minutes, while the lower membrane was exposed for 2 minutes. 
+/- Tetracycline 
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6.3 Discussion 
We postulate that a translation inhibition mechanism was operating with similarities to that in 
the fission yeast for the inhibition of translation of meiotic gene transcripts during the mitotic 
cell cycle (Harigaya et al., 2006; Yamamoto, 2010). In the fission yeast pathway, a small 
sequence within the mRNA known as the DSR serves as a target site for the inhibitory 
proteins. We postulated that if such a target site mechanism were working in humans, then 
deletion of the region encompassing this site would result in translation of the mRNA. To test 
this deletion constructs of the C20orf201 gene were made which encoded an epitope tag 
which would enable us to employ a monoclonal antibody specifically to the products of these 
constructs. It was hoped that these staggered deletions would enable us to identify a DSR-like 
region within the human C20orf201 gene. 
 
RT-PCR analysis showed strong bands in all C20orf201 fragments either in the presence and 
absence of tetracycline treatment (refer to Figure 6.22). However, the protein levels were 
detectable by Western blots only for fragments 1, 2 and 3. No C20orf201 protein fragment 
was detected in Flp-In T-REx-293 cells for the other fragments. We thought that the absence 
of the proteins for fragments 4-7 might be due to insufficient exposure time for detecting the 
protein bands. Therefore, the membrane was also exposed for 30 minutes, but the results were 
still the same: no proteins were detected for fragments 4-7 and a background appeared on the 
membrane. We also noticed that the apparent protein levels for fragments 1, 2 and 3 decreased 
gradually and we thought this was because the small molecular weight protein could have 
failed to transfer to the membrane fully. Therefore, we used a specific membrane for small 
molecular weight proteins, but the Western blot results using this membrane remained the 
same.  
 
Chapter 5 indicated the possible presence of a mechanism that permits transcription but 
inhibits the translation of the C20orf201 gene in cell lines that were not treated with 
tetracycline. The fact that the addition of tetracycline allows the translation of C20orf201 
mRNA in these cells might suggest a translational inhibitory mechanism that could lead to 
mRNA degradation, but it can only cope with low levels of a specific RNA. Such pathway 
could be related to the Mmi1 pathway in S. pombe. This mechanism involves the Mmi1 
protein, which is a YTH family protein; members of this family of proteins are also found in 
humans. The question here is whether this protein operates in humans. According to Western 
blot results, this objective was not achieved. Therefore, we can do another experiment, such 
as a knockdown of the human YTH genes, and ask if that knockdown could change the 
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translation profile of C20orf201 in cells. The cells translating the C20orf201 protein could 
confirm that the mechanism is similar to the Mmi1 pathway. However, if the mRNA un-
translated with no protein production, that may suggest that another mechanism must be 
found. The finding that a possible ubiquitinated form of C20orf201 resides at 50 KDa 
confuses the issue, as this species is present with and without tetracycline, although the levels 
do not change. 
 
6.4 Conclusion 
C20orf201 ORF was divided into seven fragments to study the mRNA expression of each 
fragment after insertion into the whole genome of the Flp-In T-REx-293 cells. The RT-PCR 
results showed strong expression of each fragment; the investigation into the translation of 
these mRNAs using an antibody against the 6X His tag showed no protein levels for 
fragments 4 to 7. Further analysis is required to address whether a translation inhibition 
mechanism is in operation. 
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Chapter 7.0: General Discussion 
----------------------------------------------------------------------------------------------------------------------------- ----------- 
 
7.1 Screening of meiotic genes in a wide range of normal and cancer tissues 
Among numerous tumour antigens, CTAs have been selected as potential targets for 
promising immunotherapy including cancer vaccination, because they are present in various 
malignant tumours, but are not present in normal adult tissues other than testis, ovary and 
placenta (Whitehurst, 2014). Consequently, we suggested that meiotic genes may provide an 
excellent source for the identification of new CTA genes. CTA gene expression profiling can 
also be used as a novel tool for cancer biomarkers for the early diagnosis of cancer (for 
example, see Rousseaux et al., 2013). The CTAs are also promising candidates as potential 
drug targets (for example, see Whitehurst et al., 2007). Therefore, identification of new CTA 
genes should improve and increase therapeutic strategies.  
 
In the current study, genes identified by a bioinformatics pipeline were used to identify a 
number of novel potential CTA genes. These genes were then tested using RT-PCR analysis 
using a range of normal tissues and the promising candidates were additionally explored in 
distinct types of cancer tissues and cell lines. The RT-PCR results presented in Chapter 3.0 
identified 11 potential CTA genes: 6 CT-restricted/selective genes and 5 CT-CNS-
restricted/selective genes. Four genes from the 32 genes screened here were also found 
expressed only in the normal testis, but not in other normal or cancer tissues and cell lines. 
However, these testis-specific genes might be expressed in other cancers not included in the 
present study. For example, a meta-analysis of Microarray data was performed for the four 
testis-specific genes (UBL4B, CST8, ODF3 and TMEM225) and one gene (UBL4B) was 
found to display expression in an ovarian cancer sample (www.cancerma.org.uk; Feichtinger 
et al., 2012b). Conversely, the results from RT-PCR analysis for UBL4B did not show any 
expression in the ovarian tumour tissue or in the three different human ovarian cancer cell 
lines (A2780, PEO14 and TO14) that were screened in the present study.  
 
One unexpected finding in this study was that 17 of the 32 genes screened showed expression 
in most normal somatic tissues, although two of these were thought to be meiosis-specific 
genes. This expression in normal tissues might be explained in two different ways. First, these 
genes have characterised functions during meiotic division, but might have other functions in 
mitotic cells. Next, some of the normal tissues might have had undiagnosed neoplasia 
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(abnormal growth), which could ultimately lead to tumour progression. For instance, a 
previous study for identification of CTA genes showed that differences in gene expression 
were found in a distinct panel of normal human tissues (Chen et al., 2005a), inferring some 
contain neoplastic cells. 
 
Importantly, 11 genes were identified in the present project as being novel CT gene 
candidates because they displayed expression that was either restricted to the normal testis or 
was found in the normal testis and fewer than two other somatic normal tissues. However, 
these candidate genes displayed expression in many types of tumours. A meta-analysis of 
Microarray was performed for the 11 promising CT genes and the results were upregulated in 
five genes (C20orf201, FSCN3, GAGE1, SSX2 and SSX5).  The SSX2 gene is a good example 
of the candidate CTA genes identified by RT-PCR. This gene was expressed in COLO800 
(melanoma cancer) and K-562 (leukaemia cancer). However, the meta-analysis indicates that 
this gene was up-regulated in four different types of cancer, such as ovarian, lung, brain and 
adrenal cancers. Therefore, this study suggests that further investigation of the SSX2 gene is 
required using different cancer samples. 
 
The SSX gene family of cancer-testis antigens consists of ten genes (SSX1-10) (Güre et al., 
2002; Smith et al., 2011). The presence of the SSX family of cancer-testis antigens has been 
correlated with more advanced stages of disease and worse patient prognosis in a number of 
human cancers (Güre et al., 2002). SSX expression has been investigated in a wide range of 
cancers (Güre et al., 2005), while reports on protein levels are limited such as, malignant 
melanoma (dos Santos et al., 2000), prostate cancer (Smith et al., 2011), hepatocellular 
carcinoma (Liang et al., 2013), and oesophageal cancer (Akcakanat et al., 2006). The SSX 
proteins are a highly homologous group of CT-X antigens with displayed immunogenicity in 
patients diagnosed with cancer. They have a number of features that make them attractive 
targets for cancer therapy. For example, a recent study reported that SSX2, in particular, may 
be a high priority target for tumour therapy, based upon certain predefined criteria for 
prioritisation of tumour antigens, such as tumour specificity, oncogenicity, expression level 
and number of identified epitopes (Cheever et al., 2009).  
 
A recent study examined the expression of SSX1, SSX2, SSX4 and MAGE-C1/CT7 in multiple 
myeloma (MM) cell lines using RT-PCR analysis. This study also validated these CTA genes 
in bone marrow (BM) cells isolated from 25 MM patients and 18 healthy volunteers. The RT-
PCR results showed that four CTA genes were expressed in MM cell lines and the expression 
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rate of each CTA gene, SSX1, SSX2, SSX4 and MAGE-C1/CT7, in the BM cells of 25 MM 
patients was 80% (20/25), 40% (10/25), 68% (17/25) and 28% (7/25), respectively. However, 
BM cells of 18 healthy volunteers did not show any expression of any member of the CTA 
genes. The conclusion drawn from this work was that these four CTA genes were co-
expressed in MM cell lines and may serve as useful targets for cancer immunotherapy in MM 
in the future (He et al., 2014). 
The SSX2 gene in the present study and other SSX family members reported in previous 
studies can be used as important indicators for early diagnosis and prognostic determination 
of different cancer types.  
 
7.2 Functional analysis of the human STRA8 gene 
The RT-PCR analysis of the human STRA8 gene using cDNAs from normal adult testis, HEP-
G2, lung tumour, breast tumours and uterus tumour gave a band 216 bp larger than expected. 
The sequence of this was therefore confirmed initially using PCR product derived from testis 
cDNA and STRA8 internal primers F1 and R1. Subsequent RT-PCR analysis of the STRA8 
gene using different sets of forward and reverse primers and different cDNA templates 
confirmed the observation that the whole ORF of STRA8 identified by RT-PCR analysis is 
1209 bp and not 993bp as recorded in GenBank (AF513502).  
The majority of the ‘additional’ base pairs potentially translate into glutamic acid residues. If 
the smaller cDNA GenBank (AF513502) sequences is expressed as protein the molecular 
weight of STRA8 should be at 37 kDa. Western blot results from HEP-G2 cell extracts 
detected a high level of STRA8 protein at a molecular weight that would include the 
additional glutamic acid residue sequence. We did not observe the predicted 37kDa protein. 
This data provides strong evidence that the ‘larger’ sequence identified via RT-PCR is 
translated into protein and could possibly be a splice variant of STRA8 with a specific 
function in cancer cells. Further study is required to confirm these extra sequences in other 
cell lines using RT-PCR and Western blot analyses. 
 
In the present study, the STRA8 gene was identified as a meiosis specific gene since its 
expression was observed only in the normal adult testis and no other normal human tissues. 
However, four different cancer cell lines expressed STRA8; therefore, this gene was identified 
as a good CTA candidate gene. Although the function of the human STRA8 is not known, a 
previous study revealed that Stra8 is required for meiotic progression in mice in both sexes 
(Anderson et al., 2008). Retinoic acid (RA) plays fundamental roles in both spermatogenesis 
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and meiotic entry (Raverdeau et al., 2012) and the Stra8 gene is up-regulated by RA in germ 
cells during both adult and foetal meiosis (Feng et al., 2014).  
 
In addition, in the present study, Flp-In T-REx-293 cell lines were inserted with the STRA8 
ORF with and without the addition of the Kozak sequences in order to study the function of 
this gene in the integrated cell lines. Overexpression of GAGE1, MAGE-A1, NUT, PRDM9, 
RAD21L, REC8, SMC1β, STAG3, SYCP1, SYCP2, SYCP3 and TEX19 meiosis genes, chosen 
randomly, was not detected in Flp-In T-REx-293 cell lines by RT-PCR analysis. It is possible 
that the RT-PCR analysis used in this study perhaps was not sufficient for studying whether 
STRA8 can promote overexpression of any meiosis-specific gene. Therefore, we thought that 
qRT-PCR analysis is also very important to validate the mRNA expression of the 12 meiosis 
genes in the cell lines integrated with the STRA8 gene; however, the qRT-PCR analysis was 
not performed in this study due to time constraints.  
 
We also considered that treating cell lines integrated with STRA8 with retinoic acid could 
induce meiosis selected genes; however, no overexpression was observed for any of the genes 
tested here. This may suggest that STRA8 could possibly induce other genes that were not 
examined here or that expression of STRA8 in these cell lines was not sufficient for meiosis 
progression. A previous study indicated that Depleted in azoospermia-like (DAZL), an RNA-
binding protein and key intrinsic factor, enables spermatogonia in mouse to express Stra8 and 
initiate differentiation and meiosis in response to RA (Lin et al., 2008). The correlation 
between DAZL and STRA8 can be investigated by comparing RT-PCR, qRT-PCR and 
Western blot analyses in the cell lines that had been integrated with STRA8 ORF to these cell 
lines without the STRA8 ORF or in cells integrated with the vector alone (negative control).  
 
Cytochrome P450, family 26, subfamily B, polypeptide 1 (CYP26B1) is one of the RA-
degrading enzymes and is expressed in both foetal and adult testis (Kasimanickam and 
Kasimanickam, 2013). CYP26B1 prevents the RA signalling and shields the RA-induced 
entry of meiosis in testis; in contrast, the absence of CYP26B1 leads to the RA-induced entry 
of meiosis in ovary and the induction of STRA8 (Bowles et al., 2006). The cell lines treated 
with retinoic acid did not show overexpression of the meiotic genes tested here. It is possible 
that this could be due to activity of the CYP26B1 gene, which led to RA degradation. 
Treating these cell lines with a CYP26B1 inhibitor could test this hypothesis. 
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7.3 Functional analysis of the human C20orf201 gene 
The RT-PCR results presented here showed that C20orf201 gene expression in normal human 
tissues was restricted to the testis and CNS tissues for splice variant 1 or to the testis, CNS 
tissues and trachea for splice variant 2. This observation for the C20orf201 variant 1 was 
confirmed in a recent study by Kamata et al., (2013), who indicated that the C20orf201 
mRNA was expressed in the same normal tissues as described here. However, the expression 
of this gene was found in various types of cancer.  
 
The results obtained by RT-PCR for C20orf201 variant 1 were confirmed by means of 
Western blot analysis using normal and cancer tissue lysates, which gave the same results 
from RT-PCR analysis; therefore, this study suggests that C20orf201 could be considered as a 
good candidate for a CTA gene and may be a good choice for a cancer-specific marker in the 
future. Indeed, subsequent work by another group member has demonstrated C20orf201 could 
be a good immunohistochemistry marker in ovarian cancer. This work is ongoing. The results 
from Western blot analysis and Immunofluorescent staining suggested that the C20orf201 
protein displayed nuclear and cytoplasmic localisations of the cell line tested here (MCF-7; 
breast cancer). One of the most important observations in this study was the mRNA 
expression of C20orf201 in MCF-7 cells. The results from RT-PCR and qRT-PCR analyses 
confirmed that this expression was extremely faint compared to other ovarian cell lines tested 
here (A2780, PEO14 and TO14); whereas, the results from Western blot analysis 
demonstrated that a higher level of the 26 KDa C20orf201 protein in MCF-7 cells. This 
observation may suggest that some mechanism could be destroying mRNA levels in these cell 
lines that were expressing high levels of C20orf201 mRNA. 
 
Moreover, in this study, the C20orf201 ORF was inserted with and without the addition of the 
Kozak sequences into the whole genome of the Flp-In T-REx-293 cell lines to address the 
function of this gene in these cell lines. Interestingly, the results from RT-PCR analysis 
indicated that expression of C20orf201 was observed in Flp-In T-REx-293 cell lines with or 
without tetracycline treatment. However, Western blot results revealed that the 26 KDa 
C20orf201 protein was found only in the presence of tetracycline. The absence of the 26 KDa 
protein in the cell line not treated with tetracycline may suggest that some mechanism exists 
that could lead to inhibition of C20orf201 translation in the absence of tetracycline. This 
potential inhibition of C20orf201 translation may represent a mechanism similar to the one 
that exists in fission yeast, termed the Mmi1 RNA elimination system. To test this possibility, 
211 
 
seven different fragments were amplified from the C20orf201 ORF and then each fragment 
was inserted individually into the Flp-In T-REx-293 cell line genome to determine which of 
these fragments could be recognised by the human YTH family (members of the Mmi1 
system). All fragments were expressed in these cell lines with and without tetracycline 
treatment; however, only three fragments showed C20orf201 protein in the presence of 
tetracycline (1-3). Fragment 3 was expressed more highly than other two fragments, but the 
protein levels were too low compared to fragments 1 and 2. A brief reiteration of the 50 KDa 
band and the fact it could be a Ub species.   
 
In conclusion, RT-PCR screening of meiotic genes, using a wide range of normal and cancer 
tissues and cell lines, identified 11 novel CT genes, and one of the four validated testis-
specific genes was up-regulated in ovarian cancer, which may suggest further study of this 
gene in more ovarian cancer samples would be worthwhile. These results therefore confirm 
our hypothesis that meiotic genes may provide an excellent source for identifying potential 
novel CTA genes. Further studies are also required to establish the protein products of the 
good CTA genes identified in the current study in cancer cells. These proteins, if any, may 
serve as useful tumour-specific targets. 
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